Regulation of Growth Factor and Nutrient Sensing Pathways by Human Papillomavirus E6 Proteins by Spangle, Jennifer Marie
 Regulation of Growth Factor and Nutrient Sensing
Pathways by Human Papillomavirus E6 Proteins
 
 
(Article begins on next page)
The Harvard community has made this article openly
available.
Please share how this access benefits you. Your story
matters.
Citation No citation.
Accessed February 19, 2015 10:58:46 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10345147
Terms of Use This article was downloaded from Harvard University's
DASH repository, and is made available under the terms
and conditions applicable to Other Posted Material, as set
forth at http://nrs.harvard.edu/urn-
3:HUL.InstRepos:dash.current.terms-of-use#LAA

 Regulation of Growth Factor and Nutrient Sensing Pathways by Human 
Papillomavirus E6 Proteins 
 
A dissertation presented  
by 
Jennifer Marie Spangle 
 
to 
The Division of Medical Sciences 
 
in partial fulfillment of the requirements  
for the degree of  
Doctor of Philosophy 
in the subject of  
Virology 
 
Harvard University 
Cambridge, Massachusetts 
January 2012 
 
 
 
 
 
 
 
 
 
 
 
© 2012 Jennifer Marie Spangle 
              All rights reserved
 
 
 iii 
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Regulation of Growth Factor and Nutrient Sensing Pathways by Human Papillomavirus 
E6 Proteins 
 
 High-risk human papillomaviruses (HPVs) are associated with nearly all cases of cervical 
cancer and also contribute to other types of anogenital and oropharyngeal cancers. The high-risk 
HPV E6 oncoprotein contributes to malignant progression in part by the targeted degradation of 
the tumor suppressor p53. The activation of growth factor and nutrient sensing pathways 
including receptor protein tyrosine kinases (RPTKs) and mTORC1 may also support cellular 
transformation. Moreover, previous studies suggested that HPV16 E6 activates mTORC1. We 
are particularly interested in understanding the mechanisms by which HPV E6 activates 
mTORC1 and the function of mTORC1 activation in HPV infection.  
 Here we show that high-risk HPV16 E6 activates mTORC1 signaling and increases cap 
dependent translation through an increase in S6K signaling and an increase in 4E-BP1 
phosphorylation. Mechanistically we found that HPV16 E6 activates AKT under conditions of 
nutrient deprivation. The combined approach of phospho-tyrosine immunoprecipitations and 
Western blot identified HPV16 E6 mediated activation of a subset of receptor protein tyrosine 
kinases. HPV16 E6 activates RPTKs at least in part by increasing the internalization of 
phosphorylated and activated receptor species. The signaling adaptor protein Grb2 associates 
with HPV16 E6, and Grb2 knockdown abrogated HPV16 E6 mediated mTORC1 activation. We 
hypothesize that Grb2 may be important in relaying E6 mediated RPTK activation to 
downstream signaling cascades.  
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 In this dissertation we also evaluate mTORC1 signaling and cap dependent translation in 
cells expressing HPV16 E6 mutants and E6 proteins from other HPV types. Binding to p53 and 
the association with proteins that contain an LXXLL motif are important for HPV16 E6 
mediated mTORC1 activation. An increase in mTORC1 activation and cap dependent translation 
is shared between high-and low-risk mucosal, but not cutaneous HPV E6 proteins. Association 
with proteins through their LXXLL binding motif is also important for low-risk mucosal HPV 
E6 activation of mTORC1 and cap dependent translation. Shared mucosal E6 activation of 
mTORC1 indicates that mTORC1 may be important for the viral lifecycle in mucosal epithelia. 
However, it does not rule out the possibility that together with other properties of high-risk HPV 
E6 proteins, mTORC1 activation may promote transformation.  
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1.1 HUMAN PAPILLOMAVIRUSES 
 
1.1.1 Classification 
 Papillomaviruses are a group of small, non-enveloped DNA viruses that comprise the 
Papillomaviridae virus family. They are species-specific viruses and are found in mammalian 
and non-mammalian vertebrates. Papillomaviruses are non-lytic viruses that infect epithelial 
cells and cause the formation of papillomas. The lesions can occur on either cutaneous or 
mucosal epithelia. A comparison of the sequence similarity of the L1 capsid protein is used to 
classify papillomaviruses as unique species within 29 distinct genera. Viruses with a sequence 
similarity of 60-70% belong to the same genera, whereas viruses sharing less than 90% 
homology within the L1 ORF are considered unique species (Bernard et al., 2010). The more 
than 200 identified human papillomavirus (HPV) types are classified within five genera – alpha, 
beta, gamma, mu and nu (Bernard et al., 2010; Schiffman et al., 2010) (Fig 1.1). Alpha-HPVs 
infect mucosal epithelia of the anogenital tract and oral cavity and are further classified as high-
risk and low-risk based on the relative propensity of the lesions that they cause to undergo 
malignant progression. High-risk alpha-HPVs, such as HPV16 and HPV18, are associated with 
potentially premalignant lesions of the cervix, oropharynx, and other tissues found within the 
anogenital tract and oral cavity. Low-risk alpha-HPVs cause generally benign genital warts that 
only rarely undergo malignant progression (Moore et al., 1999). The ubiquitous beta-HPVs 
infect cutaneous epithelium, and are typically associated with benign warts that are readily 
cleared in non-immunocompromised individuals. However, infections with beta HPVs can 
contribute to the formation of squamous cell carcinomas in immunocompromised 
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Figure 1.1. Papillomavirus phylogenetic tree. All 29 papillomavirus genera are represented by 
Greek letters, and, where applicable, Greek letters with the prefix “dyo.” HPVs are classified 
based on the sequence similarity of their L1 capsid protein into the alpha, beta, gamma, mu and 
nu genera. Of the HPVs, alpha HPVs are associated with benign condylomas and malignant 
lesions of mucosal epithelia. Beta HPVs infect the cutaneous epithelia and are most frequently 
associated with benign skin warts. Prototypic HPVs used in this dissertation are designated 
accordingly: high-risk mucosal alpha, red; low-risk mucosal alpha, blue; cutaneous beta, yellow. 
(Used with permission from (Bernard et al., 2010)). 
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individuals or those with a rare genetic disorder, epidermodysplasia verruciformis (EV) 
(Lazarczyk et al., 2009).  
 
1.1.2 Viral Life Cycle  
Viral Genome:  
 The double-stranded circular DNA HPV genome is approximately 8 kb and encodes eight 
to nine open reading frames (ORFs) that are transcribed from a single DNA strand and are 
encoded from each of the three reading frames. The genome consists of three functional regions: 
the long control region (LCR), also known as the non-coding region (NCR) or the upstream 
regulatory region (URR), the early (E) region, and the late (L) region. The approximately 1 kb 
non-coding LCR contains the viral origin of replication as well as DNA elements that regulate 
early viral transcription and contribute to the tissue tropism of HPVs (Mistry et al., 2007). The 
early region contains the E1, E2, E4, E5, E6, E7, and E8 ORFs, although not all HPVs encode 
E5 or E8. For example, HPV Type 16, the predominant virus type described here, encodes E1, 
E2, E4, E5, E6, E7, and E8. The late gene region encodes two ORFs, encoding the L1 and L2 
major and minor capsid proteins, respectively (Fig. 1.2). E1, E2, E6, and E7 are transcribed from 
the early promoter (P97 in HPV16) during the non-productive phase of the viral life cycle. The 
late promoter (P670 in HPV16) is active during productive infection, causing the elevated 
expression of the E1, E2, E4, E5 early proteins and the L1 and L2 capsid proteins (reviewed in 
(Doorbar, 2006).  
 
Infection 
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Figure 1.2. The HPV16 Genome. The HPV16 genome is approximately 7900bp in length and 
encodes the early (E) proteins E6, E7, E1, E2, E4, E5, and the late (L) proteins L1 and L2. The 
early P97 promoter is active in the undifferentiated basal epithelia, whereas the late P670 promoter 
becomes active in the differentiated epithelia. The encoded genes are translated from each of the 
three open reading frames (ORFs), as indicated by color (light grey, ORF1; dark grey, ORF2; 
black, ORF3). L1 and L2 protein expression is also regulated by mRNA transcript 
polyadenylation, indicated as polyAE or polyAL. 
 
 
 6 
 
 HPVs infect epithelial cells, with alpha HPVs infecting mucosal epithelia and beta HPVs 
infecting cutaneous epithelia. Because HPV relies on the host for viral genome replication, HPV 
must initially infect the proliferating cells of the basal epithelium in order to establish a persistent 
infection. The virus typically gains access to the basal layer through a microabrasion in the skin 
(reviewed in (Moody and Laimins, 2010)). Squamocolumnar junctions, including the 
transformation zone in the cervix, contain reserve cells that can give rise to either squamous or 
columnar epithelia. It is thought that these reserve cells are relevant targets for HPV infection 
(reviewed in (Schiffman et al., 2007)). 
 Initial attachment of the virus to cells in the basement membrane is mediated through an 
association between the L1 capsid protein and cellular heparan sulfate proteoglycans (HSPGs) 
(Giroglou et al., 2001). Association with HSPGs induces a conformational change in the capsid, 
exposing L2 for cleavage by furin or a furin-related protease (Richards et al., 2006). It is 
generally thought that the conformational change and L2 cleavage exposes a domain that binds 
the as yet-unidentified cellular receptor. An α-6-integrin containing complex has been proposed 
as a receptor for HPV, but subsequent studies showed that α-6-integrin deficient cell lines were 
still susceptible to infection (Evander et al., 1997; Sibbet et al., 2000). The intracellular 
trafficking of the viral capsid, as well as genome entry into the nucleus, is poorly defined.  
 
Productive Viral Infection 
 Viral genome replication is tightly associated with the differentiation state of infected 
cells. The early promoter is active in non-terminally differentiated epithelial cells, whereas upon 
differentiation the late promoter becomes active, at which point the late genes are transcribed 
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(reviewed in (Knipe, 2006)). Elements in the LCR also play an important role in the coordination 
of viral transcription with the differentiation state of the infected cell.  The LCR contains 
enhancer elements that are responsive to cellular factors and also contains a number of 
transcription factor-binding sites. 
 Following infection of basal epithelial cells, the viral genome is amplified to 50-100 
copies per cell and is then maintained as an episome (reviewed in (Venuti et al., 2011)). During 
this non-productive phase of the viral life cycle the viral DNA is replicated bi-directionally via 
theta structure intermediates (Yang and Botchan, 1990). The productive phase of viral life cycle 
begins when the basal cells divide. During this phase the replication factors, E1 and E2, are 
among the first viral proteins expressed. As the basal cells divide, the E2 protein tethers the 
genome of host chromosomal DNA such that it is segregated to the nuclei of the daughter cells 
(Ilves et al., 1999; Oliveira et al., 2006). In addition to viral genome segregation, the E2 protein 
also regulates viral genome replication. E2 binds to the palindromic ACC-N6-GGT sequences 
within the LCR, leading to the recruitment of the viral helicase, E1. The origin of replication is 
flanked by E2 binding sequences, and E2 associates with the viral helicase, E1, and recruits it to 
the A/T rich origin of replication. Once bound to the origin, E1 forms a double hexameric ring 
complex similar in structure and function to cellular MCM, and recruits cellular DNA replication 
factors (Gloss et al., 1987). The ATPase and DNA helicase activity of E1 is required for the 
initiation and elongation phases of DNA replication of the viral genome (Titolo et al., 1999). 
Some investigators have suggested that the endoplasmic reticulum associated E5 transmembrane 
protein may also contribute to viral genome replication, as E5 mutant viruses exhibit impaired 
genome amplification, but the mechanism for this is unclear (Hwang et al., 1995; Straight et al., 
1995).  
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  Proteins encoded by the E2 ORF also play a major role as modulators of viral gene 
expression and can function as transcriptional activators or repressors. At low levels E2 activates 
the P97 early promoter. At high levels E2 represses early gene transcription, possibly by 
displacing the Sp1 transcription factor from a site adjacent to the P97 promoter (Dong et al., 
1994).  
 The basal epithelial cells divide asymmetrically, producing one basal daughter cell and 
one suprabasal daughter cell that moves upwards and begins to differentiate. As mentioned 
previously, viral genome replication, late gene expression and viral progeny production is 
restricted to terminally differentiated epithelial cells. In order for viral genome replication to 
occur in these differentiated epithelial cells, a cellular environment suitable for DNA replication 
must be maintained. The HPV proteins E6 and E7 are necessary for this function. E7 proteins 
from cutaneous, low-risk mucosal, and high-risk mucosal HPV types associate with the 
retinoblastoma tumor suppressor protein (pRb) and related p107/p130 pocket proteins with 
varying efficiencies. The HPV E7 LXCXE motif mediates the association with the pocket 
proteins pRb, p107 and p130 (reviewed in (McLaughlin-Drubin and Munger, 2009b)). Only 
high-risk HPV E7 proteins target pRb and other pocket proteins for degradation. HPV16 E7 does 
so by associating with and reprogramming the cullin 2 ubiquitin ligase complex such that pRb, 
p107, and 130 are substrates for proteasome mediated degradation (Huh et al., 2007). The 
ubiquitin ligase that participates in targeting pRb for degradation by other high-risk HPV E7 
proteins has not yet been identified. High-risk HPV E7 mediated pRb degradation relieves pRb 
mediated E2F repression, enabling E2F transactivation of genes that encode proteins involved in 
DNA replication. HPV E6 contributes to aberrant cell cycle activation and cell proliferation 
through the formation of a tripartite complex with p53 and the E3 ubiquitin ligase E6 associated 
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protein (E6AP, UBE3A), also leading to the destabilization of p53 (Scheffner et al., 1993). High-
risk HPV E6 has other biological properties that contribute to immortalization, transformation 
and oncogenesis, which are discussed in greater detail below. In brief, the E6 and E7 
oncoproteins are responsible for inducing and/or maintaining a DNA synthesis competent state in 
differentiated epithelia that is necessary for robust genome replication and production of viral 
progeny during the late, productive stage of the viral life cycle.  
 The late stages of the viral life cycle are restricted to the differentiated epithelia where 
viral genomes are replicated to high copy number, the viral late promoter is activated and the 
viral L1 and L2 capsid proteins are produced. The major capsid protein, L1, forms a pentameric 
structure, to which one molecule of the minor L2 capsid protein centrally associates (reviewed in 
(Sapp and Bienkowska-Haba, 2009)). Assembly of L1 into capsomeres occurs in the cytoplasm, 
followed by transport into the nucleus. Following nuclear transport, PML body localized L2 
contributes to efficient virion packaging (Stauffer et al., 1998). L2 is also required for viral 
genome encapsidation. The E4 protein may be involved in viral egress, as it disrupts the keratin 
network in the differentiated epithelium and fragments the cornified cellular envelope (Doorbar 
et al., 1991). Following encapsidation, infectious virus is released as the outermost layers of the 
dermis are sloughed off, for tissue reinfection or infection of a new host.  
 
1.1.3 HPV associated disease: Prevalence, Diagnosis, Treatment and Prevention 
 HPV infection has been linked to a number of diseases, most notably cervical cancer. 
High-risk HPV infection is the number one risk factor for developing cervical cancer. HPV 
infections represent one of the most common sexually transmitted diseases and high-risk HPV 
associated cervical cancer remains a leading cause of cancer death in women worldwide despite 
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advances in cancer screening and prevention. According to the World Health Organization 2010 
Annual Report, there are an estimated 2.4 billion women aged 15 years or older who are at risk 
of developing cervical cancer. Each year approximately 530,000 new cases of HPV positive 
cervical cancer are diagnosed. Cervical cancer is the second most frequent cancer amongst 
women worldwide, causing 275,000 deaths annually. HPV infections account for nearly 100% of 
all invasive cervical cancer cases, with over 70% of these cases attributed to infections with 
HPV16 and HPV18 (WHO 2010 Annual Report). 
 Progress in HPV screening and diagnosis has been critical in the reduction of the rates of 
HPV-associated cervical carcinogenesis and mortality worldwide. The most widely used and 
available screening procedure that is used to identify HPV associated premalignant and 
malignant lesions is the Pap smear, or Pap test, named after its inventor Georgios Papanicolau. A 
swab of exfoliated cells from the endo-and ectocervical areas is collected. Cells are fixed, 
prepared as a monolayer on a microscope slide, stained, and analyzed for the presence of 
cytological abnormalities. Characteristic abnormalities include the presence of cells with 
enlarged nuclei and hyperchromasia. Cells with such abnormalities are referred to as koilocytes. 
There are currently no specific treatments for HPV positive cervical lesions, short of surgical 
removal. Benign skin lesions caused by cutaneous HPV infection or low-risk HPV associated 
genital warts can be removed if they do not spontaneously regress. Typical procedures include 
cryotherapy, surgical or laser removal, or application of chemical agents, which can also be used 
for removal of high-risk HPV associated lesions (Hellner and Munger, 2011).   
 Two prophylactic HPV vaccines that reduce HPV infection and the long-term risk of 
cervical cancer are currently available (reviewed in (Moody and Laimins, 2010)). Gardasil® is a 
quadrivalent vaccine that offers protection against the two low-risk HPVs (HPV6 and HPV11) 
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that are most commonly associated with genital warts and the two high-risk HPVs (HPV16 and 
HPV18) that are associated with the majority of cervical cancers in many regions of the world. 
Gardasil® is now FDA approved for use in young women as well as men ages 9 to 26, with a 
recommended three doses over the course of a six month period. Cervarix® is a bivalent vaccine 
protecting recipients from HPV16 and HPV18 infection. Both vaccines are made of L1 capsid 
protein assembled into virus like particles (VLPs) (Day et al., 2010). The long-term protection 
offered by these vaccines remains to be determined, although both vaccines are highly 
efficacious and have been shown to offer protection for five or more years (Romanowski, 2011).  
 
1.1.4 HPV Associated Carcinogenesis and Oncogenic Activities of the HPV E6 
Oncoprotein 
 During carcinogenesis, integration of the viral genome or subgenomic fragments into the 
host genome occurs. Integration is a nonessential and accidental event, as it terminates the viral 
life cycle. Integration results in the dysregulated expression of HPV E6 and E7 because 
expression of the E2 regulatory protein is lost. Both HPV E6 and E7 contribute to the initiation 
and maintenance of the transformed phenotype (reviewed in (Doorbar, 2006)). High-risk HPV 
E5 proteins have been shown to increase anchorage independent growth, suggesting that they 
may also function in cellular transformation. Co-expression of HPV E5 with HPV E6 causes the 
induction of cellular morphological changes such as increased nuclear size and an increase in 
koilocyte detection (reviewed in (Venuti et al., 2011)). It has also been suggested that high-risk 
HPV E5 contains hyperproliferative activity, as E5 has been reported to activate EGFR signaling 
(Pim et al., 1992). 
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The High-Risk HPV E6 Oncoprotein  
 The HPV E6 proteins are small proteins of approximately 150 amino acids in size that 
contain two CXXC-X29-CXXC zinc binding domains (reviewed in (Howie et al., 2009)) (Fig 
1.3A). Zinc binding through the CXXC motifs is important for the structural integrity of the 
HPV E6 protein. HPV E6 proteins lack enzymatic activities and do not directly associate with 
specific nucleic acid sequences, and therefore modulate cellular processes through the 
association with and modification of host cellular protein complexes. Some of the protein-protein 
interactions that drive HPV E6 activities are described in detail below. Antibodies for detection 
of some HPV E6 proteins have only recently been generated and therefore most studies have 
been performed with epitope tagged versions of E6.  Such studies suggest that high-risk HPV E6 
proteins may localize to both the nucleus and the cytoplasm (Barbosa et al., 1989; Cole and 
Danos, 1987). 
 Alternative splicing of the HPV16 E6 transcript results in the expression of at least two 
truncated HPV E6 mRNAs, termed E6* and E6** (Fig1.3B, C). Similar splice variants have also 
been reported for HPV 18E6 and other high-risk HPV E6 ORFs. Alternative splicing of HPV E6 
may occur in order to generate mRNAs from which HPV E7 is efficiently translated, since HPV 
E6 and HPV E7 ORFs mRNAs are expressed from the same transcript in different reading 
frames, with the E6 stop and the E7 start codons separated by only a few nucleotides. The 
majority of HPV transcripts identified in cervical cancer lines encode spliced E6 sequences. 
However, the biological activities of HPV E6* splice variants are poorly understood. It has been 
proposed that HPV E6* possesses dominant negative activity by binding and repressing full 
length HPV E6 and also reducing the activity of the HPVE6-E6AP complex (Pim and Banks, 
1999; Pim et al., 1997). HPV16 E6* has also been proposed to associate with procaspase 8 
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Figure 1.3. The HPV16 E6 protein. (A) HPV16 E6 is 151 amino acids in length, and has two 
zinc motifs for stability. High-risk HPV E6 proteins have several biological functions, including 
the association with the tumor suppressor p53, the targeted degradation of p53 and other proteins 
through the association with proteins through their LXXLL motif, and binding PDZ proteins. 
Three previously characterized mutations that abrogate these described functions are utilized in 
this dissertation. The HPV16 E6 Y54D mutant does not associate with p53, the I128T mutant no 
longer associates with proteins that have LXXLL motifs, such as E6AP, and the ΔPDZ mutant 
has a truncated carboxyl-terminus and no longer binds proteins that have PDZ domains. (B) 
High-risk HPV E6 proteins exist in at least three forms as a result of internal splicing events. The 
ORFs separating HPV16 E6 and HPV16 E7 are separated by two nucleotides in overlapping 
reading frames. Translation of full length HPV16 E6 excludes the translation of HPV16 E7 (top) 
HPV16 E6* (middle) and HPV16 E6** transcripts are generated from RNA splicing in which 
the donor splice site is identical but separate acceptor sites are utilized. The amino acid 
sequences of full length HPV16 E6, HPV16 E6* and HPV16 E6** are compared in (C).  
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and enhance its stability, inhibiting apoptosis. Full length HPV16 E6, on the other hand, has been 
reported to associate with procaspase 8 and to target it for ubiquitin mediated degradation 
(Tungteakkhun et al., 2010). My own proteomic analyses do not provide any evidence that the 
HPV16 E6 splice variants bind or target p53 for degradation, associate with E6AP, or associate 
with PDZ proteins (Appendix 5). 
 
E6 targets p53 for proteasomal degradation through an E6AP dependent mechanism 
 High-risk mucosal HPV E6 proteins associate with p53 and interfere with its tumor 
suppressor activities. The p53 tumor suppressor engages G1 cell cycle arrest and/or apoptosis in 
response to DNA damage and other cellular stresses. The association of HPV E6 with p53 
prohibits p53 from binding DNA, abrogating its functions as a transcription factor (Lechner and 
Laimins, 1994). To overcome p53 induced apoptosis and G1arrest, high-risk HPV E6 proteins 
target p53 for ubiquitin mediated degradation through the formation of a complex with the 
HECT family E3 ubiquitin ligase E6 associated protein (E6AP, UBE3A) (Scheffner et al., 1993). 
HPV E6 mediated p53 degradation causes the dysregulation of the normal p53 transcriptional 
program, eliminating p53 induced growth arrest and apoptosis as well as other p53 activities. 
High-risk HPV E6 proteins have also been described to target associated proteins for degradation 
through a ubiquitin-independent pathway, presumably by direct association with the proteasome 
(Camus et al., 2007). Low-risk HPV E6 proteins do not target p53 for degradation. HPV E6 
associates with E6AP through an LXXLL motif present in E6AP. This association is conserved 
amongst high- and low-risk mucosal HPV E6 proteins. Therefore, the low-risk HPV E6-E6AP 
complex may also target cellular proteins for ubiquitin-mediated degradation, although only one 
cellular substrate, the proapoptotic protein Bak, has been tentatively characterized (Thomas and 
 
 
 15 
Banks, 1999). HPV E6 proteins also bind other proteins that contain LXXLL motifs, including 
paxillin and E6BP (E6 binding protein) (Elston et al., 1998; Tong and Howley, 1997; Vande Pol 
et al., 1998). 
 
High-risk E6 proteins contribute to cellular immortalization by activating hTERT 
 High-risk HPV E6 has many functions that are independent of p53 that may contribute to 
the transforming potential of high-risk HPV. HPV16 E6 increases telomerase activity through 
the transcriptional activation of the human telomerase reverse transcriptase (hTERT) gene, 
independent of the association with p53 or PDZ proteins (Klingelhutz et al., 1996). hTERT 
activity is required for efficient replication of telomeres and the maintenance of telomerase 
activity is essential for the immortalization of primary cells grown in culture. HPV16 E6 has 
been reported to activate hTERT transcription by interacting with transcription factors cMyc and 
NFX-123 (Gewin et al., 2004; Liu et al., 2005; Veldman et al., 2003). The NFX1 isoform NFX-
91 transcriptionally represses hTERT, and is degraded by the HPV16 E6-E6AP complex to 
promote hTERT transcription activation (Gewin et al., 2004). More recently, HPV16 E6 was 
shown to directly bind to active hTERT, causing an indirect association between HPV16 E6 and 
chromosomal DNA (Liu et al., 2009). This suggests that HPV16 E6 regulates hTERT at the 
transcriptional and post transcriptional levels (Liu et al., 2009). Low-risk mucosal or cutaneous 
HPV E6 proteins do not transcriptionally activate or bind hTERT.  
 
Interaction of high-risk HPV E6 proteins with PDZ proteins mediate multiple biological 
activities 
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 The carboxyl termini of high-risk HPV E6 proteins contain a conserved binding motif, 
(S/T)-X-V-I-L, that mediates the association with cellular proteins that have one or multiple PDZ 
domains. Low-risk HPV E6 proteins do not contain a PDZ binding domain. The PDZ (PSD-95; 
Discs Large; Zonula-occludens -1) motif is a structural domain of approximately 80 to 90 amino 
acids that forms a β-sandwich and two α-helices. Proteins that contain PDZ domains are 
functionally diverse, with many serving as scaffolding proteins for signal transduction and cell 
polarity. They are frequently localized to specific subcellular compartments, such as epithelial 
junctions or neuronal synapses (Tonikian et al., 2008). Many PDZ proteins associate with high-
risk HPV E6 proteins and may be substrates for ubiquitination by the E6/E6AP complex, leading 
to their proteasomal degradation (Massimi et al., 2004; Spanos et al., 2008; Thomas et al., 2005). 
The interaction between high-risk HPV E6 and PDZ proteins is important for HPV E6 associated 
transformation and oncogenic potential. Transgenic mice that express HPV E6 that lack the PDZ 
binding domain are less susceptible to developing cancers in comparison to wild type HPV E6 
expressing mice (Nguyen et al., 2003). Considering the PDZ domain is present in more than 100 
cellular proteins, with more than 250 individual PDZ domains represented in the genome, the 
opportunities for HPV E6 mediated regulation are numerous (Tonikian et al., 2008). Some of the 
high-risk HPV E6 associated PDZ proteins that may be relevant to transformation and 
oncogenesis are discussed below.  
 
MAGUK and LAP proteins: hDlg and hScrib 
 Membrane Associated GUanylate Kinase (MAGUK) proteins are a family of proteins 
classified by containing multiple PDZ domains, and include MAGI-1, MAGI-2, MAGI-3, hDlg, 
and others. hDlg is important for the maintenance of cellular polarity and adherens junctions. Dlg 
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localization to adherens junctions also promotes PI3K localization to the cellular periphery. This 
may be the result of hDlg binding the p85 regulatory subunit of class I PI3Ks (Laprise et al., 
2004). hScrib is a member of the Leucine-Rich and PDZ domain (LAP) protein family that 
localizes to adherens junctions and the basolateral region of epithelial cells (Humbert et al., 
2008). HPV16 E6 mediated hScrib degradation disrupts tight junctions, as detected by reduced 
localization of ZO-1, a component of tight junctions (Nakagawa and Huibregtse, 2000). hScrib 
has also been implicated in signal transduction, inhibiting Ras/Raf downstream signaling and 
inhibiting Ras induced cellular migration and invasion (Dow et al., 2008).  
 
Non-receptor tyrosine phosphatases: PTPN13 and PTPN3 
 HPV16 E6 binds the putative tumor suppressors PTPN13/PTPL1 and PTPN3/PTPH1 and 
targets them for E6AP mediated degradation (Spanos et al., 2008). PTPN13 has been implicated 
in several signaling pathways including directly inactivating Src and negatively regulating ErbB2 
signaling (Glondu-Lassis et al., 2010; Zhu et al., 2008). HPV16 E6 mediated loss of PTPN13 
promotes anchorage independent growth and synergizes with Ras to support tumorigenic growth 
in mice (Spanos et al., 2008). HPV16 E6 mediated degradation of the membrane bound and 
growth factor signaling associated phosphatase PTPN3 promotes cell growth under conditions of 
restricted nutrients and growth factors, including reduced serum, without supplementary EGF or 
insulin (Spanos et al., 2008). 
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1.2 ACTIVATION OF GROWTH FACTOR RESPONSIVE RECEPTOR PROTEIN 
TYROSINE KINASES  
 
 Receptor protein tyrosine kinases (RPTKs) are transmembrane proteins that initiate 
mitogenic signaling pathways and promote cellular processes such as cell growth, size, adhesion, 
and migration in response to activation by growth factors. Following protein synthesis, RPTKs 
are post-translationally modified in the Golgi by N-linked glycosylation (Lane et al., 1985; 
Slieker et al., 1986), after which they are translocated to the plasma membrane. Here the 
receptors bind specific extracellular or cell associated ligands. Ligand binding stimulates 
receptor homo- and heterodimerization. This triggers activation of kinase activity and trans-
phosphorylation of intracellular tyrosine residues. These phosphorylated tyrosine residues then 
act as binding sites for intracellular signal transduction proteins resulting in activation and the 
initiation of mitogen signaling pathways including PI3K/AKT/mTORC1. RPTK activation by 
growth factors also causes receptor internalization, which may occur via clathrin-mediated 
endocytosis or through a clathrin-independent mechanism, depending on the receptor. RPTK 
internalization is important for their activation as the affinity of some ligands for their receptor is 
high enough such that the RPTK signaling lifespan is extended following clathrin-mediated 
endocytosis.   
 
1.2.1 ErbB/HER activation and signal transduction – EGFR 
 Over 20 different ligands have been described for ErbB RPTKs, including epidermal 
growth factor (EGF). Ligand binding and dimerization stimulate ErbB tyrosine kinase activity 
and induce autophosphorylation at multiple tyrosine residues (Guy et al., 1994). Since no ErbB2 
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ligands have been identified to date (reviewed in (Yarden and Sliwkowski, 2001)), it is generally 
accepted that ErbB2 is activated by heterodimerization with other ligand activated ErbB family 
members. Ligand binding to EGFR induces the trans-phosphorylation of at least 7 carboxyl-
terminal, intracellular tyrosine residues (Fernandes et al., 2001). EGFR tyrosine phosphorylation 
serves as a binding site for adaptor proteins through their Src homology (SH2) domains, causing 
the activation of downstream signaling cascades. The adaptor protein Grb2 directly associates 
with EGFR following Y1068 autophosphorylation, activating both the PI3K and Ras/MAPK 
signaling pathways (Rojas et al., 1996). Shc binds EGFR following Y1148 and Y1173 
autophosphorylation, activating MAPK signaling, and EGFR autophosphorylation at Y992 
promotes PLCγ binding and signal transduction (Emlet et al., 1997; Zwick et al., 1999). Tyrosine 
phosphorylation also mediates EGFR stability; Y1045 phosphorylation causes c-Cbl binding and 
subsequent targeting of EGFR for ubiquitin mediated degradation (Levkowitz et al., 1999) (Fig 
1.4). EGFR dimerization-dependent internalization through clathrin-mediated endocytosis is 
associated with receptor activation and can either lead to receptor recycling to the cell surface or 
receptor degradation (Wang et al., 2005). Robust EGFR activation is only obtained upon receptor 
internalization, although clathrin mediated internalization is biased towards receptor recycling 
rather than degradation, sustaining receptor activation (Sigismund et al., 2008).  
 
1.2.2 IR/ IGFR1-R activation and signal transduction 
 Insulin receptors (IR) and insulin-like growth factor receptors (IGFR) are also activated 
upon dimerization followed by ligand binding. While insulin and IGF-I/IGF-II are the 
physiological ligands for IR and IGFR, respectively, IR/IGFR heterodimers bind both insulin and 
IGF with reduced affinity for insulin and with comparable affinity for IGF (reviewed in  
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Figure 1.4. EGFR Activation and Regulation. EGFR is activated by ligand binding and 
dimerization, which induces the autophosphorylation of several carboxyl-terminal tyrosine 
residues. Autophosphorylation promote the association of adaptor proteins via SH2 domains with 
the receptor and activate downstream signaling cascades. SHC associates with EGFR following 
phosphorylation of Y1148 and Y1173, activating MAPK signaling; Grb2 binds after EGFR 
Y1068 phosphorylation and causes the activation of MAPK and PI3K signaling; EGFR Y992 
phosphorylation promotes PLCγ association and the activation of PKC; C-Src binds EGFR 
following Y845 phosphorylation, which activates FAK signaling. EGFR stability is regulated by 
the phosphorylation of Y1045, promoting the association with c-Cbl and the targeted EGFR 
degradation. EGFR activation is abrogated by protein tyrosine phosphatases including PTP1B 
and SHP2.  
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(Belfiore et al., 2009)). Following ligand binding, IRβ and IGFR1β-R are autophosphorylated in 
a conserved kinase activation loop at residues Y1146/1150/1151 or Y1131/1135/1136, 
respectively (Hernandez-Sanchez et al., 1995; White et al., 1988) (Fig 1.5). Autophosphorylation 
causes full receptor activation and initiates downstream effector signaling. Similar to ErbB 
RPTKs, autophosphorylation induces clathrin mediated receptor internalization. There is also 
evidence for caveolin dependent internalization. IR/IGFR1-R phosphorylation is regulated by the 
adaptor proteins Grb10 and Grb14. Grb10 and Grb14 may maintain IR/IGFR1-R activation by 
protecting the receptors from dephosphorylation by tyrosine phosphatases. Alternatively, Grb10 
regulates the stability of IGFR1-R by targeting it for NEDD4 mediated ubiquitination and 
proteasomal degradation (Vecchione et al., 2003). Grb10 is also a downstream target of 
mTORC1. mTORC1 mediated Grb10 phosphorylation increases its stability, causing feedback 
inhibition with the lipid kinase phosphoinositide 3-kinase (PI3K) , AKT, and MAPK/ERK 
signaling pathways. As a result, Grb10 may also participate in IR/IGFR1-R negative feedback 
inhibition (Hsu et al., 2011; Yu et al., 2011). The major downstream effectors of IR and IGFR1-
R signaling are the PI3K and Ras/MAPK signaling pathways. PI3K and Ras/MAPK activation is 
dependent on IR/ IGFR1-R mediated phosphorylation of insulin receptor substrates 1 and 2 
(IRS) at YxxM motifs. Phosphorylation of IRS1/2 at this motif allows for recognition and 
association of adaptor proteins Grb2 and Shc, or class Ia PI3K regulatory subunits, which in turn 
activate PI3K and Ras/MAPK signaling pathways. Protein phosphatases also regulate IR and 
IGFR1-R activity, including SHP2/PTPN11, which associates with, dephosphorylates, and 
inactivates IRS1/2 through its SH2 domain (Goldstein et al., 2000). The protein tyrosine 
phosphatase PTPN1/PTP1b dephosphorylates EGFR and IR (Haj et al., 2003; Haj et al., 2002).  
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Figure 1.5. IR Activation and Regulation. IR is activated by ligand binding and dimerization, 
which induces the autophosphorylation of the carboxyl-terminus at several tyrosine residues. IR 
is phosphorylated at Y1146/50/51, with the phosphorylation of analogous residues occurring for 
IGFR. Phosphorylation promotes the association of IR and insulin receptor substrate 1 (IRS1). 
This predominantly results in the activation of PI3K signaling, although other adaptor proteins 
including Grb2 and SHC can associate indirectly with the receptor through binding IRS-1 and 
activate downstream signaling networks. IR activation is abrogated by protein tyrosine 
phosphatases including PTP1B and SHP2.  
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1.3 mTOR SIGNALING: REGULATION AND THE ROLE OF mTORC1 
SIGNALING IN THE INITITATION OF CAP DEPENDENT TRANSLATION  
 
 The mammalian target of rapamycin (mTOR) is a protein serine-threonine kinase that is 
the catalytic subunit of at least two different complexes with distinct biological functions (Fig 
1.6). TOR was identified through genetic and biochemical screens based on sensitivity to the 
drug rapamycin. Screening yeast for genes that developed mutations that enabled them to grow 
in the presence of rapamycin initially identified TOR (Heitman et al., 1991). Crosslinking and 
affinity purification of the small Rapamycin associated protein FKBP12 from Rapamycin treated 
cells later identified mammalian TOR (Heitman et al., 1991; Sabatini et al., 1994). The mTOR 
complex 1 (mTORC1) contains the mTOR kinase, Raptor, mLST8, and PRAS40. mTORC1 
serves as a major regulator of cell growth, proliferation, and metabolism by integrating upstream 
growth factor associated signals, as well as energy status and nutrient availability. These signals 
are relayed to downstream effectors S6K and 4E-BP1, and canonical cap dependent translation is 
regulated. The specific role(s) of the mTOR complex 2 (mTORC2), which consists of the mTOR 
kinase, Rictor, mLST8 and SIN1, are less well defined. Current data suggest that unlike 
mTORC1, mTORC2 kinase activity is regulated by growth factors only (reviewed in (Zoncu et 
al., 2011)). The mTORC2 complex has been implicated in regulating cytoskeletal organization, 
and phosphorylates members of the AGC kinase family, including AKT at S473 and serum and 
glucocorticoid kinase 1 (SGK1) at S422 (Garcia-Martinez and Alessi, 2008; Sarbassov et al., 
2005). The mTORC2 complex also associates with actively translating ribosomes and 
phosphorylates nascent AKT peptides at T450 to promote AKT stability and prevent 
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Figure 1.6. mTOR functions in two biologically distinct complexes. The mTOR kinase is part 
of two complexes, mTORC1 and mTORC2. mTORC1 contains the mTOR kinase, raptor, 
mLST8, PRAS40, and DEPTOR, and is responsive to growth factors, energy status, and nutrient 
availability. mTORC1 integrates these environmental cues and regulates cell growth and 
proliferation by increasing protein synthesis through activating S6K and 4E-BP1 and increasing 
cap dependent translation. mTORC2 is comprised of the mTOR kinase, rictor, mLST8, Sin1, and 
deptor. mTORC2 is only responsive to growth factors, and phosphorylates several substrates 
including AKT and SGK1.  
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ubiquitination (Oh et al., 2010). These functions of mTORC2 connect mTORC2 activity to 
mTORC1, and the mTORC2 component Rictor is a S6K1 substrate, which is a downstream 
effector of mTORC1 (Dibble et al., 2009; Julien et al., 2010). This suggests that the two mTOR 
complexes may function in an intricate and highly connected signaling network.  
 Despite overlapping regulation by growth factors, mTORC1 and mTORC2 were initially 
characterized based on their differential sensitivity to Rapamycin. While the mTORC1 complex 
is sensitive to inhibition to Rapamycin at low concentrations on the order of minutes, the 
mTORC2 complex remains resistant to Rapamycin on the order of hours. Prolonged Rapamycin 
exposure, however, inhibits the assembly of mTORC2 complexes, reducing AKT S473 
phosphorylation and activation (Sarbassov et al., 2006). Since the discovery of Rapamycin and 
its antiproliferative and immunosuppressive properties, Rapamycin and its derivatives are 
currently under evaluation in many clinical trials for various kinds of cancers (Dowling et al., 
2010). 
 Insulin or other growth factor associated signaling at the cellular membrane have been 
most tightly linked to mTOR activation, although G protein coupled receptors have also been 
implicated. Insulin binding to dimerized insulin receptors causes receptor activation and 
subsequent phosphorylation and activation of substrates including the adaptor proteins IRS1/2. 
As a result PI3K is recruited to the plasma membrane and phosphatidylinositol (4,5)-
bisphosphate [PtdIns(4,5)P2] is phosphorylated to generate PtdIns(3,4,5)P3 (reviewed in 
(Cantley, 2002)). Association of phosphoinositide-dependent kinase -1 (PDK1) and 
PtdIns(3,4,5)P3 at the plasma membrane causes PDK1 activation and phosphorylation of PDK1 
substrates including AKT, SGK1 and other AGC kinases. 
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 The serine-threonine kinase AKT (PKB) also promotes cell growth and proliferation, 
through numerous downstream effectors. AKT reaches full activation at the plasma membrane 
through two sequential phosphorylation events. The initial phosphorylation event occurs at S473 
by mTORC2, which serves as a priming event for PDK1 mediated AKT phosphorylation at 
T308. AKT activates mTORC1 signaling through several mechanisms. 
 
1.3.1 Upstream regulators of mTORC1: AKT phosphorylation and inhibition of TSC2 
relieves mTORC1 inhibition 
 TSC1 and TSC2  (Tuberous Sclerosis Complex 1 and 2) form a heterodimeric complex 
and negatively regulate mTORC1 activity. TSC2 has GTPase-activating protein (GAP) activity, 
and when associated with the GTPase Rheb, stimulates the conversion of Rheb to the inactive, 
GDP-bound form that inhibits mTORC1. Activated AKT inhibits TSC2 by phosphorylating it on 
at least four residues (Inoki et al., 2002; Manning et al., 2002) (Fig 1.7). Mutation of TSC2 
residues that are phosphorylated by AKT cause marked reduction of phosphorylation of the 
mTORC1 downstream effectors S6K and 4E-BP1. TSC2 is also regulated by the energy sensing 
AMP-activated protein kinase (AMPK) pathway. Regulated by LKB1, the heterotrimeric AMPK 
complex responds to the cellular AMP/ATP ratio. Conditions of limited nutrient availability 
stimulate AMPK to phosphorylate TSC2 at S1387. This promotes TSC2 activation and 
subsequent mTORC1 inhibition (Inoki et al., 2003). mTORC1 is phosphorylated at several sites, 
including S2448 and S2481. The kinase that phosphorylates S2448 is controversial; AKT was 
initially proposed to phosphorylate S2448, and PI3K inhibition with Wortmannin abrogated this 
event (Nave et al., 1999). S2448 phosphorylation was later shown to be Rapamycin dependent.  
 
 
 27 
 
 
 
 
 
Figure 1.7. Multiple kinases regulate mTORC1 activation and inhibition. mTORC1 is 
activated upon the following events: (1) PI3K/AKT is activated, inhibiting TSC2 by 
phosphorylating it at four residues. (2) PI3K/AKT is activated, causing the phosphorylation and 
dissociation of PRAS40 from the mTORC1 kinase complex. (3) PI3K/AKT activation 
phosphorylates and activates raptor. (4) Low levels of mTORC1 activity promote S6K 
activation, which phosphorylates mTORC1. (5) Activated mTORC1 phosphorylates DEPTOR, 
targeting DEPTOR for ubiquitin-mediated degradation. mTORC1 activity is repressed following 
AMPK phosphorylation and activation of TSC2, which in turn inhibits mTORC1. The 
association of mTORC1 with PRAS40 and DEPTOR are also inhibitory.  
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Moreover, siRNA against S6K abrogated S2448 phosphorylation, demonstrating that S6K is 
likely involved in the phosphorylation of this site (Holz and Blenis, 2005).  
 
1.3.2 Additional mechanisms of mTORC1 regulation 
 The PI3K/AKT/TSC2 signaling pathway can also activate mTORC1 through alternative 
mechanisms. The mTORC1 component Raptor is phosphorylated in a PI3K/AKT/TSC2 
dependent manner. Insulin stimulates phosphorylation of Raptor at S863, and treatment with the 
PI3K inhibitor Wortmannin inhibits this phosphorylation event. Moreover, there is a marked 
reduction in S863 Raptor phosphorylation in TSC2 -/- mouse embryonic fibroblasts (MEFs) 
(Foster et al., 2010). AKT also phosphorylates PRAS40 (Fig 1.6). PRAS40 is a Raptor 
interacting protein that inhibits mTORC1 under conditions of growth factor deprivation. 
Alternatively, insulin stimulates AKT- mediated phosphorylation of PRAS40 at T246. 
Phosphorylation at this site promotes the dissociation of PRAS40 from the mTORC1 complex 
and relieves PRAS40 induced mTORC1 repression (Sancak et al., 2007). Other regulatory 
proteins of the mTORC1/2 complexes have been identified using biochemical purification of 
these complexes. DEPTOR, a PDZ protein with dysregulated expression in many cancers, was 
identified as an mTORC1/2 interacting protein and inhibitor. DEPTOR expression is regulated 
by mTORC1/2, with reduced or loss of expression causing mTORC1/2 activation and the 
activation of S6K, SGK1, and AKT. However, DEPTOR over-expression causes S6K inhibition. 
This relieves the S6K negative feedback loop on insulin signaling and enables activation of AKT 
(Peterson et al., 2009). mTORC1 also regulates its own activation by directly phosphorylating 
DEPTOR (Fig 1.6), an event that targets DEPTOR for βTRCP mediated proteasomal 
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degradation (Gao et al., 2011). Collectively, loss of DEPTOR or PRAS40 expression causes 
increased cell growth and proliferation. 
 The dephosphorylation of proteins involved in mTORC1 signaling negatively regulates 
mTOR activation. The lipid phosphatase and tensin homologue deleted on chromosome 10 
(PTEN) is an inhibitor of PI3K signaling dephosphorylates PtdIns(3,4,5)P3 and represses PI3K 
mediated signaling to PDK1. Other protein phosphatases also negatively regulate 
PI3K/mTORC1 signaling, including SHP2 (Zito et al., 2007). 
 
1.3.3 The role of mTOR signaling in translation initiation: mTORC1 effectors  
 The activation of mTOR signaling promotes the initiation of cap dependent translation 
through at least two downstream effectors: S6K and 4E-BP1. 
 
S6K  
 A series of at least three phosphorylation events by three distinct kinases activate the 70-
kDa ribosomal subunit 6 kinase 1 (S6K1) (Keshwani et al., 2011). GSK3β first phosphorylates 
S6K1 at S371 in the turn-helix regulatory motif in the linker region. This event is critical for S6K 
conformational stability and is necessary for S6K T389 phosphorylation. (Shin et al., 2011). (Fig 
1.8) S6K is thought to be phosphorylated next in the activation loop of the catalytic domain by 
PDK1 at T229 (Pullen et al., 1998). The final phosphorylation of the S6K hydrophobic motif in 
the linker region at T389 by mTORC1 results in fully activated S6K. S6K1 also participates in a 
negative feedback inhibitory loop that causes attenuated mTORC1 signaling. Insulin resistance 
and inhibition of downstream signal transduction can occur when S6K1 phosphorylates IRS-1, 
whereas S6K inhibition can restore signaling and insulin responsiveness  
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Figure 1.8. Sequential phosphorylation events activate S6K. S6K1, shown here, has an 
amino-terminal nuclear localization signal (NLS) and several domains that regulate its activity. 
Residues within the catalytic domain and linker region are phosphorylated by kinases that 
regulate S6K activity, and the autoinhibitory domain (AID) also can be phosphorylated. S6K 
activation is stepwise. First, GSK3β phosphorylates S6K in a turn motif within the linker region. 
This stabilizes S6K for later phosphorylation in the hydrophobic motif also in the linker region. 
PDK1 next phosphorylates S6K in the catalytic domain. Lastly, the mTORC kinase complex 
phosphorylates the hydrophobic motif of S6K.  
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(Harrington et al., 2004; Um et al., 2004) (Fig 1.5). S6K also associates with the protein 
phosphatase 2A (PP2A), and under conditions of mTOR inhibition, PP2A can dephosphorylate 
and inactivate S6K. Under conditions of mTORC1 activation, mTORC1 phosphorylates and 
inactivates PP2A, maintaining downstream S6K activation (Peterson et al., 1999). 
 S6K1 phosphorylation activates numerous downstream effectors, including those 
associated with ribosome biogenesis and translation elongation. S6K1 is one of several kinases 
that phosphorylates 40S ribosomal protein S6 on residues S235/36 and S240/44. S6 
phosphorylation promotes the translation of mRNAs through several mechanisms. S6K may 
increase the translation of mRNAs containing the 5’ terminal oligopyrimidine tract (5’ TOP), or 
a stretch of four to 15 CU rich nucleotides located in a relatively short and unstructured 5’ UTR, 
under insulin rich conditions. Many genes involved in translation have been reported to contain a 
5’ TOP, including ribosomal genes, supporting ribosome biogenesis (reviewed in (Meyuhas, 
2000)). Translation of many 5’TOP mRNAs is Rapamycin sensitive, although an increase in the 
translation of some 5’TOP mRNAs has been detected in S6K1 and S6K2 double knock out 
MEFs (Pende et al., 2004). Other targets of S6K1 include eukaryotic translation factors such as 
initiation factor eIF4B and elongation factor eEF2K (Raught et al., 2004; Wang et al., 2001) S6K 
functions to generally increase cap dependent translation through the phosphorylation of eIF4B, 
which in turn activates the eIF4A helicase and unwinds highly structured and long mRNA 
5’UTRs for efficient translation initiation (Raught et al., 2004; Shahbazian et al., 2006). 
Although not all mRNA 5’ UTRs are highly structured, a subset encode proteins with critical 
functions including HIF1α, Cyclin D1, and MYC. (Fig 1.9) 
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Figure 1.9. S6K regulates the translation of several types of mRNAs. Substrates of activated 
S6K are involved in translation initiation and translation elongation. The ribosomal protein S6 is 
the best-studied S6K substrate, and is phosphorylated at several residues by S6K. Upon S6 
phosphorylation, S6K also phosphorylates eIF4B, recruiting it to eIF4A, enhancing eIF4A 
helicase activity. Phosphorylation of eIF4B also increases its recruitment to the scaffolding 
complex eIF3, to which the 40S ribosome later binds. S6K regulates translation elongation by 
phosphorylating the elongation factor eEF2K. This phosphorylation event promotes translation 
by facilitating the dephosphorylation and activation of eEF2. mTORC1/S6K regulates both 
general cap dependent translation, but has also been shown to increase the translation of specific 
mRNA species. The translation of mRNAs that have 5’UTRs much longer than the average 
length of 150 base pairs, and thus potentially are more structured are increased. The translation 
of 5’TOP mRNAs are increased, although more recent data suggest that this is mTORC1 
dependent but independent of S6K.  
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4E-BP1 
 The eukaryotic translation initiation factor 4E binding protein-1 (4E-BP1), is another 
downstream effector of mTORC1 signaling. 4E-BP1 negatively regulates the association of the 
eukaryotic translation initiation factor eIF4E with the 5’ mRNA cap (Fig 1.10). eIF4E is present  
in rate limiting quantities within the cell. Thus, eIF4E association with the 5’ mRNA cap and 
initiating the recruitment of the remainder of the eIF3 complex is considered a key regulatory 
event in translation initiation (Jackson et al., 2010). 4E-BP1 can be phosphorylated at multiple 
sites. Hypophosphorylated 4E-BP1 binds eIF4E tightly, preventing its association with the 5’ 
mRNA cap. Sequential phosphorylation at multiple residues leads to hyperphosphorylated 4E-
BP1 and eIF4E dissociation, relieving eIF4E repression and freeing eIF4E to associate with the 
5’ mRNA cap and participate in translation initiation. 4E-BP1 is basally phosphorylated at 
T37/46, which occurs in vitro by mTORC1, priming it for subsequent phosphorylation (Gingras 
et al., 1999; Mothe-Satney et al., 2000a). Subsequent serum-induced phosphorylation at T70 and 
S65 promote the 4E-BP1 dissociation from eIF4E, both of which are regulated by PI3K and 
mTORC1 activity (Gingras et al., 2001; Mothe-Satney et al., 2000b). 
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Figure 1.10. Phosphorylation of the eukaryotic translation initiation factor 4E binding 
protein (4E-BP1) increases cap dependent translation initiation by relieving eIF4E 
repression. mTORC1 hyperphosphorylates 4E-BP1 at four residues. Hypophosphorylated 4E-
BP1 associates with the translation initiation factor eIF4E such that it cannot bind the 5’ mRNA 
cap. 4E-BP1 T37/46 phosphorylation are priming events. mTORC1 next phosphorylates T70, 
and lastly S65, fully activating 4E-BP1. Hyperphosphorylated 4E-BP1 is no longer able to 
associate with eIF4E. eIF4E then binds the 5’mRNA cap and recruits eIF4G and the eIF3 
complex to initiate translation.  
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1.4  DNA VIRUSES AND THE REGULATION OF THE RPTK/PI3K/AKT/mTORC1 
SIGNALING AXIS 
 
 Multiple DNA tumor viruses dysregulate the RPTK-AKT-mTORC1 signaling axis. 
Polyomaviruses, including simian virus 40 (SV40) and murine polyomavirus, activate signaling 
cascades that are important for translational regulation. The plasma membrane bound 
polyomavirus middle T antigen (mT) activates AKT and other downstream mitogenic pathways 
through association with and subsequent recruitment of the Class I PI3K p85 regulatory subunit 
(Ichaso and Dilworth, 2001; Kaplan et al., 1987; Summers et al., 1998; Whitman et al., 1985). 
Additionally, polyomavirus mT physically associates with insulin receptor and IGF-1R and 
recruits Src, increasing AKT and ERK1/2 activity (Novosyadlyy et al., 2009). Polyomavirus 
small T (sT) antigens relieve repression of mitogenic signaling by functioning as a subunit of 
PP2A (Rodriguez-Viciana et al., 2006). Recently the first human cancer-associated 
polyomavirus, Merkel cell polyomavirus (MCPyV) was identified from Merkel cell carcinoma, a 
rare but highly lethal form of cancer. Like SV40 sT and polyomavirus mT proteins, MCPyV sT 
activates signaling downstream of AKT and mTORC1 (Shuda et al., 2011). MCPyV St activates 
4E-BP1, contributing to its transforming capacity, although the mechanism of activation is 
unclear (Shuda et al., 2011). 
 Adenoviruses also activate growth factor associated signaling cascades that increase 
cellular translational output. The adenovirus early proteins E4Orf1 and E4Orf4 have been 
reported to activate PI3K and mTORC1 signaling as indicated by AKT and S6K 
phosphorylation, respectively (O'Shea et al., 2005). In combination, E4Orf1 and E4Orf4 can 
activate signaling downstream of mTORC1 independent of growth factors and nutrients, which 
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is similar to what we have described in HPV16 E6 expressing cells in subsequent chapters of this 
dissertation (O'Shea et al., 2005; Spangle and Munger, 2010). Although it appears that 
adenovirus E4Orf1 and E4Orf4 have some overlapping functions including promoting assembly 
of the 5’ mRNA cap to enhance cap dependent translation initiation, only E4Orf4 binds and 
relocalizes PP2A, causing S6K phosphorylation and activation (O'Shea et al., 2005). 
Additionally, the adenoviral early protein E1A has been reported to regulate translation by 
increasing 4E-BP1 hyperphosphorylation (Gingras and Sonenberg, 1997) 
 Within the Herpesviridae family, proteins with similar functions in activating metabolic 
signaling pathways have been identified. During infection, human cytomegalovirus engages 
cellular receptors, causing AKT activation, which is sustained by the expression of immediate 
early genes IE1 or IE2 (Yu and Alwine, 2002). Similarly, the Epstein-Barr virus encoded 
oncogenes LMP1 and LMP2A activate AKT. LMP2A also activates mTORC1 and increases the 
phosphorylation and activation of 4E-BP1 but not S6K (Fukuda and Longnecker, 2007; Moody 
et al., 2005; Scholle et al., 2000; Shair et al., 2007; Swart et al., 2000). LMP1 may also 
phosphorylate STAT3, promoting the formation of p50/Bcl-3 complexes and increasing EGFR 
transcription (Kung and Raab-Traub, 2008).  
 RNA viruses also engage in activities that increase viral RNA translation and may 
contribute to the shut off of host mRNA translation. Such examples include viruses belonging to 
the picornaviridae and the orthomyxoviridae families. The genome of Polioviruses 
(Picornaviridae) encodes and utilizes an internal ribosomal site (IRES) for translation initiation, 
eliminating the need to initiate canonical cap-dependent translation in the absence of (1) a 5’ 
mRNA cap; and (2) appropriate upstream signals from mTORC1/4E-BP1. Alternatively, each 
genome segment from the Influenzavirus (orthomyxoviridae) lacks a 5’ mRNA cap and cleaves 
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the 5’mRNA cap from host transcripts and the subsequently fuses the displaced 5’mRNA cap 
onto the viral RNA genome segment, causing enhanced viral RNA translation and a reduction in 
the translation of host transcripts.  
 One cause of viral induced mTORC1 activation is the increase in cap dependent 
translation. The maintenance of cellular translation is of general importance for a successful viral 
replication and progeny virion production. It is beneficial for viruses to encode proteins that 
maintain or dysregulate the activation of cellular pathways that control protein synthesis. 
Keeping these pathways activated is beneficial for cellular and viral protein translation. This may 
promote viral genome replication and support the translation of viral proteins necessary for 
virion packing and encapsidation. Further, the sustained activation of translation may also enable 
the translation of viral proteins with more diverse functions such as virally encoded proteins 
important for host immune evasion or shutoff. The cellular immune response to viral infection 
emphasizes the importance of protein synthesis on infection, as the innate immune system can 
also respond by immune system shutoff and activating PKR. 
 Maintaining a replication competent cellular milieu with abundant amino acids and 
energy is likely very important for human papillomaviruses given infection is initiated in the 
basal epithelium with nutrient rich conditions, but viral genome amplification and virion 
packaging only occurs in the outer layers of the differentiated epithelium. Under normal 
uninfected conditions, these cells are removed from the nutrient rich basal epithelium, with few 
opportunities for nutrient and gas exchange. Successful production of progeny virus is therefore 
dependent on the maintenance or temporary activation of metabolic pathways that promote 
translation and cell growth while minimizing apoptosis, and tightly regulating autophagy. The 
HPV oncoproteins may contribute independently to the coordinate regulation of these pathways. 
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HPV16 E7 has been reported to increase the formation of autophagic puncta in primary human 
foreskin keratinocytes (Zhou and Munger, 2009). HPV16 E7 has been reported to cause a shift in 
energy production from oxidative phosphorylation to anaerobic fermentation, i.e. the conversion 
of pyruvate to lactate. HPV16 E7 has reported to increase the dissociation of the tetrameric form 
of pyruvate kinase M2 (M2-PK) to a dimeric form. Dimeric M2-PK has a reduced affinity for 
phosphoenolpyruvate, which reduces its conversion to pyruvate for entrance into the citric acid 
cycle (Mazurek et al., 2001a; Zwerschke et al., 1999). As a result, following glycolysis, dimeric 
M2-PK shifts the equilibrium away from oxidative phosphorylation to fermentation i.e., 
generation of lactate from pyruvate, altogether a much less efficient mechanism to generate ATP. 
This phenomenon, first described by Otto Warburg, is commonly observed in oncogenesis. Thus, 
HPV16 E7 may cause metabolic reprogramming and reduce available ATP levels. It is tempting 
to speculate that HPV16 E6 overrides HPV E7 induced metabolic effects by turning on 
mTORC1 signaling. HPV16 E6 has been reported to activate mTORC1 signaling through the 
E6AP dependent degradation of the mTORC1 negative regulator TSC2 (Lu et al., 2004). 
Cervical carcinomas and high grade squamous intraepithelial lesions, which express high-risk 
HPV E6 and HPV E7 proteins, have increased activation of mTORC1 and S6K as indicated by 
immunohistochemistry (Feng et al., 2009; Oh et al., 2006). Moreover, the activation of 4E-BP1, 
mTORC1, and S6K in relevant HPV positive cervical cancer cell lines and patient derived 
specimens supports HPV16 E6 mediated activation of metabolic signaling pathways. Chapters in 
this dissertation suggest novel mechanisms for HPV16 E6 to activate mTORC1 through receptor 
protein tyrosine kinases and increasing cap dependent translation (Spangle and Munger, 2010; 
Zhou and Munger, 2009). 
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SUMMARY AND SIGNIFICANCE 
 HPV is associated with over 99 percent of all cases of cervical cancer, worldwide. HPV 
is also associated with other malignancies of the anogenital tract and with head and neck 
carcinomas most prominently oropharyngeal cancers. Unlike other types of solid human tumors, 
the genetic factors that contribute to HPV associated carcinogenesis are well defined. The HPV 
E6 and E7 oncoproteins are necessary and sufficient for the induction and maintenance of 
transformation. High-risk HPVs infect the nutrient rich cells of the epithelial basement 
membrane, where HPV genomes are maintained as an episome. The basal epithelial cells 
undergo asymmetric cell division, giving rise to the more differentiated, but also nutrient 
deprived layers of the outer squamous epithelium. Viral genome replication and progeny virion 
assembly is confined to the differentiated cells of the epithelium. It is well understood that the 
destabilization of pRb by high-risk HPV E7 maintains S phase competence and drives the cell 
cycle while the HPV E6 mediated destabilization of p53 eliminates cell cycle checkpoints 
enabling aberrant DNA replication. It is, however, unclear how completion of the viral life cycle 
can occur in the presumed absence of abundant nutrients and energy sources that are required for 
active DNA replication and then also stimulate protein synthesis.  
 HPV16 E7 has been reported to cause metabolic stress by switching energy generation 
from oxidative phosphorylation to anaerobic fermentation. Moreover, HPV16 E7 induces 
autophagy (Zhou and Munger, 2009). In the following chapters I first describe HPV16 E6 
mediated activation of mTORC1 and subsequent increase in protein synthesis. Initial efforts to 
delineate the mechanism of mTORC1 activation suggested that HPV16 E6 sustains AKT 
activation under conditions of nutrient deprivation. HPV16 E6 mediated AKT activation is 
attributed to the activation of PDK1 and mTORC2. A comparative analysis of cutaneous and 
 
 
 40 
high- and low-risk mucosal HPV E6 demonstrated that the ability to activate mTORC1 and 
increase cap dependent translation is shared amongst mucosal HPV E6 proteins. Mutational 
analysis mapped HPV E6 mediated activation of these pathways to the LXXLL binding motif. 
Several proteins associate with HPVE6 through an LXXLL motif, including the E3 ubiquitin 
ligase E6AP (UBE3A). Lastly I evaluated upstream signaling events that may cause mTORC1 
activation and increase cap dependent translation. I show that HPV16 E6 increases the activation 
of receptor protein tyrosine kinases including EGFR, IR, and IGFR. Receptor activation appears 
to be mediated by the increased internalization and degradation of phosphorylated receptor 
species. HPV16 E6 also associates with the signaling adaptor protein Grb2, which may be 
contributing to increased receptor activation, internalization, and degradation. These data have 
lead to the model that the biological properties of high-risk HPV E6 and HPV E7 are balanced to 
meet the metabolic needs during successful viral infection and/or genome replication (Zhou et 
al., 2009). Ultimately HPV E6 stimulates signaling cascades that promote protein synthesis and 
generates the cellular machinery that may be necessary for DNA replication as well as viral 
capsid proteins necessary for packaging.  
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Abstract 
The mammalian target of Rapamycin (mTOR) kinase acts as a cellular rheostat that integrates 
signals from a variety of cellular signal transduction pathways that sense growth factor and 
nutrient availability as well as intracellular energy status. It was previously reported that the 
human papillomavirus type 16 (HPV16) E6 oncoprotein may activate the S6 protein kinase 
(S6K) through binding and E6AP-mediated degradation of the mTOR inhibitor tuberous 
sclerosis complex 2 (TSC2) (Lu et al., 2004; Zheng et al., 2008). Our results confirmed that 
HPV16 E6 expression causes an increase in mTORC1 activity through enhanced 
phosphorylation of mTOR and activation of downstream signaling pathways S6K and eukaryotic 
initiation factor binding protein 1 (4E-BP1). However, we did not detect a decrease in TSC2 
levels in HPV16 E6-expressing cells. We discovered, however, that HPV16 E6 expression 
causes AKT activation through the upstream kinases PDK1 and mTORC2 under conditions of 
nutrient deprivation. We show that HPV16 E6 expression causes an increase in protein synthesis 
by enhancing translation initiation complex assembly at the 5’ mRNA cap and an increase in 
cap-dependent translation. The increase in cap-dependent translation likely results from HPV16 
E6-induced AKT/mTORC1 activation, as the assembly of the translation initiation complex and 
cap-dependent translation are Rapamycin sensitive. Lastly, coexpression of the HPV16 E6 and 
E7 oncoproteins does not affect HPV16 E6-induced activation of mTORC1 and cap-dependent 
translation. HPV16 E6-mediated activation of mTORC1 signaling and cap-dependent translation 
may be a mechanism to promote viral replication under conditions of limited nutrient supply in 
differentiated, HPV oncoprotein-expressing proliferating cells. 
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Introduction 
 HPVs initially infect basal epithelial cells, where the viral episome is maintained 
extrachromosomally at a low copy number. High-level viral genome replication and production 
of progeny virus is confined to the outer, terminally differentiated layers of the infected 
squamous epithelium, where metabolic activity of the host cells and available nutrients are 
presumably more limited. Moreover, it has been reported that HPV16 E7 expression induces the 
“Warburg effect”, a switch from an oxidative phosphorylation-based to a glycolytic mode of 
glucose metabolism (Mazurek et al., 2001a, b). This may trigger an autophagy-like process when 
HPV16 E7 is expressed in human keratinocytes (Zhou and Munger, 2009) to generate 
metabolites that can be used for energy consuming processes including viral replication.  
 The mammalian target of Rapamycin complex 1 (mTORC1) signaling cascade serves as 
a metabolic sensor, integrating a diverse array of signals, including nutrient and growth factor 
availability. mTORC1 signaling regulates a variety of cellular processes including cell growth, 
viability, and proliferation, at least in part through the activation of protein translation (reviewed 
in (Ma and Blenis, 2009). mTORC1 kinase activity is negatively regulated through TSC1/TSC2 
mediated inhibition of the Ras homologue and mTOR activator Rheb (Zhang et al., 2003). TSC2 
itself is regulated through phosphorylation at eight or more sites by a diverse set of kinases 
including AKT (reviewed in reference (Ma and Blenis, 2009)). TSC2 phosphorylation by AKT 
at multiple sites inhibits TSC2, releasing mTOR from repression for subsequent activation of 
downstream signaling cascades that regulate protein translation; the ribosomal S6 protein kinase 
(S6K) and the eukaryotic initiation factor binding protein 1 (4E-BP1) pathways ((Inoki et al., 
2002), reviewed in (Ma and Blenis, 2009; Mamane et al., 2006)) 
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Previous studies have suggested that HPV16 E6 may activate mTORC1 signaling. A yeast two-
hybrid screen with E6 as the bait initially identified peptides corresponding to TSC2 and the 
homologous protein E6TP1 (Elston et al., 1998; Gao et al., 1999). Subsequent studies suggested 
that HPV16 E6 may bind and degrade TSC2 through an E6AP dependent mechanism, thereby 
activating mTORC1 (Lu et al., 2004; Zheng et al., 2008). These latter studies, however, were 
performed by transient transfection, and it remained unclear whether in cells with stable 
expression of E6, TSC2 levels are decreased, whether increased mTORC1 activity can be 
detected, whether this is relevant in the context of a nutrient deprived state, and if the increase in 
mTORC1 signaling in E6 expressing cells results in a corresponding increase in cap-dependent 
translation. 
 Here we report that HPV16 E6 expression does not reduce the steady state levels of 
TSC2, but instead HPV16 E6 activates mTORC1 as a result of increased AKT activity through 
the PDK1 and mTORC2 pathways. Moreover, mTORC1 activity is sustained in HPV16 E6 
expressing primary human foreskin keratinocyte populations under conditions of nutrient 
deprivation. Furthermore, HPV16 E6 expression causes activation of the S6K and 4E-BP1 
translation regulatory pathways, causes enhanced binding of translation initiation factors to a 
synthetic cap structure and increases cap dependent translation as measured by luciferase 
reporter assays. The HPV16 E6 mediated increases in binding of translation initiation factors to 
the cap and cap-dependent translation are Rapamycin sensitive, suggesting a connection between 
HPV16 E6 mediated increase in mTORC1 activation and enhanced cap dependent translation. 
Lastly, co-expression the HPV E7 oncoprotein does not affect these processes, suggesting that 
the ability of E6 to activate mTORC1 signaling and cap-dependent translation may be relevant in 
the context of an HPV infection. 
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Materials and Methods 
Plasmids. Plasmids used in this study include the retroviral vectors pLXSN (control), pLXSN 
HPV16 E6, pLXSN HPV16 E7, pLXSN HPV16 E6/E7 (Halbert et al., 1992), a set of human ß-
actin promoter driven expression vectors, p1318 (control), p1435 (HPV16 E7), p1436 (HPV16 
E6), p1321 (HPV16 E6/E7), and p1319 (HPV16 early coding region) (Munger et al., 1989), a 
pCMV Bam Neo based vector (Baker et al., 1990; Munger et al., 1989). The pFR_CrPV_xb 
bicistronic firefly/Renilla luciferase reporter plasmid (Petersen et al., 2006) was used for 
translation reporter assays and was obtained from Phil Sharp through Addgene (plasmid 11509).  
 
Cells lines and Culture. 293, 293T and U2OS cells (ATCC) were maintained in Dulbecco’s 
modified Eagle Media (DMEM) (Invitrogen) supplemented with 10% fetal bovine serum (FBS), 
50U/ml penicillin, and 50µg/ml streptomycin. RKO pC cells (pCMV control cells) and RKO 
10.2 (HPV16 E6-expressing) cells (Kessis et al., 1993), were generously provided by Kathleen 
Cho (University of Michigan, Ann Arbor, MI) and maintained in modified McCoy’s medium 
(Invitrogen) supplemented with 10% newborn calf serum (NCS), 50 U/ml penicillin, 50 µg/ml 
streptomycin, and 500 µg/ml G418. Primary human foreskin keratinocytes (HFKs) were isolated 
from anonymous newborn circumcisions as previously described (McLaughlin-Drubin et al., 
2008) and maintained in Keratinocyte Serum Free Media (KSFM) supplemented with human 
recombinant epidermal growth factor 1-53, bovine pituitary extract (Invitrogen), 50 U/ml 
penicillin, 50 µg/ml streptomycin, 20 µg/ml gentamycin, and 1 µg/ml amphotericin B. All 
experiments were performed with HFKs passaged less than ten times. For growth factor 
withdrawal experiments, HFKs were seeded onto poly-d-lysine coated plates (BD). For nutrient 
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deprivation assays, 90% confluent HFKs were washed twice with phosphate buffered saline 
(PBS), followed by incubation in PBS for 15-30 minutes prior to lysis.  
 
Western blotting and Antibodies. Cell lysates were prepared by incubating the cells in ML 
buffer (McLaughlin-Drubin et al., 2008) (300 mM NaCl, 0.5% Nonidet P-40 [NP-40], 20 mM 
Tris-HCl [pH 8.0], 1 mM EDTA supplemented with one Complete EDTA-free protease inhibitor 
cocktail tablet (Roche) per 25 ml lysis buffer and one PhosSTOP phosphatase inhibitor cocktail 
tablet (Roche) per 5 ml lysis buffer. Cells were then scraped and lysates cleared by centrifugation 
at 16,110 x g for 10 minutes at 4°C. Protein concentrations were determined using the Bradford 
method (Bio-Rad). Proteins were separated by SDS-polyacrylamide electrophoresis (SDS-
PAGE) and transferred onto polyvinylidene difluoride membranes (Immobilon-P; Millipore). 
The membranes were blocked in 5% nonfat dry milk in TBST (137 mM NaCl, 2.7 mM KCl, 25 
mM Tris [pH 7.4], 0.1% Tween-20) and probed with the appropriate antibody. Primary 
antibodies were used at a 1:1000 dilution, unless otherwise specified: ß-actin (#1501; 
Chemicon), p53 (Ab-6; Calbiochem), SGK1 (ab43606; Abcam), Firefly Luciferase (ab498; 
Abcam), Renilla Luciferase (PM047; MBL), SGK1 S422 (1:500, sc-16745-R, Santa Cruz), Flag 
(#3165, Sigma), mTOR (#2972), mTOR S2448 (#2971), S6K (#9202), S6K T389 (#9206), S6 
(#2317), S6 S235/36 (#4858), S6 240/44 (#4838), TSC2 (#3635), 4E-BP1 (#9644), 4E-BP1 
T37/46 (#2855), 4E-BP1 S65 (#9451), 4E-BP1 T70 (#9455), Akt (#9272), Akt S473 (#4060), 
Akt T308 (#9275), eIF4G (#2498), and SGK1 T256 (#2939), all from Cell Signaling 
Technology. Secondary anti-mouse and anti-rabbit antibodies conjugated to horseradish 
peroxidase (Amersham) were used at 1:10,000 and 1:15,000 dilutions, respectively. Proteins 
were visualized by enhanced chemiluminescence (Perkin Elmer) and exposed on Kodak BioMax 
 
 
 48 
XAR film or electronically acquired with a Kodak Image Station 4000R equipped with Kodak 
Imaging Software, version 4.0.  
 
7-Methyl GTP binding assays. Proteins that interact with a synthetic 7-Methyl-GTP RNA cap 
structure were purified as previously described (Kumar et al., 2000). In brief, 250 µg aliquots of 
cell lysates were precleared with 25 µl sepharose pre-washed in Buffer D for one hour and 
combined with 30 µl of a 50% slurry of 7-methyl-GTP-Sepharose (GE Healthcare, UK) pre-
washed in Buffer D (50 mM HEPES pH 7.4, 40 mM NaCl, 2 mM EDTA, 0.1% Triton X100), 
and incubated for one hour at 4°C. After washing the resin three times with Buffer D, samples 
were analyzed by SDS PAGE and immunoblotting.  
 
Transfections and luciferase assays. U2OS cells were transfected in six-well plates in triplicate 
for luciferase reporter assays using FuGene6 reagent (Roche). One µg pFR_CrPV_xb was 
cotransfected with two µg p1318, p1435, p1436, p1319, or p1321. HFKs were transfected in six-
well plates in triplicate (seeded at 300,000 cells/well) using FuGene6 reagent (Roche) with 0.5 
µg pFR_CrPV_xb and 1.5 µg of the previously described plasmids. Both U2OS cells and HFKs 
were lysed forty-eight hrs post transfection in 450 µl passive lysis buffer (dual luciferase reporter 
kit; Promega) per well. The supernatants were subjected to the dual luciferase reporter assay. The 
fold change in activity was determined by calculating the ratio of firefly luciferase activity to 
renilla luciferase activity as compared to control vector transfected cells. At least three 
independent experiments were performed.  
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Results 
mTORC1 signaling is increased in HPV16 E6 expressing RKO cells. The tuberous sclerosis 
tumor suppressor 2 (TSC2), sometimes also referred to as tuberin, is a negative regulator of 
mTORC1 activity (Figure 1A). Previous studies suggested the HPV16 E6 oncoprotein may be 
able to associate with TSC2 (Elston et al., 1998). Moreover, transient expression studies in HEK 
293 cells suggested that HPV16 E6 not only binds to but can also enhance E6AP mediated TSC2 
degradation, thereby activating mTORC1 signaling (Lu et al., 2004). Based on these findings we 
evaluated mTORC1 signaling in RKO human colon cancer cells with stable expression of 
HPV16 E6 (RKO E6) (Kessis et al., 1993) as well as control RKO cells. RKO cells have intact 
p53 and pRB tumor suppressor pathways and previous work has shown that p53 activities are 
lost upon E6 expression (Havre et al., 1995). Consistent with the published results, RKO E6 cells 
showed evidence of increased mTORC1 activity as evaluated by phosphorylation of the mTOR 
kinase at serine residue (S) 2448 (Figure 1B). TSC2 steady state levels, however, were not 
decreased in RKO E6 cells as compared to control cells. In contrast, p53 tumor suppressor levels 
were dramatically decreased in RKO E6 cells, indicating that there are no defects in E6/E6AP 
induced proteasomal degradation in these cells (Fig 2.1A). Similarly, HPV16 E6 expression did 
not reduce TSC2 levels in multiple experiments with several different primary human foreskin 
keratinocyte (HFK) populations (Figure 2.1F) or upon transient transfection of HPV16 E6 in 
HEK293 or U2OS cells (data not shown). Moreover, we did not detect association of HPV16 E6 
with TSC2 by immunoprecipitation experiments (data not shown). 
 To determine whether the observed increased mTOR S2448 phosphorylation causes 
increased mTORC1 activity we evaluated the phosphorylation status of downstream 
phosphorylation targets in RKO E6 and control RKO cells. The eukaryotic translation 
 
 
 50 
 
 
 
 
 
Figure 2.1 HPV16 E6 expression activates mTOR1, 4E-BP1, S6K, and S6 phosphorylation 
through a TSC2-independent mechanism. (A) Schematic diagram of mTORC1 signaling. See 
text for details. (B to E) Western blot analysis of mTOR phosphorylation (B), TSC2 expression 
(with quantifications shown below) (C), 4E-BP1 phosphorylation (D), and S6K and S6 
phosphorylation (E) in HPV16 E6-expressing and control RKO cells. A p53 blot is shown in 
panel B to document HPV16 E6 expression, and actin blots are shown as loading controls. Also 
shown are results from Western blot analysis of 4E-BP1 (F) and TSC2 expression and S6K and 
S6 phosphorylation (G) (with quantifications shown below) in HPV16 E6-expressing and control 
(LX) primary human foreskin keratinocyte cultures (HFKs). A p53 blot is shown in panel F to 
document HPV16 E6 expression, and actin blots are shown as loading controls.  
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initiation factor 4E binding protein-1 (4E-BP1) regulates formation of a functional mRNA cap 
structure. Hypophosphorylated 4E-BP1 inhibits functional interaction of eukaryotic translation 
initiation factor 4E (eIF4E) with the 5’ mRNA cap structure (reviewed in (Jackson et al., 2010)). 
Upon mTORC1 activation, 4E-BP1 is sequentially phosphorylated by mTOR at at least four 
residues. 4E-BP1 phosphorylation at threonine (T)37 and T46 serve as priming phosphorylation 
events that are required for subsequent phosphorylation and activation at T70 and S65. 
Hyperphosphorylated 4E-BP1 is released from the cap, allowing for recruitment of eIF4E and 
other translational initiation factors to the 5’ mRNA cap (Gingras et al., 2001). Consistent with 
increased mTORC1 activity in RKO E6 cells, phosphorylation of 4E-BP1 at T37/46, S65 and 
T70 was strikingly increased in these cells (Fig 2.1C).  
 The S6 kinase (S6K) is another well-established mTORC1 substrate. Once 
phosphorylated at T389 by mTORC1, S6K activates and phosphorylates the ribosomal subunit 6 
(S6), an important factor in ribosome biogenesis and a subunit of the 40S ribosome, at serines 
235, 236, 240 and 244 (Ferrari et al., 1991). Phosphorylated S6 is incorporated into the 40S 
ribosome at the mRNA binding site and has been correlated with an increase in protein synthesis 
(reviewed in (Jastrzebski et al., 2007)). Phosphorylation of S6K at T389 and its substrate S6 at 
S235/236 and S240/244 was strikingly increased in RKO E6 cells as compared to control RKO 
cells (Fig. 2.1D). These results further support the notion that HPV16 E6 expression in RKO 
cells causes increased mTORC1 signaling.  
 To ensure that the observed activation of mTORC1 by HPV16 E6 is not specific to the 
RKO cell line, we performed similar experiments in HPV16 E6 expressing primary HFK 
populations. As compared to control vector transfected HFKs, HFK E6 cells showed increased 
phosphorylation of 4E-BP1 (Fig. 2.1E) as well as S6K and its substrate S6, while TSC2 steady 
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state levels were unchanged (Fig 2.1F). Similar results were obtained with a second 
independently derived set of HFK E6 and HFK control populations.  Of note, we also 
consistently found evidence for increased S6K and S6 steady state levels in HKF E6 populations, 
which in combination with mTORC1 activation (as evidenced by increased 4E-BP1 
phosphorylation) may contribute to the increased detection of S6 phosphorylation at S235/36 and 
S240/44 (Fig. 2.1E, F).  
 In order to confirm that the observed effects on 4E-BP1, S6K and S6 phosphorylation are 
a result of mTORC1 activation, we treated RKO E6 and RKO control cells with 100 nM 
Rapamycin for one hour. Phosphorylation of S6K, S6 and 4E-BP1 was decreased in RKO E6 
cells, consistent with our model that these phosphorylation events are a result of mTORC1 
activation (Figure 2.2).  
 In combination these results show that HPV16 E6 expression causes increases mTORC1 
activity through a mechanism that does not appear to involve TSC2 degradation.  
 
HPV16 E6 mediated mTORC1 activation is mediated by PDK1 and mTORC2 activation. 
Since we found no evidence for decreases in TSC2 steady state levels in HPV16 E6 expressing 
cells (Figs 2.1B, F and data not shown) and we did not detect an association of HPV16 E6 with 
TSC2 by immunoprecipitation experiments (data not shown), we evaluated alternative signaling 
events upstream of mTORC1 activation.  
 Members of the AKT serine/threonine kinase family are important activators of 
mTORC1 signaling (Pearce et al., 2010). 3-Phosphoinositide-dependent kinase 1 (PDK1) is 
downstream of Phosphoinositide 3-kinase (PI3K) and activates AKT by T308 phosphorylation, 
which in turn causes mTORC1 activation (Alessi et al., 1997) and, the mTORC2 kinase complex  
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Figure 2.2. HPV16 E6 expression causes increased S6K, S6, and 4EBP1 phosphorylation 
through mTORC1 activation. Western blot analysis of mTORC1 downstream signaling 
components in RKO control and HPV16 E6-expressing RKO cells, treated with dimethyl 
sulfoxide (DMSO) or 100 nM Rapamycin (Rap) for 1 h prior to lysis. Relative levels of 
unphosphorylated and phosphorylated species of S6 and 4EBP1 are indicated. Actin blots are 
shown as loading controls. 
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activates AKT by S473 phosphorylation (Fig 2.3A). Hence we assessed AKT T308 and S422 
phosphorylation in RKO E6 and RKO control cells. RKO E6 cells showed increased AKT T308 
phosphorylation as compared to control RKO cells. In contrast, RKO E6 and RKO control cells 
each showed high levels of AKT S473 phosphorylation. To confirm that PDK1 activity is 
increased in RKO E6 cells, we also evaluated T256 phosphorylation of the PDK1 substrate 
serum- and glucocorticoid-inducible kinase 1 (SGK1). Consistent with increased PDK1 activity, 
SGK1 T256 phosphorylation was increased in RKO E6 as compared to RKO control cells (Fig 
2.3B).  
 Given that RKO cells are a colon cancer derived line that may harbor mutations, which 
may cause aberrant AKT phosphorylation, we next evaluated AKT T308 and S473 
phosphorylation in HPV16 E6 expressing primary HFK and control HFK populations. When 
grown in growth factor containing keratinocyte serum free medium, AKT was phosphorylated at 
T308 and S473 even in control HFKs (data not shown). To assess AKT phosphorylation of cells 
in a nutrient deprived state, we incubated the cells in phosphate buffered saline (PBS) for 15 or 
30 minutes. Under these conditions of nutrient deprivation, we detected increased AKT S473 and 
T308 phosphorylation in HFK E6 as compared to control HFKs (Fig 2.3C). Similar results were 
obtained when HFKs were treated with Earle’s balanced salt solution containing 1 mg/ml 
glucose (data not shown). These results suggest that AKT S473 and T308 phosphorylation is 
maintained in HPV16 E6 expressing HFKs under conditions of limited growth factor availability 
 To assess whether sustained AKT S473 and T308 phosphorylation in HPV16 E6 
expressing HFKs is a result of sustained PDK1 and mTORC2 activity, respectively, we assessed 
SGK1 phosphorylation. PDK1 phosphorylates SGK1 at T256, whereas mTORC2 phosphorylates 
SGK1 at S422. Consistent with our model, SGK1 S256 and S422 phosphorylation was sustained  
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Figure 2.3. HPV16 E6 expression causes AKT activation. (A) Schematic diagram of AKT 
phosphorylation through PDK1 and mTORC2 pathways. (B) Western blot analysis of AKT 
phosphorylation in control and HPV16 E6-expressing RKO cells. SGK1 is phosphorylated by 
PDK1 at T256 and is included as a control for PDK1 activation in HPV16 E6-expressing RKO 
cells. Actin blots are shown as loading controls. (C) Sustained AKT activation in control (LX) 
and HPV16 E6-expressing HFK populations under conditions of nutrient deprivation. SGK1 is 
phosphorylated by PDK1 at T256 and by mTORC2 at S422 and is included as a control for 
PDK1 and mTORC2 activation in HPV16 E6-expressing HFKs. Actin blots are shown as 
loading controls. (D) Sustained S6K activation in control (LX) and HPV16 E6-expressing HFK 
populations under conditions of nutrient deprivation. A TSC2 blot with quantification is shown 
to document similar expression in the two cell populations after nutrient deprivation; an actin 
blot is shown as a loading control. 
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in HFK E6 cells under conditions of nutrient deprivation (Fig. 2.3C). Moreover, S6K T389 
phosphorylation was detected in HFK E6 but not in HFK control cells under conditions of 
nutrient deprivation. Of note, TSC2 levels were not decreased in HFK E6 cells undergoing 
growth factor restriction as a result of PBS treatment (Fig. 2.3D).  
 These results suggest that HPV16 E6 expression activates mTORC1 at least in part 
through PDK1 and mTORC2 mediated AKT phosphorylation and that this activation is sustained 
during conditions of nutrient deprivation.  
 
HPV16 E6 expression increases the assembly of the translation initiation complex at the 
mRNA cap. 4E-BP1 phosphorylation by mTORC1 allows association of translation initiation 
factors to the 5’ mRNA cap structure thereby activating cap-dependent translation (Jackson et 
al., 2010). To evaluate whether HPV16 E6 expression enhances the assembly of the translation 
initiation complex at the mRNA cap, we performed in vitro cap-binding assays. Lysates from 
RKO E6 and RKO control cells were incubated with 7-Methyl GTP Sepharose and association of 
initiation factor eIF4G was assessed by Western blotting. As expected, we detected increased 
eIF4G binding to the synthetic cap structure with lysates from RKO E6 cells as compared to 
RKO control cells (Fig 2.4). To determine whether the observed increase in eIF4G binding 
observed with RKO E6 cell lysates is caused by increased mTORC1 activity, we also performed 
experiments with cell lysates prepared from RKO E6 and RKO control cells that were treated 
with the mTORC1 inhibitor Rapamycin for 1 hour prior to harvesting. Inhibition of mTORC1 
abrogated eIF4G binding to the cap structure in RKO E6 cells (Fig. 2.4).  
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Figure 2.4. Increased binding of the translation initiation factor eIF4G to a synthetic 7-
methyl-GTP (7MeGTP) mRNA cap structure in HPV16 E6-expressing RKO cell lysates, 
which is sensitive to Rapamycin treatment. Control and HPV16 E6-expressing RKO cells 
were treated with dimethyl sulfoxide (DMSO) or 100 nM Rapamycin (Rap) for 1 h prior to lysis. 
Cap binding assays were performed as described in Materials and Methods. Levels of eIF4G in a 
50-µg sample, representing 25% of the cap-binding reaction, together with an actin blot, are 
shown in the top panel (Input). Blot results for cap-bound eIF4G are shown in the bottom panel. 
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 These results show that binding of translation initiation factors to the 5’ mRNA cap is 
increased in HPV16 E6 expressing cells and that this most likely represents a consequence of 
mTORC1 activation. 
 
HPV16 E6 expression causes increased translation of capped mRNA. Given the observed 
increased binding of eIF4G to a synthetic cap in vitro with RKO E6 cells we next determined if 
HPV16 E6 expression might increase cap dependent translation. The U2OS human osteosarcoma 
line was used for the initial experiments because it is contains wild type p53 and is highly 
transfectable.  We performed dual luciferase reporter assays utilizing a bicistronic reporter 
vector, pFR_CrPV_xb (Petersen et al., 2006), that drives expression of the firefly and renilla 
luciferase genes from a minimal thymidine kinase promoter. Firefly luciferase is translated by a 
cap dependent mechanism, whereas translation of renilla luciferase is through a cap-independent 
mechanism from a cricket paralysis virus (CrPV) internal ribosomal entry site (IRES) (Fig. 2.5A, 
upper panel). Co-expression of HPV16 E6 caused a 3.56±0.68 fold increase in firefly luciferase 
activity compared to control vector cotransfection. In contrast renilla luciferase activity was only 
increased 1.22±0.24 fold compared to vector cotransfection. When normalized to Renilla 
luciferase activity, HPV16 E6 co-transfection caused a statistically significant 2.92±0.33 fold (p 
<0.0001) increase in firefly luciferase activity (Fig 2.5A, lower panels) as compared to vector 
transfected cells. To confirm that the HPV16 E6 mediated increase in cap dependent translation 
is not a result of transcriptional regulation or aberrant splicing of the bicistronic mRNA, we 
performed quantitative real time reverse transcription PCR for firefly and Renilla luciferases. 
These experiments showed that the mRNA levels of firefly and Renilla luciferase were 
unchanged (data not shown). Moreover, we also directly assessed steady state levels of firefly  
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Figure 2.5. HPV16 E6 expression causes as increase in cap-dependent translation, which is 
sensitive to Rapamycin treatment. (A) Diagram of bicistronic firefly Renilla reporter plasmid, 
pFR_CrPV_xb, used for these experiments. Firefly luciferase is translated through a cap-
dependent mechanism, whereas Renilla luciferase is expressed from an internal ribosomal entry 
site (IRES) through a cap-independent mechanism (top). HPV16 E6 expression causes an 
increase in firefly but not Renilla luciferase activity (bottom). U2OS cells were transfected with 
control or HPV16 E6 expression vector, and lysates were processed for Renilla and firefly 
luciferase assays at 48 h posttransfection. The data are presented as the change of firefly and 
Renilla luciferase activities normalized to control vector-transfected cells (left and middle) and 
the fold change of normalized firefly compared to normalized Renilla luciferase activity 
(FF/Ren) (right). The bar graphs represent averages and standard deviations of four experiments, 
each performed in triplicate. The asterisk denotes statistical significance (P < 0.0001). (B) 
Western blot analysis of firefly and Renilla luciferase expression in U2OS cells transiently 
transfected with the indicated plasmids. U, untransfected cells. (C) Western blot analysis of 
eIF4G binding to a synthetic 7-methyl-GTP (7MeGTP) mRNA cap upon transient transfection of 
HPV16 E6 or control vector in U2OS cells. (D) HPV16 E6-mediated increase in cap-dependent 
translation is Rapamycin sensitive. U2OS cells were transfected with pFR_CrPV_xb and the 
indicated plasmids; 18 h prior to lysis, cells were treated with dimethyl sulfoxide (DMSO) or 100 
nM Rapamycin (Rap). The graph represents averages and standard deviations of four 
experiments, each performed in triplicate. (E) Western blot analysis of S6K phosphorylation in 
U2OS cells transiently transfected with HPV16 E6 or control vector. One hour prior to lysis, 
cells were treated with DMSO or 100 nM Rapamycin (Rap). Decreases in p53 levels are shown 
to document HPV16 E6 expression, and an actin blot is included as a loading control. (F) 
Transient transfection of HPV16 E6 activates cap-dependent translation in primary HFKs. Cells 
were transfected with pFR_CrPV_xb and the indicated plasmids and processed for Renilla and 
firefly luciferase assays at 48 h posttransfection. Firefly and Renilla luciferase activities were 
normalized to control vector-transfected cells and are presented as fold changes of normalized 
firefly relative to normalized Renilla luciferase activity. The bar graph represents the average and 
standard deviation of four experiments, each performed in triplicate; asterisks indicate statistical 
significance (P = 0.0001). 
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and Renilla luciferase proteins by Western blotting in U2OS cells that were transiently co-
transfected with the reporter plasmid and HPV16 E6 or the control vector.  Consistent with the 
enzyme activity results, expression of HPV16 E6 caused an increase in firefly but not Renilla 
luciferase levels (Fig 2.5B). We also performed cap binding experiments and similar to what we 
observed in RKO cells with stable expression of HPV16 E6 (Fig 2.4), transient expression of 
HPV16 E6 in U2OS cells caused increased association of eIF4G with a synthetic mRNA cap 
structure (Fig 2.5C). To confirm that mTORC1 signaling is necessary for the HPV16 E6 
mediated increase in cap dependent translation, dual luciferase reporter assays were performed 
with cells that were treated with 100 nM Rapamycin for 24 hours prior to harvesting.  These 
experiments results show that cap dependent translation is reduced in Rapamycin treated HPV16 
E6 as well as control vector transfected U2OS cells (Fig. 2..5D). To further confirm that HPV16 
E6 expression increases mTORC1 activity in U2OS cells and that this is inhibited by Rapamycin 
treatment, we also evaluated mTORC1 dependent S6K phosphorylation at T389. As expected, 
transient expression of HPV16 E6 caused S6K T389 phosphorylation that was reduced upon 
treatment with Rapamycin (Fig 2.5E). 
 To assess whether HPV16 E6 expression can cause increased cap-dependent translation 
in biologically relevant cells, we performed dual luciferase reporter assays in primary HFKs. 
Similar to what we observed with U2OS cells, co-transfection of HPV16 E6 caused a statistically 
significant 3.49±0.56 fold (p = 0.0001) increase in firefly luciferase as compared to control 
vector transfected cells. 
 Hence, HPV16 E6 expression can increase cap dependent translation and that mTORC1 
signaling is necessary for HPV16 E6 to modulate this process.  
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HPV16 E7 co-expression does not affect E6 induced activation of mTORC1 and cap 
dependent translation. Since HPV E6 and E7 oncoproteins are co-expressed in high-risk HPV 
associated lesions and cancers, we also evaluated mTORC1 signaling and cap dependent 
translation in HPV16 E6/E7 co-expressing cells. Phosphorylation of S6K at T389 by mTORC1 
was similarly increased in HFK populations with co-expression of HPV16 E6/E7 as in HPV16 
E6 expressing HFKs (Fig 2.6A). While expression of HPV16 E7 alone did not affect cap 
dependent, expression of HPV16 E6/E7 or the entire HPV16 early coding region in U2OS cells 
caused statistically significant (2.40±0.30 fold; p = 0.0013) and (2.36 ±0.23 fold; p = 0.0005) 
increases in firefly luciferase activity, respectively, similar to E6 co-transfection (2.97±0.31 fold; 
p < 0.0001) (Fig 2.6B).  
 Hence, HPV16 E7 co-expression does not markedly affect the ability of HPV16 E6 to 
activate mTORC1 activity and to augment cap dependent translation. 
 
Discussion 
 Previous reports have suggested that mTOR is activated in cells transiently expressing 
HPV16 E6, as indicated by an increase in S6K phosphorylation (Lu et al., 2004). This activity 
was attributed to the ability of HPV16 E6 to interact with and accelerate TSC2 degradation 
through an E6AP-dependent pathway (Zheng et al., 2008). In our experiments, TSC2 steady-
state levels were unaltered in HPV16 E6-expressing RKO cells and HFKs relative to that in 
control cells (Fig. 2.1C and G and Fig. 2.3D) and upon transient transfection of HPV16 E6 in 
HEK293 or U2OS cells (data not shown). Moreover, we did not detect association of HPV16 E6 
with TSC2 by immunoprecipitation experiments (data not shown). Hence, the reported E6AP-
mediated TSC2 degradation by HPV16 E6 is not a rate-limiting mechanism by which HPV16 E6  
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Figure 2.6. HPV16 E7 coexpression does not affect E6-induced S6K T389 phosphorylation 
or cap-dependent translation. (A) Western blot analysis of S6K T389 phosphorylation in HFK 
populations with stable expression of HPV16 E6 or HPV16 E6/E7 or control vector (LX)- 
transduced HFKs. An actin blot is shown as a loading control. (B) U2OS cells were transiently 
transfected with pFR_CrPV_xb and human _-actin-promoter-driven expression vectors for 
HPV16 E6, E7, E6/E7, the entire HPV16 early coding region (ER), or empty vector as a control 
and processed for Renilla and firefly luciferase assays at 48 h posttransfection. Firefly and 
Renilla luciferase activities were normalized to control vector-transfected cells and are presented 
as fold changes of normalized firefly relative to normalized Renilla luciferase activity. The bar 
represents the average and standard deviation of four experiments, each performed in triplicate; 
asterisks indicate statistical significance (P ≤ 0.0013). 
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expression causes mTORC1 activation in our experimental systems. 
 Here we report that cells with stable HPV16 E6 expression show evidence of active 
mTORC1 signaling, as evidenced by activation of the S6K and 4E-BP1 downstream cascades 
(Fig. 2.1). Most importantly, mTORC1 activity is sustained in HPV16 E6-expressing HFKs 
under conditions of nutrient deprivation (Fig. 2.3). In contrast to the previously published 
studies, we did not find any evidence for HPV16 E6 binding to TSC2 and/or lowering its steady-
state levels in the cells that we studied (Fig. 2.1C and G and Fig. 2.3D). Our results, however, 
suggest that HPV16 E6 expression causes mTORC1 activation, at least in part, through an AKT-
dependent mechanism. HPV16 E6 expression in primary human epithelial cells caused AKT 
activation through at least two distinct pathways, PDK1 and mTORC2 (Fig. 2.3C). As with 
mTORC1, our results show that AKT remains active in HPV16 E6-expressing HFKs under 
conditions of nutrient deprivation. HPV16 E6 expression also caused an increase in cap-
dependent translation (Fig. 2.5 and 2.6). This effect correlated with increased binding of 
translation initiation factors to a synthetic cap (Fig. 2.4 and 2.5C) and was inhibited by the 
mTORC1 inhibitor Rapamycin (Fig. 2.4 and Fig. 2.5D and E), suggesting that HPV16 E6-
mediated activation of translation may represent a consequence of mTORC1 activation. 
 
The HPV16 E6 and E7 oncoproteins play important functions during the viral life cycle (Flores 
et al., 2000; Thomas et al., 1999). Whereas HPVs initially infect proliferative basal epithelial 
cells, high-level viral genome replication and synthesis of viral progeny is restricted to terminally 
differentiated epithelial cells. The HPV E6 and E7 proteins contribute to the viral life cycle by 
uncoupling the process of epithelial cell differentiation from cell cycle withdrawal. The HPV E7 
protein, in particular, through degradation of the retinoblastoma tumor suppressor pRB and the 
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related family members p107 and p130, causes increased transcription of E2F-responsive genes, 
many of which encode enzymes that are rate limiting for cellular DNA synthesis (reviewed in 
references (Havre et al., 1995; Longworth and Laimins, 2004; McLaughlin-Drubin and Munger, 
2009a). Since HPV genome replication is acutely dependent on expression of host cellular 
replication proteins, one might envision that the ability of HPV16 E6 to activate translation of 
capped mRNAs represents an additional facet of this strategy in order to ensure adequate 
expression of cellular proteins that are necessary for viral genome replication. In addition, or 
alternatively, the ability of HPV16 E6 to activate protein synthesis may also contribute to high-
level synthesis of viral proteins, particularly the L1 and L2 capsid proteins that need to be 
abundantly expressed during productive viral replication. While there is no direct evidence for 
such a mechanism, translational control of the L1 capsid protein synthesis has been suggested by 
results from experiments where HPV31 episome-containing human epithelial cells were induced 
to undergo differentiation by suspension in methylcellulose-containing medium. Under these 
conditions, the authors observed abundant expression of L1-encoding mRNAs; however, there 
was no evidence for L1 protein synthesis (Ruesch et al., 1998). There is also evidence for 
translational regulation of early protein synthesis during epithelial cell differentiation in HPV-
positive cells. When HPV16-positive CaSki cervical carcinoma cells were cultured in 
methylcellulose- or CaCl2-containing medium to induce differentiation, increased expression of 
the E7 oncoprotein was observed. This increase was not at the level of transcription or protein 
stability, but rather the authors observed an increase in association of E7-encoding mRNAs to 
polysomes. These authors also observed sustained phosphorylation of 4E-BP1 upon 
differentiation of CaSki cells but not with HPV-negative HaCaT cells or primary HFKs. 
Moreover, mTORC1 inhibition by Rapamycin treatment reduced 4E-BP1 phosphorylation and 
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HPV16 E7 oncoprotein expression in these cells (Oh et al., 2006).  
 Increased mTOR S2448 and S6K T389 phosphorylation was also observed in HPV-
positive high-grade cervical squamous intraepithelial lesions (Feng et al., 2009), and there is also 
evidence for increased AKT phosphorylation in HPV-positive high-grade cervical squamous 
intraepithelial lesions (Menges et al., 2006). Given our results, it is tempting to speculate that 
these effects may at least in part represent a consequence of HPV16 E6 expression. 
 There are several reports that have shown that HPV16 E7 expression may also cause 
AKT activation (Menges et al., 2006; Pim et al., 2005). Several mechanisms have been proposed. 
HPV16 E7 may activate AKT by a pRB-dependent process, causing p27kip1 cytoplasmic 
accumulation and induction of cellular migration (Charette and McCance, 2007; Menges et al., 
2006). It has also been reported that HPV16 E7 can activate AKT independently of the pRB 
pathway through binding and inhibition of protein phosphatase 2A (Pim et al., 2005). In another 
study, however, cells that ectopically expressed HPV16 E7 and activated AKT showed a 
significantly higher rate of cellular proliferation and migration than either AKT or HPV16 E7-
expressing cells (Dow et al., 2008). These results would suggest that HPV16 E7 expression is not 
sufficient to fully activate AKT. While our experiments did not directly address the possible 
contribution of HPV16 E7 in AKT phosphorylation, there was no evidence that coexpression of 
HPV16 E6 and E7 caused an increase in mTORC1 signaling compared to HPV16 E6-expressing 
cells (Fig. 2.6A). Moreover, HPV16 E7 expression did not increase cap-dependent translation in 
our reporter assays (Fig. 2.6B). 
 Aberrant activation of AKT and mTORC1/2 is frequently observed in human cancers, 
and mTORC1 inhibitors have been evaluated as antineoplastic agents (Dowling et al., 2010; 
Menon and Manning, 2008; Shor et al., 2009). As the regulation of mTORC2 and its 
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downstream signaling pathways are increasingly understood, it is becoming apparent that the 
development of mTORC2-specific rictor inhibitors may also limit aberrant cellular growth and 
proliferation associated with human cancers. Hence it is conceivable that HPV16 E6-mediated 
AKT and mTORC1 and mTORC2 activation may also contribute to the transforming activities 
of HPV16 E6. If that was the case, inhibition of AKT and mTORC1 and/or mTORC2 should be 
evaluated as a therapeutic modality for HPV-associated lesions and cancers. 
 Our studies presented here were focused on AKT, but they do not exclude the possibility 
that HPV16 E6 expression may also affect mTORC1 activity through other pathways. Activation 
of the p53 tumor suppressor inhibits mTORC1 activity through sestrin 1 and sestrin 2. These two 
proteins are transcriptional targets of p53 and activate the AMP-responsive protein kinase 
(AMPK). AMPK phosphorylates and activates the mTOR inhibitor TSC2, thereby inhibiting 
mTOR (Budanov and Karin, 2008). E6/E6AP-mediated p53 degradation may therefore be 
predicted to short-circuit this regulatory loop and may contribute to sustained mTORC1 activity. 
 In addition, several PDZ proteins have been implicated in mTOR signaling. Inactivation 
of hScribble, which is targeted for degradation by HPV16 E6 (Nakagawa and Huibregtse, 2000), 
was shown to dysregulate MAP kinase signaling (Dow et al., 2008), which is predicted to 
activate mTORC1. More recently, Sabatini’s group identified a novel mTORC1/mTORC2-
associated inhibitor, DEPTOR, which contains a PDZ domain (Peterson et al., 2009) and thus 
may be a potential candidate for HPV16 E6 association and degradation. 
 Our results show that HPV16 E6 expression in primary epithelial cells activates AKT 
through at least two pathways, PDK1 and mTORC2, but the exact mechanism remains unknown. 
PDK1 is downstream of PI3K signaling. Several transforming viral proteins have been reported 
to activate PI3K, including SV40 small tumor antigen and the mouse polyomavirus middle tumor 
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antigen (reviewed in reference (Cheng et al., 2009)). Our future experiments will explore 
whether PI3K is activated by HPV16 E6 expression. A number of scenarios are possible, 
including activation of upstream signaling events, direct activation of PI3K, or inhibition of the 
phosphatase and tumor suppressor PTEN. Alternatively, HPV16 E6 may activate PDK1 by a 
PI3K-independent mechanism. Importantly, PDK1 also activates kinases other than AKT, 
including SGK1 (Fig. 2.3) and the Rho/Rac effector target PKN (Dong et al., 2000), a 
serine/threonine protein kinase, with a catalytic domain that is similar to that of protein kinase C. 
Interestingly, PKN has been reported to associate with high-risk HPV E6 proteins (Gao et al., 
2000). It will be interesting to determine the biological consequences of PDK1-mediated 
activation of kinases other than AKT. 
 Our results also suggest that HPV16 E6 activates mTORC2 signaling. Recent reports 
suggest that rictor expression is critical to the activation of mTORC2, with rictor overexpression 
activating the kinase complex and resulting in increased cell growth and motility in gliomas, and 
rictor short hairpin RNA (shRNA) knockdown inhibiting cellular proliferation in colon cancer 
cell lines (Masri et al., 2007; Roulin et al., 2010). Interestingly, the FOXO1 transcription factor 
regulates rictor transcription, which is in turn regulated by AKT (Chen et al., 2010). These 
authors suggest that FOXO1 balances mTORC1 inhibition and mTORC2 activation through two 
separable transcriptional activities of FOXO1: direct inhibition of mTORC1 through sestrin-3 
gene transcription and activation of mTORC2 through rictor gene transcription as a coactivator 
of a distinct transcriptional activating complex. Collectively this results in the maintenance of 
cellular energy homoeostasis even under conditions of nutrient stress. It is possible that the 
HPV16 E6 oncoprotein expression uncouples these processes through independent activation of 
mTORC1 and mTORC2. Alternatively, the PDZ protein and mTOR inhibitor DEPTOR 
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described above inhibits both mTORC1 and mTORC2 and thus should be evaluated as a 
potential candidate for HPV16 E6-mediated mTORC2 regulation. 
 We initiated these studies after we discovered that HPV16 E7 expression in normal 
human epithelial cells triggers an autophagy-like response (Zhou and Munger, 2009). Autophagy 
is a survival pathway that allows survival of cells under conditions of metabolic stress (reviewed 
in reference (Levine and Kroemer, 2008)). While we do not know the exact mechanism by which 
E7 expression may trigger such a response, it has been reported that HPV16 E7 expression 
causes the “Warburg effect,” a metabolic switch from an oxidative phosphorylation-based 
pathway to a glycolytic pathway (Zwerschke et al., 1999). While such a switch may offer a 
number of advantages for a rapidly proliferating cell, including efficient growth under conditions 
of lower oxygen concentrations and increased synthesis of metabolic precursors (Vander Heiden 
et al., 2009), conversion of glucose to lactate generates far less energy in the form of ATP than 
conversion to CO2 through oxidative phosphorylation. Particularly under conditions of limiting 
supply of nutrients, as may be the case in terminally differentiated cells in a squamous 
epithelium, autophagy may eventually lead to the demise of the cell. It is thus tempting to 
speculate that the ability of HPV16 E6 to activate mTORC1 signaling, a major regulator of 
autophagy, may function to dampen the autophagy response to HPV16 E7 expression and limited 
availability to nutrients. In such a model, expression of the HPV16 E6 protein would induce a 
cellular state of “blissful ignorance” and allow metabolically stressed, HPV-infected cells to 
survive long enough to support synthesis of viral progeny (Zhou et al., 2009). 
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The ability of mucosal Human Papillomavirus E6 proteins to increase protein synthesis is 
dependent on the integrity of the LXXLL binding motif 
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Abstract: 
The HPV16 E6 protein was previously shown to activate mTORC1 signaling and increase 
protein synthesis. It remains unclear whether HPV E6-mediated mTORC1 activation and 
subsequent events are important for viral replication and progeny virion production. Here we 
report that mucosal HPV E6 proteins from high- and low-risk HPV types activate protein 
synthesis by increasing cap dependent translation.  In contrast, however, the E6 proteins encoded 
by the cutaneous beta HPV5 and 8 do not. Utilizing previously characterized HPV16 E6 mutants, 
we identified the LXXLL binding motif as a contributing factor to cap dependent translation 
activation. The LXXLL binding motif mediates the association with cellular binding partners 
including the ubiquitin ligase E6AP and others through their LXXLL motif. Mutational analysis 
of HPV6b and HPV11 E6 identified analogous HPV6b E6 and HPV11 E6 LXXLL binding 
mutants that are also important in the low-risk HPV E6-mediated increase in protein synthesis. 
Moreover, high- and low-risk HPV E6 LXXLL binding mutants have reduced mTORC1 
activation. This shared function amongst mucosal HPV types suggests that activation of 
upstream metabolic signaling cascades such as mTORC1 may be important for the viral lifecycle 
in specific epithelial tissue types. Alternatively, in conjunction with other functions of high-risk 
HPV E6 that are absent in low-risk HPV E6, mTORC1 activation may contribute to 
transformation.  
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Introduction: 
Human papillomaviruses (HPVs) are small double stranded DNA viruses with a tropism for 
mucosal and cutaneous epithelial cells. Over 200 HPV types have been identified, of which 
approximately 30 infect the mucosal epithelium. Mucosal HPV types are further categorized by 
their propensity to cause lesions that can progress to carcinogenesis. Low-risk mucosal HPV 
types including HPV6b and HPV11 are most frequently associated with benign genital warts, 
whereas high-risk mucosal HPV types such as HPV16 and HPV18 cause squamous 
intraepithelial lesions that can progress to cancer. High-risk HPVs are associated with over 99% 
of cervical cancers and also with other anogenital cancers at a reduced prevalence. High-risk 
HPV infection is also associated with head and neck cancer, accounting for approximately 25% 
of all oral cancers, including those of the oropharynx and tonsil (reviewed in references 
((McLaughlin-Drubin and Munger, 2009a) and (Schiffman et al., 2007)). HPV-induced 
carcinogenesis is often associated with the integration of the viral genome into host 
chromosomal DNA. This results in the dysregulated expression of the HPV E6 and E7 proteins. 
The high-risk E6 and E7 proteins are sufficient for the induction and maintenance of 
transformation of cervical epithelial cells in culture. High-risk HPV E6 and E7 also sufficient for 
carcinogenesis in transgenic mouse models (reviewed in reference (McLaughlin-Drubin and 
Munger, 2009a)).The high-risk HPV E6 and E7 onocoproteins lack enzymatic and nucleic acid 
binding activities, and therefore modulate cellular processes through the association with and 
modification of cellular protein complexes. The most well characterized cellular targets of high-
risk HPV E6 and E7 oncoproteins are the p53 and retinoblastoma (pRb) tumor suppressors, 
respectively (reviewed in references (Howie et al., 2009; McLaughlin-Drubin and Munger, 
2009b)).  
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 High-risk HPV E6 proteins form a tripartite complex with p53 and the cellular ubiquitin 
ligase E6AP, targeting p53 for ubiquitination and proteasome-mediated degradation (Scheffner 
et al., 1993). High-risk HPV E6 oncoproteins also associate with cellular PDZ proteins including 
MUPP1, Dlg, hScrib, PTPN13, and PTPN3 through the HPV E6 carboxyl-terminal PDZ binding 
domain (Gardiol et al., 1999; Glaunsinger et al., 2000; Jing et al., 2007; Kiyono et al., 1997; Lee 
et al., 2000; Lee et al., 1997; Nakagawa and Huibregtse, 2000; Spanos et al., 2008). Associated 
cellular PDZ proteins may also be targeted for proteasomal-mediated degradation via the 
E6/E6AP complex. High-risk HPV E6 proteins also contribute to cellular transformation and 
immortalization through transcriptionally activating hTERT, the catalytic protein subunit for 
human telomerase (Klingelhutz et al., 1996). A large number of additional potential cellular 
targets of E6 proteins have been reported. Yeast two-hybrid screens using HPV16 E6 as bait 
separately identified the mTORC1 associated GTPase activating protein (GAP) E6TP, and ERC-
55/E6BP, two proteins that are putatively involved in HPV16 E6 associated transformation 
(Chen et al., 1995; Gao et al., 1999). 
 Despite differences in the lesions they are associated with, low-risk and high-risk HPV 
E6 proteins share several cellular targets. For example, HPV16 E6 and E7 independently 
stabilize HIF1α under hypoxic conditions (Nakamura et al., 2009). This stabilization is also 
observed in HPV11 genome expressing keratinocytes, although it is unclear if this is attributed to 
HPV11 E6 and/or E7 (Nakamura et al., 2009).The most extensively studied shared biological 
activity of high- and low-risk mucosal HPV E6 proteins is the association with the E3 ubiquitin 
ligase E6AP via the LXXLL motif on E6AP (Brimer et al., 2007). LXXLL motifs are defined as 
leucine rich amphipathic helices with limited leucine substitution for hydrophobic residues and at 
least one negatively charged amino acid in an ‘X’ position (reviewed in (Howie et al., 2009)). 
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Many high-risk HPV E6-E6AP substrates have been identified, including the aforementioned 
tumor suppressor p53 and a subset of PDZ proteins, whereas very few have been proposed for 
low-risk HPV E6 proteins. The pro-apoptotic protein Bak associates with high- and low-risk 
mucosal HPV E6 proteins and is a substrate for the HPVE6/E6AP complex (Thomas and Banks, 
1999). Cutaneous HPVE6 proteins have also been shown to associate with and target Bak for 
degradation, although the mechanism remains unclear (Underbrink et al., 2008). A yeast-two 
hybrid screen using HPV18 and HPV6 E6 as the bait identified GPS-2, a suppressor of G-protein 
and MAPK activation, as a putative binding partner of high- and low-risk HPV E6 proteins. 
Over-expression of high- and low-risk HPV E6 proteins reduced GPS-2 detection, suggesting 
that HPV E6 expression may target GPS-2 for degradation, although additional experiments are 
necessary to confirm this (Degenhardt and Silverstein, 2001). Mucosal E6 proteins have been 
reported to associate with other proteins aside from E6AP through the LXXLL binding motif, 
including paxillin and E6BP (Elston et al., 1998; Tong and Howley, 1997). Despite the 
conserved LXXLL binding motif, paxillin was shown to associate with the bovine 
papillomavirus-1 (BPV1) and high-risk HPV16 E6 proteins but not low-risk HPV6b or HPV11 
E6 proteins (Tong and Howley, 1997). E6-E6BP association was only tested with BPV1 E6 
(Chen et al., 1995; Tong and Howley, 1997).  
 The mammalian target of rapamycin complex 1 (mTORC1) signaling pathway has been 
established as a major regulator of cellular metabolism. mTORC1 responds to a variety of 
cellular signals including, but not limited to, nutrient and growth factor availability, and cellular 
ATP and amino acid levels. Upstream signals converge upon the mTORC1 kinase complex, 
which consequently regulates downstream cellular processes including cell proliferation, growth, 
and size. Mechanistically, mTORC1-mediated regulation of cellular anabolic processes is 
 
 
 75 
dependent at least in part on the activation of protein synthesis. mTORC1 regulates cap 
dependent translation by phosphorylating the mitogen-activated p70S6 Kinase (S6K), which in 
turn phosphorylates and activates the ribosomal protein S6, which is involved in translation 
initiation. mTORC1 also phosphorylates the eukaryotic translation initiation factor 4E binding 
protein 1 (4E-BP1). 4E-BP1 hyperphosphorylation relieves repression of the translation initiation 
factor eIF4E. (reviewed in (Ma and Blenis, 2009)). mTORC1 is negatively regulated by the 
tuberous sclerosis complex 1 and 2 (TSC1/TSC2) complex. When activated, the GTPase 
activating protein (GAP) TSC2 inhibits the Ras homologue and GTPase Rheb. Consequently 
mTORC1 is inhibited as is the phosphorylation and activation of downstream pathways S6K and 
4E-BP1. 
 Previous studies have suggested that high-risk HPV E6 proteins increase protein 
synthesis and activate upstream mTORC1 signaling. Yeast-two hybrid screening using HPV 16 
E6 as bait identified peptides corresponding to TSC2 and E6TP1 (Elston et al., 1998; Gao et al., 
1999). HPV16 E6 was also reported to bind TSC2 and target it for E6AP dependent proteasome 
mediated degradation (Lu et al., 2004). Previous data suggested that E6 mediated TSC2 
degradation was not conserved amongst high-risk HPV E6 proteins, but rather restricted to 
HPV16 E6 (Lu et al., 2004). We have previously reported that HPV16 E6 activates mTORC1 
signaling and increases protein synthesis independently of TSC2. We found that HPV16 E6 
activates mTORC1 and downstream signaling cascades S6K and 4E-BP1 in primary human 
foreskin keratinocytes (HFKs), RKO, and U2OS cells under transient and stable expression 
systems. Mechanistically, we found that HPV16 E6 increases the phosphorylation and activation 
of at least two upstream kinases PDK1 and mTORC2 (Spangle and Munger, 2010).  
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 Here we report that high-risk HPV16, HPV18 and low-risk mucosal HPV6b and HPV11 
E6 proteins share the ability to activate mTORC1 and increase cap dependent translation, 
whereas cutaneous HPV5 and HPV8 E6 proteins do not. Utilizing previously characterized 
HPV16 E6 mutants, we show that the LXXLL binding motif, as well as the p53-binding motif, 
are important for the HPV16 E6 mediated increase in protein synthesis.  
 
Materials and Methods: 
Plasmids:  
Plasmids used in this study include a set of human β-actin promoter driven expression vectors, 
p1318 (control), p1436no* (HPV16 E6), HPV18 E6, HPV6b E6, HPV11 E6, HPV5 E6, HPV8 
E6 (Munger et al., 1989); a set of pCMV BamNeo N vectors (with Flag-hemagglutinin fused to 
the amino terminus of the HPV E6 protein) pNCMV, pNCMV HPV16 E6no*, pNCMV HPV18 
E6no*, pNCMV HPV6b E6, pNCMV HPV11 E6; a set of lentiviral vectors pLentiN (control), 
pLenti HPV16 NE6no*, pLenti HPV18 NE6no*, pLenti HPV6b NE6, pLenti HPV11 NE6, 
pLenti HPV5 NE6, pLenti HPV8 NE6, and were generated by Gateway cloning into the 
pLenti6.3/V5 TOPO gateway compatible vector (Invitrogen). Additional HPV E6 mutants were 
generated using site directed mutagenesis (Quikchange, Stratagene). For the purposes of this 
study, the HPV16 and HPV18 E6 expression vectors were mutagenized such that they do not 
splice to form the previously characterized ‘*’ or ‘**’ major splice variants (Sedman et al., 
1991). Site directed mutagenesis was used to eliminate two donor splice site within HPV16 E6, 
with the resulting HPV16 E6 termed HPV16 E6no*. Mutagenesis at this site causes a coding 
mutation in E6 (V42L and V44L, for HPV16 and 18, respectively) that does not interfere with 
the ability of HPV16 E6 to contribute to epithelial cell immortalization. Site directed 
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mutagenesis was also used to introduce mutations into HPV6b, 11, and 18 E6 proteins such that 
E6AP binding may be compromised, based on original data that that implicated HPV16 residues 
L110, I128, and G130 in efficient E6AP binding. These mutants were made in the β-actin and 
pLentiN6.3 E6 background. Site directed mutagenesis was also used to generate a HPV16 E6 
mutant that no longer associated with PDZ proteins, based on previous studies that implicated 
HPV18 E6 carboxyl-terminus in associating with PDZ proteins (Gardiol et al., 1999). This 
mutant was made in the β-actin and pLentiN6.3 E6 background 
 
Primers: 
HPV16 E6no* (V42L) 
 F: 5’-
TACTGCAAGCAACAGTTACTGCGACGCGAGCTATATGACTTTGCTTTTCGGGA-3’ 
 R: 5’-
TCCCGAAAAGCAAAGTCATATAGCTCGCGTCGCAGTAACTGTTGCTTGCAGTA-3’ 
HPV18 E6no* (V44L) 
 F: 5’-
CAAGACAGTATTGGAACTTACAGAGGCATTTGAATTTGCATTTAAAGATTTAT-3’ 
 R: 5’-
ATAAATCTTTAAATGCAAATTCAAATGCCTCTGTAAGGTCCAATACTGTCTTG-3’ 
HPV18 E6I130T  
 F: 5’-TGAAAAACGACGATTCCACAACACAGCTGGGCACTA-3’ 
 R: 5’-TAGTGCCCAGCTGTGTTGTGGAATCGTCGTTTTTCA-3’ 
HPV6b E6L111Q  
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 F: 5’-CTGTGTCACAAACCGCAGTGTGAAGTAGAAAAGG-3’ 
 R: 5’-CCTTTTCTACTTCACACTGCGGTTTGTGACACA-3’ 
HPV6b E6I127T  
 F: 5’-TAACCAAGGCGCGGTTCACAAAGCTAAATTGTACGTG-3’ 
 R: 5’-CACGTACAATTTAGCTTTGTGAACCGCGCCTGGGTTA-3’ 
HPV6b E6L129T 
 F: 5’-CAAGGCGCGGTTCATAAAGACAAATTGTACGTGGAAGGGT-3’ 
 R: 5’-ACCCTTCCACGTACAATTTGTCTTTATGAACCGCGCCTTG-3’ 
HPV11 E6L111Q  
 F: 5’-TTGTTACCTGTGTCACAAGCCGCAGTGTGAAATAGAAAAACTAAAGC-3’ 
 R: 5’-GCTTTAGTTTTTCTATTTCACACTGCGGCTTGTGACACAGGTAACAA-3’ 
HPV11 E6I127T 
 F: 5’-TTGGGAAAGGCACGCTTCACAAAACTAAATAACCAGTGG-3’ 
 R: 5’-CCACTGGTTATTTAGTTTTGTGAAGCGTGCCTTTCCCAA-3’ 
HPV11 E6L129T 
 F: 5’-GGGAAAGGCACGCTTCATAAAAACAAATAACCAGTGGAAGGG-3’ 
 R: 5’-CCCTTCCACTGGTTATTTGTTTTTATGAAGCGTGCCTTTCCC-3’ 
HPV16 E6 ΔPDZ 
 F: 5’-GTCTTGTTGCAGATCATCAAGAACATGAAGAGAAACCCAGC-3’ 
 R: 5’-GCTGGGTTTCTCTTCATGTTCTTGATGATCTGCAACAAGAC-3’ 
 
 
 
 79 
The pFR_CrPV_xb bicistronic firefly/Renilla luciferase vector was used for luciferase reporter 
assays and was obtained from Phil Sharp through Addgene (plasmid 11509) (Petersen et al., 
2006).  
 
Cell lines and Culture: 
293T and U2OS cells (ATCC) were maintained in Dulbecco’s modified eagle medium (DMEM) 
(Invitrogen), supplemented with 10% fetal bovine serum (FBS), 50 U/ml penicillin and 50 µg/ml 
streptomycin. Primary human foreskin keratinocytes were isolated from anonymous newborn 
circumcisions as previously described (McLaughlin-Drubin et al., 2008), and maintained in 
keratinocyte serum-free medium (KSFM) supplemented with human recombinant epidermal 
growth factor 1-53, bovine pituitary extract (Invitrogen), 50 U/ml penicillin and 50 µg/ml 
streptomycin, 20 µg/ml gentamicin, and 1 µg/ml amphotericin B. HPV onocogene expressing 
HFKs were generated by lentiviral infection with the corresponding pLenti6.3N vectors. 
pLenti6.3N vector expressing cells were maintained following blasticidin selection (3 µg/ml). 
All experiments were performed with HFKs passaged less than ten times. For nutrient 
deprivation assays, HFKs were grown to 90% confluence, at which point they were washed 
twice with phosphate buffered saline (PBS), followed by an incubation in either PBS for 15 
minutes or starved of EGF for 2 hrs prior to lysis. Poly-D-lysine coated plates (BD Biosciences) 
were used for experiments in which HFKs were starved in PBS for 15 minutes. Cells were then 
scraped and cleared by centrifugation at 16,110 x g for 10 min at 4oC.  
 
Western blotting and antibodies: 
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Cell lysates unless otherwise indicated were prepared by incubating the cells in ML buffer (300 
mM NaCl, 0.5% Nonidet P-40 [NP-40], 20 mM Tris-HCl [pH 8.0], 1 mM EDTA) supplemented 
with one complete EDTA-free protease inhibitor cocktail tablet (Roche) per 25 ml lysis buffer 
and one PhosSTOP phosphatase inhibitor cocktail tablet (Roche) per 7.5 ml lysis buffer 
(McLaughlin-Drubin et al., 2008). Lysates intended for HA immunoprecipitation were prepared 
by incubating the cells in MC lysis buffer (50 mM Tris [pH 7.5], 150 mM NaCl, 0.5% NP-40), 
supplemented with one complete EDTA phosphatase inhibitor cocktail tablet (Roche). Cells 
were then scraped and lysates cleared by centrifugation at 16,110 x g for 10 min at 4oC. Protein 
concentrations were determined using the Bradford method (Bio-Rad). Proteins were separated 
by SDS-PAGE and electrotransferred onto polyvinylidene difluoride membranes (Immobilon-P; 
Millipore). Unless otherwise noted, membranes were blocked in 5% nonfat dry milk in TBST 
(137 mM NaCl, 2.7 mM KCl, 25 mM Tris [pH 7.4], 0.1% Tween 20) and probed with the 
appropriate antibody. The following antibodies were used at a 1:1000 dilution unless otherwise 
specified: β-Actin (1501; Chemicon), p53 (Ab-6, Calbiochem), Flag (4 µg/ml, F3165, Sigma), 
UBE3A/E6AP (1:500, H00007337-M01, Novus Biologicals), S6K (9202), S6K T389 (9206), S6 
(2317), S6 S235/36 (4858), S6 S240/44 (4838), all from Cell Signaling Technology. Secondary 
anti-mouse and anti-rabbit antibodies conjugated to horseradish peroxidase were used at 
dilutions of 1:10,000 or 1:15,000, respectively. Proteins were visualized by enhanced 
chemiluminescence (Perkin Elmer, Millipore) and exposed on Kodak BioMax XAR film, or 
electronically acquired and quantified with a Kodak Image Station 4000R equipped with Kodak 
Imaging Software, version 4.0, or with a Carestream Gel Logic 4000.   
 
Immunoprecipitation 
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For HA immunoprecipitations, one 15cm plate of 293T cells was seeded and CaCl2 transfected 
with the appropriate pLenti6.3N vector (N, 16E6no*, 16E6no* I128T, 18E6 no*, 18E6no* 
I130T, 6bE6, 6bE6 L111Q, 6bE6 I127T, 6bE6 L129T, 11E6, 11E6 L111Q, 11E6 I127T, or 11E6 
L129T. 72 hours post transfection the cells were lysed as described above in MC buffer. Lysates 
were cleared with low-binding durapore PVDF 0.45 µM membrane spin filters (Millipore) and 
protein concentration was subsequently measured using the Bradford Method (Bio-rad). 
Prewashed HA antibody-agarose conjugate (Sigma) was then incubated with lysate for 2 hrs, 
washed, and sample buffer added.  
 
Transfections and Luciferase Assays 
Primary human foreskin keratinocytes were transfected as described (Spangle and Munger, 
2010). In brief, cells were transfected in triplicate in 6-well plates for luciferase reporter assays 
using FuGene 6 (Roche). One microgram of pFR_CrPV_xb was co-transfected with two µg of 
the appropriate β-actin promoter driven vector. Forty-eight hours post transfection, cells were 
lysed and scraped in 125 µl passive lysis buffer (dual luciferase reporter kit; Promega) per well. 
The supernatants were subjected to the dual luciferase reporter assay. The fold change in activity 
was determined by calculating the ratio of firefly activity to Renilla luciferase activity compared 
to the control vector-transfected cells. At least three independent experiments were performed 
and the Student’s T test was used to calculate statistical significance.  
 
Results: 
Mucosal but not cutaneous HPV E6 proteins increase cap dependent translation. Our 
previous studies suggested that HPV16 E6 increases cap dependent translation (Spangle and 
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Munger, 2010). Based on these findings, we evaluated the ability of other HPV types to activate 
cap dependent translation in U2OS osteosarcoma cells and primary human foreskin keratinocytes 
(HFKs). U2OS cells were selected for these experiments because of their high transfection 
efficiency, while HFKs are the more cumbersome but physiologically more relevant cell culture 
model. We utilized a bicistronic luciferase reporter construct pFR_CrPV_xb, expressing firefly 
and Renilla luciferase as a single transcript from the minimal TK promoter. They are translated 
independently because they are separated by an internal ribosomal entry site (IRES). Firefly 
luciferase is translated by a cap dependent mechanism whereas Renilla luciferase is translated by 
a cap independent mechanism that is dependent on the IRES of Cricket Paralysis Virus (Petersen 
et al., 2006). Transient co-expression of high-risk mucosal HPV16 and HPV18 E6 proteins 
robustly activated cap dependent translation in U2OS cells (4.32 ± 1.04, p < 0.001, and 3.24 ± 
0.58 fold, p < 0.001, respectively and relative to control). Low-risk mucosal HPV6b and HPV11 
E6 proteins activated cap dependent translation but not as efficiently as high-risk HPV E6 
proteins (2.94 ± 0.91, p < 0.001, and 2.19 ± 0.47 fold, p < 0.003, respectively and relative to 
control), whereas cotransfection of the cutaneous HPV5 and HPV 8 E6 proteins had no effect 
(1.21 ± 0.18, p = 0.059 and 1.16 ± 0.19 fold, p = 0.16, respectively) (Fig 3.1, left). Luciferase 
reporter assays performed in primary HFKs yielded similar results despite their comparatively 
low transfection efficiency (Fig 3.1, right).  
 These results show that the ability of HPV E6 proteins to activate cap dependent 
translation and increase protein synthesis is conserved amongst high- and low-risk mucosal 
HPVs.  
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Figure 3.1. Mucosal but not cutaneous HPV E6 proteins increase cap dependent 
translation. U2OS cells (left) were transiently co-transfected with the pFR_CrPV_xb bicistronic 
reporter construct and the CMV promoter driven expression vectors for high-risk mucosal E6 
proteins (16 or 18), low-risk mucosal E6 proteins (6b or 11), cutaneous E6 proteins (5 or 8), or 
empty vector as a control. HFKs (right) were transiently co-transfected with the pFR_CrPV_xb 
construct and the human β-actin promoter driven E6 expression vectors. Cells were lysed and 
Renilla and firefly luciferase were measured 48h post transfection. Firefly and Renilla luciferase 
values were normalized to control vector-transfected cells and are presented as the fold change of 
normalized firefly luciferase relative to normalized Renilla luciferase. The bars represent the 
average and one standard deviation from four independent experiments for U2OS and five 
independent experiments for HFKs.  
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The LXXLL binding motif and p53 binding are important for the HPV16 E6 mediated 
increase in cap dependent translation. Utilizing previously characterized HPV16 E6 mutants, 
we evaluated which sequences in HPV16 E6 are important for its ability to activate cap 
dependent translation. We tested HPV16 E6 mutants deficient in p53 binding (Y54D) and 
LXXLL motif binding (I128T) (Liu et al., 1999). Truncation of the carboxyl-terminal six amino 
acids in HPV18 E6 yields a mutant that is defective for binding and degradation of cellular PDZ 
proteins (Gardiol et al., 1999). Thus, we also generated an equivalent carboxyl-terminal 
truncation HPV16 E6 mutant, ΔPDZ (Fig 3.2). Bicistronic luciferase reporter assays in primary 
HFKs suggest that all tested HPV16 E6 mutants do not activate cap dependent translation as 
efficiently as wild type HPV16 E6 (Fig 3.3). However, the HPV16 E6 Y54D and I128T mutants 
that affect p53 binding and LXXLL motif binding, respectively, significantly decreased the 
HPV16 E6 mediated increase in protein synthesis (wild type HPV16 E6 1.80 ± 0.08 fold. HPV16 
E6 Y54D 1.26 ± 0.23, p = 0.125 relative to control and p = 0.0177 relative to HPV16 E6. HPV16 
E6 I128T 1.16 ± 0.11 fold, p = 0.0873 relative to control and p = 0.0013 relative to HPV16 E6). 
In contrast, the HPV16 E6 ΔPDZ mutant had an intermediate phenotype (1.47 ± 0.07 fold, p = 
0.003 relative to control with a reduced fold change in comparison to wild type HPV16 E6 (p = 
0.0066 relative to HPV16 E6). 
 Therefore, these results suggest that more than one biological activity may contribute to 
the ability of E6 mediated to activate cap dependent translation. Combinatorial LXXLL binding 
motif/PDZ binding HPV16 E6 mutants have also been tested for activation of cap dependent 
translation, with no additive inhibitory effect (data not shown). 
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Figure 3.2. HPV16 and 18E6 PDZ binding mutants. High-risk mucosal HPV16 and 18E6 
proteins are aligned from the C terminus. The PDZ binding consensus, XT/SXV, is shown in red 
and blue. The grey box indicates the residues that were eliminated with the introduction of the 
premature stop codon. These mutants were generated based on the mutants described by (Gardiol 
et al., 1999). 
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Figure 3.3. The LXXLL binding motif and p53 binding are important for HPV16 E6 
mediated increase in cap dependent translation. HFKs were transiently co-transfected with 
the pFR_CrPV_xb reporter construct and the human β-actin promoter driven expression vectors 
for wild type HPV16 E6, p53 binding mutant (HPV16E6 Y54D), LXXLL binding motif mutant 
(HPV16E6 I128T, PDZ binding mutant (HPV16E6 ΔPDZ), or empty vector as a control. Cells 
were lysed and firefly and Renilla luciferase measured 48h post transfection. Firefly and Renilla 
luciferase values were normalized to control vector-transfected cells and are presented as the fold 
change of normalized firefly luciferase relative to normalized Renilla luciferase. The bars 
represent the average and one standard deviation from three independent experiments.  
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High-and low-risk HPV E6 proteins increase protein synthesis through overlapping 
mechanisms. High- and low-risk HPV E6 proteins activate cap dependent translation. The 
LXXLL binding motif is conserved amongst all mucosal HPV E6 proteins whereas p53 binding 
and the carboxyl-terminal PDZ binding domain are not. We therefore utilized low-risk HPV E6 
proteins to determine the shared mechanism by which mucosal HPV E6 proteins increase cap 
dependent translation. Only E6AP has thus far been identified to associate with both high- and 
low-risk HPV E6 proteins through the LXXLL binding motif. Therefore, we generated 
previously characterized and novel putative LXXLL binding motif defective HPV6b and HPV11 
E6 proteins and tested their ability to (1) bind E6AP, and (2) activate cap dependent translation 
by luciferase reporter assays. Previous studies identified leucine residue 111 (L111) in HPV11 
E6 as important for E6AP binding, which was also established for the analogous residue in 
HPV16 E6 (Brimer et al., 2007; Liu et al., 1999). Similarly, previous work also revealed that in 
addition to I128, glycine residue 130 (G130) in HPV16 E6 was also important for E6AP binding. 
Therefore, we generated three putative LXXLL/E6AP binding motif defective HPV6b and 
HPV11 E6 mutants: L111Q, I127T, and L129T (Fig 3.4A). Transient transfection of 293T cells 
with Flag-HA tagged HPV E6 proteins followed by HA immunoprecipitation and E6AP Western 
blot confirms that HPV16 E6 binds E6AP, whereas E6AP binding by the HPV16 E6 I128T 
mutant is abrogated (Fig 3.4B, Left). Similar results were obtained for HPV18 E6 and the 
previously characterized E6AP binding mutant HPV18 I130T (Fig 3.4B, Middle). Consistent 
with previously published results (Brimer et al., 2007), the HPV11 E6 L111Q mutant is defective 
for E6AP association. The HPV11 E6 I127T mutant exhibits reduced E6AP binding whereas the 
HPV111 E6 L129T mutation only has a minor effect on E6AP binding (Fig 3.4B, right). Using 
this set of mutants we next determined whether an intact LXXLL binding motif, as assessed by  
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Figure 3.4. High and low-risk HPV E6 proteins increase cap dependent translation through 
overlapping mechanisms. (A) Mucosal E6 protein carboxyl-terminal sequence homology. 
Sequence alignment based on the conserved CxxC zinc binding sites, shown in blue. The HPV16 
E6 L110Q, I128T, G130V, and HPV11E6 L111Q residues were previously implicated in the 
association with cellular proteins via an LXXLL binding motif. These mutants and analogous 
mutants are shown in green (HPV18E6 I130T, HPV6b and 11E6 L111Q, I127T, L129T). The 
carxboxyl-terminal high-risk HPV E6 PDZ binding domain is shown in red. (B) Western blot 
analysis of HA immunoprecipitations from 293T cells transiently transfected with N-terminally 
Flag-HA tagged CMV (NCMV) promoter driven E6 expression vectors (HPV16 E6 and mutant, 
left; HPV18 E6 and mutant; middle, HPV11E6 and mutants, right) into 293T cells. Proteins 
immunoprecipitated by anti-HA agarose were identified by Western blotting for HPV E6 
proteins (anti-Flag) and E6AP. Input represents 1% of IP, and actin is shown as a loading 
control. (C) U2OS cells were transiently co-transfected with the pFR_CrPV_xb bicistronic 
reporter construct and the human β-actin promoter driven E6 expression vectors or empty vector 
as a control. Cells were lysed and Renilla and firefly luciferase were measured 48h post 
transfection. Firefly and Renilla luciferase values were normalized to control vector-transfected 
cells and are presented as the fold change of normalized firefly luciferase relative to normalized 
Renilla luciferase. The bars represent the average and one standard deviation from three 
independent experiments.  
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E6AP binding, is important for HPV E6 proteins to increase cap dependent translation. We 
transiently co-transfected primary HFKs with a panel of high- and low-risk HPV E6 proteins and 
their respective LXXLL binding motif mutants and the bicistronic luciferase reporter and 
evaluated cap dependent translation. The results suggest that the LXXLL binding motif is 
important for high- and low-risk HPV E6 proteins to activate cap dependent translation, as it is 
reduced upon expression of the HPV16 I128T and HPV18 I130T mutants (Fig 3.4C). The 
HPV6b and HPV11 E6 L111Q and I127T mutants exhibit reduced activation of cap dependent 
translation whereas the HPV6b and HPV11 E6 L129T mutants activated cap dependent 
translation comparably to wild type HPV6b and HPV11 E6 proteins (Fig 3.4C).  
 Hence, these experiments are consistent with a model that the integrity of the LXXLL 
binding motif is important for high-risk as well as low-risk mucosal HPVE6 proteins to activate 
cap dependent translation.  
 
Multiple sequences, including the LXXLL binding motif contribute to the ability of high-
risk mucosal HPV E6 proteins to activate mTORC1 signaling. We tested the previously 
characterized HPV16 E6 mutants deficient in p53 binding (Y54D), LXXLL motif binding 
(I128T) (Liu et al., 1999), and PDZ binding (ΔPDZ) for mTORC1 activation, using S6K 
phosphorylation as a surrogate marker. HFKs with stable expression of these HPV16 E6 mutants 
were generated. Expression of HPV16 E6 I128T and Y54D mutants, which target the LXXLL 
motif and p53 binding, respectively, exhibited reduced S6K phosphorylation (Fig 3.5A). The 
expression of the HPV16 E6 ΔPDZ mutant showed S6K phosphorylation similar to wild type 
HPV16 E6 expressing cells (Fig 3.5A). These results are similar to what we observed with the 
bicistronic luciferase reporter assays (Fig 3.3). This suggests that the ability of HPV16 E6 to  
 
 
 90 
 
 
 
 
 
 
Figure 3.5. The LXXLL binding motif is important for mucosal HPV E6 mediated 
mTORC1 activation. (A) Western blot analysis of S6K T389 phosphorylation in HPV16 E6, 
Y54D, I128T, and ΔPDZ expressing and control vector (LXSN) HFKs. (B) Western blot analysis 
of S6K T389 phosphorylation in HPV16 E6, 16E6 I128T (left); HPV18 E6, 18E6 I130T 
(middle); HPV11 E6, 11E6 L111Q, 11E6 I127T, 11E6 I129T (right) expressing and control 
vector (pLentiN6.3) HFKs. Actin is shown as a loading control.  
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activate mTORC1 signaling correlates with the ability of HPV16 E6 to activate cap-dependent 
translation. Given that the ability to associate with LXXLL motif containing proteins such as 
E6AP is conserved with low-risk and high-risk HPV E6 proteins, we next investigated whether 
the integrity of the LXXLL motif binding sequence is also important for the ability of low-risk 
HPVE6 proteins to activate mTORC1 signaling using S6K phosphorylation as surrogate marker. 
As expected expression of the HPV16 and 18 E6 LXXLL motif binding mutants 128T and 
I130T, respectively, in HFKs do not cause increased S6K phosphorylation (Fig 3.5B, left and 
middle, respectively). Similarly, expression of the HPV11 L111 and I127 E6 mutant showed low 
levels of S6K phosphorylation (Fig 3.5B, right), suggesting that similar to what we observed 
with HPV16 E6, the integrity of the LXXLL motif in the high-risk HPV18 E6 protein as well as 
the low-risk HPV11 E6 protein is important for their ability to activate mTORC1 signaling and 
that this correlated with their ability to increase cap-dependent translation as determined by 
luciferase reporter assays (Fig 3.4C).  
 Taken together our results show that the integrity of LXXLL binding motif that is 
conserved in low-risk as well as high-risk mucosal HPV E6 proteins, but not in cutaneous HPV 
E6 proteins importantly contributes to the ability of mucosal HPV E6 proteins to activate 
mTORC1 signaling and cap dependent translation.  
 
Discussion: 
 It was previously shown that HPV16 E6 activates mTORC1 signaling. Several 
mechanisms have been proposed, including association with and subsequent destabilization of 
the mTORC1 negative regulator TSC2 (Lu et al., 2004). Our own experiments suggest that in 
primary HFKs stable HPV16 E6 expression does not activate mTORC1 through TSC2 
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destabilization but rather through the activation of at least two kinases upstream of AKT; PDK1 
and mTORC2 (Spangle and Munger). We also showed that HPV16 E6 increases cap dependent 
translation by increasing cap dependent translation and that this is, at least in part dependent on 
mTORC1 activation (Spangle and Munger, 2010). 
 Here we show that the ability to activate mTORC1 and increase cap dependent 
translation is conserved amongst high- and low-risk mucosal HPV E6 proteins (Fig 3.1). High-
risk HPV16 and HPV18 E6 proteins increase cap dependent translation whereas low-risk 
mucosal HPV E6 proteins from type 6b and 11 do so to a lesser extent. All mucosal HPV E6 
proteins tested activate mTORC1 signaling to a similar level. In contrast, cutaneous HPV E6 
proteins do not activate cap dependent translation. Since infection with low-risk mucosal HPV 
types are rarely associated with carcinogenesis, it is likely that the ability of mucosal HPV E6 
proteins to activate mTORC1 and enhance cap-dependent translation are related to a common 
requirement during the viral life cycle. Given that all HPVs, including those that infect the 
cutaneous epithelia, require adequate production of viral and cellular proteins necessary for viral 
genome replication and progeny virion production it is surprising that cutaneous HPV E6 
proteins do not detectably activate mTORC1 signaling or increase cap-dependent translation. 
One might hypothesize that mucosal HPV E6 proteins evolved a distinct repertoire of biological 
properties as a result of tissue tropism, explaining the specificity of mucosal HPV E6 mediated 
activation of mTORC1 and cap dependent translation. One cannot rule out the possibility that 
successful viral genome replication or progeny virion production in the mucosal epithelium 
involves unique requirements as a result of different gene expression profiles. Transcriptional 
regulation is also different between mucosal and cutaneous HPVs. Introduction of HPV16 and 
HPV5 long control region (LCR) reporter constructs into cutaneous and mucosal epithelial cells 
 
 
 93 
demonstrated that appropriate cellular tropism is important for robust transcriptional activation 
(Mistry et al., 2007). This cell type dependent promoter activation may be caused by the 
differential expression and participation of transcription factors. Given these apparent differences 
in the cellular milieus of cutaneous and mucosal epithelia, it is thus tempting to speculate that 
corresponding HPV types may have evolved distinct molecular strategies to optimally exploit the 
available host cellular environment. 
 The bicistronic reporter assays utilizing high-risk HPV16 E6 mutants indicated that more 
than one biochemical activity is important for cap dependent translation, including LXXLL motif 
binding. We therefore evaluated the contribution of the LXXLL binding motif in a simpler 
model – the low-risk mucosal HPV E6 protein. Low-risk HPV E6 proteins lack the transforming 
potential of high-risk HPV E6 proteins as they do not bind and degrade p53 or associate with 
PDZ proteins through a carboxyl-terminal PDZ binding domain. The LXXLL binding motif, 
however, while absent in cutaneous HPV E6 proteins, is conserved between high-risk and low-
risk mucosal HPV E6 proteins. We generated known and novel HPV6b and HPV11 E6 LXXLL 
binding motif mutants and confirmed the loss of E6AP binding for these mutants. Bicistronic 
luciferase reporter assays in primary HFKs indicated that the LXXLL binding motif is required 
for mucosal HPV E6 proteins, including the low-risk HPV6b and HPV11 E6 proteins, to activate 
cap dependent translation (Fig 3.4). Considering that the E3 ubiquitin ligase E6AP is the only 
currently identified LXXLL motif partner shared by low-risk and high-risk mucosal HPV E6 
proteins, E6AP is an attractive candidate to mediate mTORC1 activation and enhance cap 
dependent translation. However, to date only the pro-apoptotic protein Bak has been identified as 
a low-risk HPV E6/E6AP substrate and it is difficult to envision how Bak degradation might 
cause increased cap dependent translation. It is possible, however, that E6AP binding is required 
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for HPV E6 mediated increase in mTORC1 and protein synthesis, but the ubiquitin ligase 
activity of E6AP may be dispensable. It has been reported that E6AP may serve as a 
transcriptional coactivator of estrogen receptor alpha (ERα), and that the ubiquitin ligase activity 
is dispensable for this activity (Nawaz et al., 1999). Several ERα target genes have been 
implicated in upstream signaling events of mTORC1 and cap dependent translation, including 
insulin growth factor binding protein 4 (IGFBP4), ErbB4, as well as other growth factor and 
metabolism associated genes such as NDRG1, a downstream effector of mTORC2 signaling (Lin 
et al., 2004). Future experiments will be focused on directly addressing the potential 
contributions of E6AP in mucosal HPV E6 mediated activation of mTORC1 signaling and 
enhancement of cap-dependent translation. 
 It is conceivable that the LXXLL binding motif may mediate the association of additional 
cellular proteins with mucosal HPV E6 proteins. Our group and others have been utilizing large-
scale proteomics to identify high- and low-risk HPV E6 associated proteins. Proteomics studies 
in our group (Appendix 2) have putatively identified another E3 ubiquitin ligase that may 
associate with high- and low-risk HPV E6 proteins, HUWE1/MULE/ARFBP1. HUWE1 has 14 
putative LXXLL motifs, one being the prototypic amphipathic helix with at least one negatively 
charged amino acid in the “X” position. We are currently in the process of validating association 
of mucosal HPV E6 proteins with HUWE1. Interestingly, HUWE1 regulates processes such as 
cell proliferation and apoptosis, through the targeted ubiquitination of substrates including the 
apoptotic protein Mcl-1, N-Myc, and also p53. It is possible that a currently unidentified 
substrate(s) of either or both the E6/E6AP or E6/HUWE1 complex may contribute to mTORC1 
activation or cap dependent translation.  
 
 
 95 
 Using previously characterized HPV16 E6 mutants, we show that the E6 mediated 
activation of cap dependent translation correlates with an intact LXXLL binding motif as well as 
p53 binding. There was also a small but statistically significant contribution of the carboxyl-
terminal PDZ binding domain to HPV16 E6 mediated cap dependent translation. The HPV16 E6 
mutants that we used for our studies are well characterized and each maintain separable 
biological functions, e.g., the HPV16 E6 LXXLL motif binding I128T mutant has been reported 
to associate with p53 by immunoprecipitation, but does not degrade p53 as it can no longer 
associate with E6AP. These results suggest that multiple biochemical activities of high-risk HPV 
E6 proteins contribute to full activation of cap dependent translation, some of which may be 
dependent of binding p53, PDZ proteins, or association with proteins such as E6AP through their 
LXXLL binding motif.  
 We have recently identified that high-risk HPV16 E6 activates growth factor sensitive 
receptor protein tyrosine kinases through the association with the signaling adaptor protein Grb2 
(see chapter four). E6 expression also causes increased internalization of activated receptor 
species, increased receptor degradation and decreased EGFR half-life. It is possible that HPV16 
E6 associates with and functionally modifies the Grb2 complex through the targeted 
ubiquitination of a Grb2 associated protein, in turn regulating Grb2 function. This is reasonable, 
as Grb2 has been implicated in both in receptor activation and internalization (Sigismund et al., 
2008). We are therefore actively pursuing additional proteomics studies of high-and low-risk 
HPV E6 associated proteins under normal growth conditions and proteasomal inhibition.  
 Given that the activation of cap dependent translation is dependent at least in part on the 
upstream activation of mTORC1 (Spangle and Munger, 2010), we are currently comparing the 
ability of cutaneous and mucosal HPV E6 proteins to activate mTORC1, as indicated by an 
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increase in S6K phosphorylation. It is expected that cutaneous HPV E6 proteins will not activate 
mTORC1, as they do not activate cap dependent translation in the bicistronic luciferase reporter 
assays. We will also be evaluating signaling events upstream of mTORC1, and expect that 
mucosal HPV E6 proteins will activate mTORC1 through PDK1 and mTORC2, under conditions 
of nutrient deprivation.  
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CHAPTER FOUR 
 
The HPV16 E6 oncoprotein promotes the phosphorylation of 
receptor protein tyrosine kinases and increases internalization of 
phosphorylated receptor species  
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Abstract:  
The high-risk human papillomavirus E6 proteins promote transformation and oncogenesis. 
HPV16 E6 sustains the activity of the mTORC1 and mTORC2 signaling cascades under 
conditions of growth factor withdrawal. This may be relevant during viral infection as the viral 
life cycle is completed in nutrient poor, terminally differentiated, and non-dividing host epithelial 
tissue. Phosphotyrosine immunoprecipitations and Western blots demonstrated that the HPV16 
E6 oncoprotein increases the phosphorylation of receptor protein tyrosine kinase effector 
signaling pathways and we determined the origin of the activation to be at the level of growth 
factor sensitive receptor protein tyrosine kinases ErbB2/EGFR/IGFR/IR. HPV16 E6 also 
increased the internalization of phosphorylated receptor species, which is suggestive of enhanced 
receptor activity. The receptor protein tyrosine kinase signaling adaptor protein Grb2 was 
identified as a binding partner of HPV16 E6, and Grb2 knockdown ablated HPV16 E6 mediated 
activation of mTORC1. Lastly HPV16 E6 expression increased cellular migration in wound 
healing and transwell migration assays through an EGFR/IR/IGFR dependent mechanism. This 
work identifies a novel mechanism of perturbing the host signaling machinery to promote energy 
consuming processes that may support cellular transformation and carcinogenesis by the HPV16 
E6 oncoprotein.  
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Introduction:  
Human papillomaviruses (HPVs) are small viruses with double stranded DNA genomes that 
infect squamous epithelial tissue. To date, over HPV 200 types have been identified and 
categorized based on the type of host epithelial tissue they infect. The majority of HPVs infect 
the cutaneous epithelium where they cause generally benign warts. Approximately 30 HPVs 
infect the mucosal epithelium and these HPVs are classified as “low-risk” or “high-risk” based 
on the propensity for malignant progression of the lesions that they cause. Low-risk mucosal 
HPVs, such as HPV types 6 (HPV6) or 11 (HPV11), can cause genital warts that are typically 
cleared and do not progress to malignancy. In contrast, infection with high-risk mucosal HPV 
type 16 (HPV16) or 18 (HPV18) can cause squamous intraepithelial lesions that can progress to 
cancer. High-risk HPVs, such as HPV16 and HPV18, are commonly associated with anogenital 
tract carcinomas, and are the causative agent for nearly 100% of all diagnosed cervical cancers 
worldwide (WHO Annual Report 2010). High-risk HPVs are also associated with other 
anogenital tract cancers and oropharyngeal carcinomas. A frequent hallmark of HPV-associated 
carcinogenesis is the integration of the HPV genome or a portion thereof into a host 
chromosome. This results in the dysregulated expression of the high-risk HPV E6 and HPV E7 
oncoproteins. The HPV E6 and E7 oncoproteins together are sufficient for the initiation and 
maintenance of the transformed phenotype of cervical cancer cells. HPV E6 and E7 oncoprotein 
expression has also been shown to cause cancer in a transgenic mouse model (reviewed in 
reference (McLaughlin-Drubin and Munger, 2009a)). The high-risk HPV E6 and HPV E7 
oncoproteins each have many described biological activities, with the most predominant being 
the association with and subsequent targeting of the p53 and pRb tumor suppressors for 
degradation, respectively (reviewed in references (Howie et al., 2009) and (McLaughlin-Drubin 
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and Munger, 2009b)). High-risk HPV E6 proteins associate with the E3 ubiquitin ligase E6AP 
(UBE3A) through the LXXLL binding motif in E6. High-risk HPV E6 proteins form a tripartite 
complex with E6AP and p53, targeting p53 for ubiquitination and subsequent degradation 
through the proteasome (Scheffner et al., 1993). The E6/E6AP complex has been reported to 
target other HPV E6 binding partners for degradation, including members of a diverse group of 
PDZ proteins that have been reported to associate with high-risk mucosal HPV E6 proteins 
through a carboxyl-terminal PDZ binding domain. Reported high-risk HPV E6 binding partners 
or substrates include the PDZ proteins hDlg, hScribble, MUPP1, MAGI1, and the non-receptor 
protein phosphatases PTPN3 and PTPN13 (Gardiol et al., 1999; Glaunsinger et al., 2000; Jing et 
al., 2007; Kiyono et al., 1997; Lee et al., 2000; Lee et al., 1997; Nakagawa and Huibregtse, 2000; 
Spanos et al., 2008). High-risk HPV E6 proteins also contribute to the immortalization of the 
host cell through activating hTERT, the catalytic component of the human telomerase enzyme 
(Klingelhutz et al., 1996).  
 
High-risk HPVs infect the basal epithelial cells, which presumably occupy a nutrient rich 
environment. The basal epithelial cells undergo asymmetric cell division, in which one daughter 
cell remains a basal cell and the other becomes a cell that is poised to differentiate as part of the 
nutrient deprived squamous epithelium. Viral genome replication and progeny virion assembly is 
confined to the otherwise non-dividing differentiated cells of the epithelium. High-risk HPV E7 
maintains S phase competence by destabilizing pRb. The simultaneous HPV E6 mediated 
destabilization of p53 eliminates cell cycle checkpoints enabling aberrant DNA replication. It is, 
however, much less characterized how completion of the viral life cycle can occur in an 
environment with presumed restricted nutrients and energy sources that are required for DNA 
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replication and protein synthesis. HPV16 E7 expression has been reported to cause a metabolic 
switch from oxidative phosphorylation to glycolysis and anaerobic fermentation, a phenomenon 
commonly referred to as the “Warburg effect” (Zwerschke et al., 1999). Further, serum 
starvation of HPV16 E7 expressing cells induces the trophic sentinel response. This is a response 
to oncogene expression sending signals of growth despite a shortage of nutrients and growth 
factors that causes caspase independent cell death without cytochrome C release (Eichten et al., 
2004). Co-expression of HPV16 E6 was shown to abrogate the trophic sentinel response 
triggered by E7. Our group reported that HPV16 E7 induces autophagy, which is the catabolic 
process of recycling cellular organelles through the lysosomal machinery. HPV E7-induced 
autophagy increased the number of LC3b positive vesicles and increased the conversion of 
LC3bI to LC3bII (Zhou and Munger, 2009). The HPV16 E7-mediated increase in autophagy is 
likely balanced by activities of the high-risk HPV E6 oncoprotein, namely E6 mediated 
activation of mTORC1. Our group and others have reported that HPV16 E6 activates mTORC1 
signaling under normal growth and nutrient deprived conditions (Lu et al., 2004; Spangle and 
Munger, 2010). mTORC1 functions as a cellular rheostat, integrating environmental cues of 
energy status, growth factors, amino acids, and nutrient availability. We found that HPV16 E6 
mediated mTORC1 activation causes an increase in cap dependent translation, which is at least 
in part a consequence of mTORC1 activation (Spangle and Munger, 2010). mTORC1 activation 
directly inhibits autophagy, suggesting that during HPV infection, HPV16 E6 expression may 
suppress HPV E7-induced autophagy. The combined effects of pRb and p53 inactivation coupled 
with mTORC1 activation and autophagy suppression support the model that the biological 
properties of high-risk HPV E6 and HPV E7 are balanced to meet the metabolic needs during 
successful viral infection and/or genome replication (Zhou et al., 2009). HPV16 E6 
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counterbalances the E7 induced effects of reduced energy availability and increased autophagy 
by activating mTORC1 and thus inhibiting autophagy. This results in the short-term increase in 
protein synthesis that may be used to generate the cellular machinery necessary for DNA 
replication as well as viral capsid proteins necessary for packaging.  
 
HPV16 E6 was previously shown to activate mTORC1 through the upstream kinases PDK1 and 
mTORC2 under conditions of nutrient derivation. AKT and mTORC1 are activated 
independently of TSC2 destabilization (Spangle and Munger, 2010). PDK1 is downstream of 
PI3K and can be activated through multiple membrane-associated signaling events including the 
activation of G coupled protein receptors (GPCRs) and receptor protein tyrosine kinases 
(RPTKs). Hence, we addressed the hypothesis that HPV16 E6 may activate mTORC1 through 
RPTKs. RPTKs are transmembrane proteins with cytoplasmic tyrosine kinase activity and 
initiate mitogenic signaling pathways, including the PI3K/AKT/mTORC1 signaling axis. The 
biological processes that are regulated by RPTKs are diverse and include cell growth, cell size, 
adhesion, migration, invasion and others. Here we focus on the ErbB family and the related 
insulin receptor (IR) and insulin-like growth factor receptor (IGFR). Ligand binding and 
subsequent dimerization initiates RPTK activation through receptor autophosphorylation. 
Signaling adaptor proteins are then recruited to the receptors via their SH2 domain and activation 
downstream effector cascades. EGFR activation is well characterized, with distinct 
autophosphorylation events triggering the activation of multiple downstream effectors, including 
Grb2, Shc, and PLCγ (Fernandes et al., 2001; Levkowitz et al., 1999; Rojas et al., 1996). IR and 
IGFR are autophosphorylated in a conserved kinase activation loop that also activates 
downstream effector signaling (Hernandez-Sanchez et al., 1995; White et al., 1988). ErbB and 
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IR/IGFR autophosphorylation induces receptor internalization through clathrin mediated 
endocytosis, an event that is also associated with receptor activation and can either lead to 
receptor recycling to the cell surface or receptor degradation (Sigismund et al., 2008; Wang et 
al., 2005). The consequences of either ErbB or IR/IGFR receptor activation have the shared 
effect of activating downstream signaling cascades including AKT and mTORC1, which has 
been shown previously to be activated by HPV16 E6.  
 
Here we report that HPV16 E6 activates RPTK signal transduction under conditions of nutrient 
deprivation. We show that HPV16 E6 increases the phosphorylation of IR, IGFR, and ErbB 
RPTKs. RPTK activation causes the activation of downstream signaling pathways under 
conditions that simulate metabolic stress and increased viral oncoprotein expression as would 
occur naturally during HPV induced infection. We also show that HPV16 E6 causes an increase 
in the internalization of phosphorylated receptor species. We identify the association of HPV16 
E6 with Grb2 and demonstrate that Grb2 knockdown abrogates HPV16 E6 mediated mTORC1 
activation. We also show that the HPV16 E6 mediated increase in RPTK activation causes an 
increase in cellular migration, and that HPV16 E6 can maintain an increase in cellular migration 
in the absence of growth factors, which may be relevant to HPV associated carcinogenesis. 
Together these results show that HPV16 E6 activates RPTKs and the RPTK 
PI3K/AKT/mTORC1 and Ras/MEK/ERK effector signaling pathways in the absence of growth 
factor ligands.  
 
Materials and Methods 
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Plasmids:  
Plasmids used in this study include the retroviral vectors pLXSN (control) and pLXSN HPV16 
E6 (Halbert et al., 1992); and pCMV N (control) and pCMV HPV16 NE6no* (Baker et al., 1990; 
Munger et al., 1989). Lentiviral vectors including pLentiN (control) and pLenti HPV16 NE6no* 
were generated by Gateway cloning into the pLenti6.3 gateway compatible vector (Invitrogen). 
For the purposes of this study, the HPV16 E6 expression vectors were mutagenized such that 
they no longer have the capacity to generate the major splice variants (Sedman et al., 1991). Site 
directed mutagenesis was used to eliminate two donor splice site within HPV16 E6, with the 
resulting HPV16 E6 V42L mutant termed HPV16 E6no*. Mutagenesis at this site yields a 
coding in E6 that does not interfere with the ability of HPV16 E6 to contribute to epithelial cell 
immortalization. The pFR_CrPV_xb bicistronic firefly/Renilla luciferase vector (Petersen et al., 
2006) was used for luciferase reporter assays and was obtained from Phil Sharp through 
Addgene (plasmid 11509).  
 
Cell lines and Culture: 
293T and U2OS cells (ATCC) were maintained in Dulbecco’s modified Eagle medium (DMEM) 
(Invitrogen), supplemented with 10% fetal bovine serum (FBS), 50 U/ml penicillin and 50 µg/ml 
streptomycin. Primary human foreskin keratinocytes were isolated from anonymous newborn 
circumcisions as previously described (McLaughlin-Drubin et al., 2008), and maintained in 
keratinocyte serum-free medium (KSFM) supplemented with human recombinant epidermal 
growth factor 1-53, bovine pituitary extract (Invitrogen), 50 U/ml penicillin and 50 µg/ml 
streptomycin, 20 µg/ml gentamicin, and 1 µg/ml amphotericin B. HPV onocogene expressing 
HFKs were generated by either retroviral infection with the corresponding pLXSN based vectors 
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or lentiviral infection with the corresponding pLenti6.3N based vectors. pLXSN or pLenti6.3N 
vector expressing cells were maintained following neomycin selection (250 µg/ml) or blasticidin 
selection (3 µg/ml), respectively. All experiments were performed with HFKs passaged less than 
ten times. For nutrient deprivation assays, HFKs were grown to 90% confluence, at which point 
they were washed twice with phosphate buffered saline (PBS), followed by incubation in either 
PBS for 15 minutes or KSFM lacking EGF for 2 hours prior to analysis. Poly-D-lysine coated 
plates (BD Biosciences) were used for experiments in which HFKs were starved in PBS for 15 
minutes. Cells were then scraped and cleared by centrifugation at 16,110 x g for 10 min at 4°C.  
 
Western blotting and antibodies: 
Unless otherwise indicated, protein lysates were prepared by incubating the cells in ML buffer 
(300 mM NaCl, 0.5% Nonidet P-40 [NP-40], 20 mM Tris-HCl [pH 8.0], 1 mM EDTA) 
supplemented with one complete EDTA-free protease inhibitor cocktail tablet (Roche) per 25 ml 
lysis buffer and one PhosSTOP phosphatase inhibitor cocktail tablet (Roche) per 7.5 ml lysis 
buffer) (McLaughlin-Drubin et al., 2008). Cell lysates intended for global phosphotyrosine 
Western blots were prepared by incubating the cells in RIPA buffer (150 mM NaCl, 1% NP-40, 
0.5% Deoxycholic acid [DOC], 0.1% SDS, 50 mM Tris-HCl [pH 7.5]), supplemented as 
described above for ML Buffer with the addition of 50 mM Pervanadate). Cell lysates intended 
for HA immunoprecipitation and immunoaffinity purification were prepared by incubating the 
cells in MC lysis buffer (50 mM Tris [pH 7.5], 150 mM NaCl, 0.5% NP-40, supplemented with 
one complete EDTA protease inhibitor cocktail tablet (Roche). Cells were then scraped and 
lysates cleared by centrifugation at 16,110 x g for 10 min at 4oC. Protein concentrations were 
determined using the Bradford method (Bio-Rad). Proteins were separated by SDS-PAGE and 
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electrotransferred onto polyvinylidene difluoride membranes (Immobilon-P; Millipore). Unless 
otherwise noted, membranes were blocked in 5% nonfat dry milk in TBST (137 mM NaCl, 2.7 
mM KCl, 25 mM Tris [pH 7.4], 0.1% Tween 20) and probed with the appropriate antibody. The 
following antibodies were used at a 1:1000 dilution unless otherwise specified: β-Actin (1501; 
Chemicon), p53 (Ab-6, Calbiochem), Grb2 (ab86713, Abcam), Flag (4 µg/ml, F3165, Sigma), 
anti-phosphotyrosine (05-1050X, Millipore), EphRA2 (NBP1-47400, Novus Biologicals), 
PDGFR (3174), ErbB2 (2165), EGFR (4267), EGFR Y992 (2235), EGFR Y1068 (3777), EGFR 
Y1173 (4407), S6K (9202), S6K T389 (9206), RSK (9333), RSK S380 (9335), ERK (9102), 
ERK T202/Y204 (4370), IGF-1Rβ (3027), IGF-1Rβ Y1135/36/IRβ Y1150/51 (3024), PI3K 
p110α (4249), PI3K p110β (3011), PI3K Class III (3358), PTEN (9188), all from Cell Signaling 
Technology. Secondary anti-mouse and anti-rabbit antibodies conjugated to horseradish 
peroxidase were used at dilutions of 1:10,000 or 1:15,000, respectively. Proteins were visualized 
by enhanced chemiluminescence (Perkin Elmer, Millipore) and exposed on Kodak BioMax XAR 
film, or electronically acquired and quantified with a Kodak Image Station 4000R equipped with 
Kodak Imaging Software, version 4.0, or with a Carestream Gel Logic 4000 pro, equipped with 
Kodak Imaging Software, version 4.0. 
 
Immunoaffinity purification  
For HA immunoaffinity purifications, four 15cm plates of 293T cells were seeded at a density of 
40% and CaCl2 transfected with the appropriate NCMV vector (NCMV, HPV16 E6no*, HPV16 
E6no* I128T, HPV16 E6no*PDZ, HPV18 E6 no*, HPV6b E6, HPV11 E6, HPV5 E6, or HPV8 
E6) at 24 hours after seeding. 72 hours post transfection the cells were lysed in MC buffer and 
lysates were subsequently cleared by centrifugation at 16,110 x g for 10 min at 4oC. Protein 
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concentrations were determined using the Bradford method (Bio-Rad). Lysates were cleared with 
low-binding Durapore PVDF 0.45 µM membrane spin filters (Millipore) and protein 
concentration was subsequently measured using the Bradford method (Bio-rad). 60µl of 
prewashed HA antibody-agarose conjugate (Sigma) was then incubated with 3 ml lysate for 2 
hrs, washed, and eluted three times for 30 min with 250 µg/ml HA peptide (Sigma) in PBS. Ten 
percent of total eluate was separated by SDS PAGE and silver stained using the Silverquest 
staining kit (Invitrogen). The remainder was concentrated by precipitation with 20% 
trichloroacetic acid (TCA) and analyzed mass spectrometry at the Taplin Mass Spectrometry 
Core facility (Harvard Medical School).  
 
Phosphotyrosine Immunoprecipitations 
For phosphotyrosine immunoprecipitations, cells were grown under normal growth conditions or 
starved of EGF in KSFM lacking EGF for 2 hrs, at 37oC, prior to lysis. Cell lysates were 
prepared in ML buffer. Lysates were pre-cleared in 25 µl prewashed Sepharose (Sigma) for 1 
hour, rocking at 4oC and then incubated with 25 µl prewashed anti-phosphotyrosine antibody-
agarose conjugate (Millipore) for 3 hrs, rocking at 4oC. Following immunoprecipitation, the 
beads were washed and sample buffer added, and proteins separated by SDS PAGE and 
transferred onto PVDF membrane for Western blotting against ERBB2, EPHA2, PDGFR, and 
actin.  
 
Receptor Internalization Assay 
Internalization Assay: Primary HFKs were seeded into 15cm dishes and internalization and 
degradation assays were performed when the cells reached 90% confluence. Cells were washed 
 
 
 109 
twice in ice cold PBS-CM buffer (PBS, 1 mM MgCl2, 0.l mM CaCl2) followed by a 40 min 
incubation in 5 ml PBS-CM with the addition of 0.5 mg/ml sulfo NHS-SS-Biotin (Pierce), 
rocking at 4oC. Cells were then washed two additional times in PBS-CM and incubated with PBS 
containing 50 mM NH4Cl for 10 min, rocking at 4oC, followed by two washes in PBS-CM. 
Considering HFKs are sensitive to brief changes in nutrient availability, cells were at this point 
considered “starved” (Spangle and Munger, 2010). KSFM without any growth factors and 
supplements was added to one plate in order to investigate ligand independent receptor 
internalization over 180 minutes. A true generalized ligand independent internalization 
experiment would have involved incubation in PBS over the full 180 min time course, but that is 
not feasible in HFKs due to their loss of adherence in the absence of growth media at 37oC. Total 
cell surface receptors were measured by directly lysing one plate without stimulation or 
subsequent glutathione reduction. Following stimulation, cells were washed twice with PBS-CM 
and reduced by washing twice for 15 min each with Glutathione Buffer (50 mM reduced 
glutathione, 90 mM NaCl, 1 mM MgC12, 0.1 mM CaC12, 60 mM NaOH) rocking, at 4°C. Cells 
were then washed twice with PBS-CM followed by one 15 min wash with PBS-IAA (PBS 
containing 50mM Iodoacetamide), rocking at 4oC. Lysates were then prepared by incubating 
cells with ID lysis buffer (200 mM NaCl, 75 mM Tris [pH 7.5], 2.5 mM EDTA, 2.5 mM EGTA, 
1.5% Triton X-100, 0.75% NP40, 0.1% SDS), supplemented with one complete EDTA protease 
inhibitor cocktail tablet (Roche) and one PhosStop phosphatase inhibitor cocktail tablet (Roche). 
Receptor internalization assays were performed by pre-clearing lysate with 40 µl Pansorbin 
(Calbiochem) for 45 min, after which the Pansorbin was removed by centrifugation at 16,110 x g 
for 10 min at 4oC. The pre-cleared lysate was then incubated with 40 µl of washed Streptavidin-
agarose resin (Thermo Scientific) for 16 hrs, rocking at 4oC, after which the beads were washed 
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four times in ID buffer, 2X sample buffer was added, and proteins separated by SDS PAGE and 
electrotransferred onto PVDF for Western blotting with EGFR, IR/IGFR, and actin antibodies.  
 
Wound Healing Assay 
Primary HFKs were seeded into 6cm dishes and a wound was introduced into the monolayer 
with a p200 pipette tip when the cells reached 90% confluence. Just prior to wounding the 
monolayer, the cells were washed two times with PBS and the media was replaced with KSFM 
lacking EGF for the minus EGF condition or with complete KSFM for the plus EGF condition, 
plus inhibitors when applicable. The cells were then incubated over a time course at 37oC. 
Images of the wounded monolayer were captured at t = 0, t = 13h, and t = 25h for the minus EGF 
condition and t = 0, t = 7h, t = 13h, and t = 25hr for the plus EGF condition using a Zeiss light 
microscope equipped with the Axiovision Release 4.4 SP2 software package. The surface area of 
each resulting image was calculated using Image J software (NIH). The surface area relative to 
the samples at t = 0 was determined. A total of 3 independent experiments were performed and 
statistical significance was calculated using the Student’s T test.  
 
Transwell Migration Assay 
Primary HFKs were trypsinized and resuspended in KSFM minus EGF. 30,000 HFKs were 
resuspended in 150 µl of KSFM minus EGF and placed in the upper chamber of a transwell 
permeable support membrane insert (8.0 µM, Costar® product 3422) pre-wetted with 50 µl 
KSFM minus EGF. The bottom chamber was filled with 600 µl KSFM minus EGF, and the cells 
were incubated at 37oC for 30 minutes or one hour. Cells were then scraped from the upper 
chamber of the transwell membrane and the membrane was fixed with 100% methanol for 30 
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minutes and stained with Crystal Violet. Cells remaining on the underside of the membrane were 
then counted in three separate fields of view per experiment. A total of three independent 
experiments were performed and statistical significance calculated using the Student’s T test.  
 
Transfections and luciferase Assays 
U2OS cells were transfected as described in (Spangle and Munger, 2010). In brief, cells were 
transfected in triplicate in 6-well plates for luciferase reporter assays using FuGene 6 (Roche). 
One microgram of pFR_CrPV_xb was co-transfected with two µg NCMV or NCMV 16E6no*. 
Forty-eight hours post transfection, cells were lysed in 450 µl passive lysis buffer (dual 
luciferase reporter kit; Promega) per well. The supernatants were subjected to the dual luciferase 
reporter assay. The fold change in activity was determined by calculating the ratio of firefly 
activity to Renilla luciferase activity compared to the control vector-transfected cells. Three 
independent experiments were performed and the Student’s T test was used to calculate 
statistical significance.  
 
siRNA Transfections 
HFKs were seeded in 6 well dishes in triplicate and siRNA against Grb2 (smart pool, 
Dharmacon) or scrambled siRNA was transfected with Lipofecamine 2000 (Invitrogen) to a final 
concentration of 40 nM. Lysates were prepared 72 hrs post transfection.  
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Results:  
Receptor protein tyrosine kinase signaling pathways remain activated in HPV16 E6 
expressing cells subjected to EGF deprivation. We previously published that HPV16 E6 
activates S6K and 4E-BP1 through mTORC1. We determined that persistent AKT 
phosphorylation under conditions of nutrient deprivation resulted from PDK1 and mTORC2 
activation (Spangle and Munger, 2010). To determine the origin of activation, we first evaluated 
the phosphorylation of receptor protein tyrosine kinases (RPTKs). Activation of RPTK signaling 
is initiated by the autophosphorylation of tyrosine residues on the intracellular domains of these 
proteins. We therefore determined if HPV16 E6 expression increases the phosphorylation of 
cellular proteins at tyrosine residues in primary HFKs under conditions of nutrient deprivation. 
Cells were starved either by EGF withdrawal for two hours or with PBS treatment for 15 
minutes, followed by evaluation of tyrosine phosphorylation. HPV16 E6 expression sustains the 
phosphorylation of tyrosine residues in HFKs starved of EGF for two hours (Fig 4.1). Tyrosine 
phosphorylation is also sustained at a higher level in HPV16 E6 expressing cells than in control 
cells upon more stringent PBS starvation.  
 We next specifically evaluated ErbB2 tyrosine phosphorylation. Phosphotyrosine 
immunoprecipitation followed by Western blotting demonstrates that HPV16 E6 increases the 
phosphorylation of ErbB2 growing normally in keratinocyte serum free media (Figure 4.2A, 
left). ErbB2 tyrosine phosphorylation is also higher in HPV16 E6 expressing cells as compared 
to control cells when the cells were grown for 2 hrs in the absence of EGF in the growth medium 
(Figure 4.2A, right). In contrast, the tyrosine phosphorylation of the unrelated EphRA2 and 
PDGFR was comparable in HPV16 E6 and control cells grown under conditions of normal 
growth media and in the absence of EGF (Fig 4.2A). EGFR autophosphorylation and 
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Figure 4.1. HPV16 E6 increases global phosphorylation of cellular proteins at tyrosine 
residues in nutrient deprived HFKs. Western blot analysis of proteins phosphorylated at 
tyrosine residues in HFK populations with stable expression of a control vector or HPV16 E6 
experiencing nutrient deprivation by EGF withdrawal for two hours (left) or PBS starvation for 
15 minutes (right). Actin is shown as a loading control 
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activation is well described, with the phosphorylation of specific tyrosine residues linked to the 
subsequent recruitment of adaptor proteins and the activation of specific effector signaling 
pathways. We next evaluated EGFR autophosphorylation at specific tyrosine residues. Under 
conditions of EGF starvation, Western blot experiments with phosphospecific antibodies 
revealed that HPV16 E6 maintains the autophosphorylation and presumably activation of EGFR 
at least three identified residues: Y992, Y1068, and Y1173, which are associated with PLCγ 
activation, Grb2 binding and MAPK/PI3K signaling, and Shc binding and MAPK signaling, 
respectively (Figure 4.2B). It should be noted that we did not detect a change in the 
phosphorylation of EGFR Y1045 in HPV16 expressing HFKs, which is associated with c-Cbl 
mediated targeting of EGFR for degradation (data not shown). We next considered the 
possibility that HPV16 E6 may be activating multiple RPTKs. We evaluated the phosphorylation 
status and activation of insulin receptor-β (IRβ) and insulin-like growth factor receptor-β (IGFI-
Rβ) utilizing an antibody that recognizes specific phosphorylated tyrosine resides on both 
receptors: Y1135/36 on IRβ and Y1150/51 on IGFI-Rβ HPV16 E6 maintains the 
autophosphorylation of IRβ/IGF-IRβ under conditions of nutrient deprivation (Figure 4.2C).  
 Thus, immunoprecipitation and Western blot experiments confirm the activation of ErbB, 
IR, and IGFR by HPV16 E6 under normal growth conditions as well as after EGF starvation.  
 
HPV16 E6 causes the activation of RPTK effector signaling. Our group and others have 
shown that HPV16 E6 activates mTORC1 (Lu et al., 2004; Spangle and Munger, 2010), and that 
E6 mediated mTORC1 activation causes an increase in translation of capped mRNAs (Spangle 
and Munger, 2010). HPV16 E6 has also been reported to activate FAK signaling, which is also 
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Figure 4.2. ERBB2 phosphorylation is increased in HPV16 E6 expressing primary HFKs. 
(A) Western blot analysis of ERBB2, EPHRA2, and PDGFR following phospho-tyrosine 
immunoprecipitation (IP) of HFK lysates stably expressing HPV16 E6 or the pLentiN6.3 control 
vector under two separate growth treatments (KSFM, left; EGF withdrawal for 2 hours, right). 
For each IP, 10% input is on the left of the IP. (B) and (C) Western blot analysis indicating the 
phosphorylation status of EGFR(B) or IR/IGFR (C) in HPV16 E6 or LXSN control vector 
expressing stable HFKs. 
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a RPTK effector (McCormack et al., 1997; Vande Pol et al., 1998). Given that we detected a 
maintenance of EGFR Y1068 and Y1173 phosphorylation, and IRβ/IGFI-Rβ phosphorylation, 
all of which are associated with RAS/MAPK signaling, we evaluated MAPK activity under 
conditions of EGF withdrawal. HPV16 E6 expression sustains the phosphorylation and 
activation of MAPK effectors ERK1/2, and the ERK substrate RSK in comparison to control 
cells (Figure 4.3A). In addition to mTORC1, Ras/MAPK signaling can activate cap dependent 
translation through the RSK mediated phosphorylation of the ribosomal protein S6 (S6 S235/36). 
To determine if MAPK signaling is required for HPV16 E6 to activate cap dependent translation, 
we utilized a bicistronic luciferase reporter construct (Petersen et al., 2006). In brief, U2OS cells 
were transiently transfected with the reporter construct and a vector expressing HPV16 E6 or 
empty vector, and MAPK activity was inhibited with the MEK inhibitor U0126 or DMSO. 
DMSO treatment indicates that HPV16 E6 increases cap dependent translation, as previously 
described (Figure 4.3C, black bars) (Spangle and Munger, 2010). However, the HPV16 E6 
mediated increase in cap dependent translation is sensitive to MEK inhibition (Figure 4.3C, dark 
grey bars). It was previously shown that mTORC1 activity is partially required for HPV16 E6 to 
activate cap dependent translation (Spangle and Munger, 2010). To determine the relative 
contribution of MAPK and mTORC1 activation in HPV16 E6 mediated increase of protein 
synthesis, Rapamycin and U0126 were used to simultaneously inhibit mTORC1 and MAPK. The 
sensitivity of HPV16 E6 mediated increase in cap dependent translation to MAPK and mTORC1 
co-inhibition is additive (Figure 4.3C, light grey bars). Western blots demonstrate that U0126 
treatment effectively inhibits MEK signaling and are shown in Figure 4.3B.  
 
 
 117 
 
 
 
 
Figure 4.3. Signaling pathways downstream of RPTKs are activated by HPV16 E6. (A) 
Western blot analysis of MAPK signaling in primary HFKs stably expressing HPV16 E6 or 
LSXN control vector and experiencing nutrient withdrawal. (B) Western blot analysis of MAPK 
signaling in primary HFKs stably expressing HPV16 E6 or LXSN control vector under 
conditions of MAPK inhibition. 30 minutes prior to lysis, cells were treated with DMSO or the 
MEK inhibitor U0126 (15 µM). (C) HPV16 E6 mediated increase in cap dependent translation is 
dependent on MEK and mTORC1 signaling. U2OS cells were transfected with pFR_CrPV_xb 
and the indicated plasmids and processed for firefly and Renilla luciferase activity at 48 hours 
post transfection. 20 hours prior to lysis, cells were treated with DMSO, 10 µM U0126, or a 
combination of 10 µM U0126 and 100 nM rapamycin. Firefly and Renilla luciferase were 
normalized to DMSO treated cells and presented as fold changes of normalized firefly relative to 
normalized Renilla activity. The bar graph represents the average and standard deviation of three 
experiments, each performed in triplicate.  
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EGFR or IR/IGFR inhibition reduces mTORC1 activation in HPV16 E6 expressing 
primary HFKs. We next hypothesized that if RPTK signal transduction is required for HPV16 
E6 mediated mTORC1 activation, RPTK inhibition should abrogate the E6 mediated mTORC1 
activation. Treatment of cells with Gefitinib reduced EGFR autophosphorylation on Y1068 in 
control and HPV16 E6 expressing cells (Fig 4.4A). EGFR inhibition with Gefitinib partly 
inhibited the E6 mediated increase in S6K phosphorylation. There was some increase in S6K 
phosphorylation over the time course of inhibitor treatment in both control and E6 expressing 
cells. This may be due to a compensatory activation of other RPTKs that activate mTORC1, such 
as IRβ/IGFI-Rβ. IRβ/IGFI-Rβ inhibition with OSI-906 had similar effects with efficient receptor 
inhibition in both E6 and control cells, although receptor inhibition in E6 expressing HFKs was 
not as complete as in control HFKs at early time points (Fig 4.4B). Shortly after IR/IGFR 
inhibition S6K phosphorylation increased in both control and HPV16 E6 expressing cells, 
potentially suggesting compensatory S6K phosphorylation, perhaps via EGFR signaling. Indeed, 
AKT activation has been shown to occur upon MAPK inhibition (Yu et al., 2002). 
 These results demonstrate that EGFR and IRβ/IGFI-Rβ RPTKs may independently 
activate mTORC1 in HPV16 E6 expressing HFKs.  
 
HPV16 E6 increases internalization of activated receptor species. HPV16 E6 may activate 
RPTK and RPTK effector signaling through several different mechanisms. HPV16 E6 may be 
targeting protein or lipid phosphatases for degradation. We evaluated PTEN, SHP1 and PTP1b  
by Western blot and found no evidence for destabilization under normal growth conditions (Fig 
4.5A and data not shown) or after nutrient deprivation by PBS starvation (Fig 4.5B). It has also 
been reported that PTEN activity may be dependent on subcellular localization, since NEDD4.1 
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Figure 4.4. RPTK inhibition reduces mTORC1 activation in HPV16 E6 expressing HFKs. 
(A) Western blot analysis of EGFR and mTORC1 activation in HFKs stably expressing HPV16 
E6 or pLentiN6.3 control vector following EGFR chemical inhibition with Gefitinib. Cells were 
treated with DMSO or 1 µM Gefitinib over a 24 hour time course. Actin is shown as a loading 
control. (B) Western blot analysis of IRβ/IGFRβ and mTORC1 activation in HFKs stably 
expressing HPV16 E6 or pLentiN6.3 control vector following IRβ/IGFRβ chemical inhibition 
with OSI-906. Cells were treated with DMSO or 150 nM OSI-906 over a 6 hour time course. 
Actin is shown as a loading control.  
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Figure 4.5. HPV16 E6 mediated activation of AKT/MAPK is not due to the destabilization 
or change in localization of phosphatases. For (A) and (B), actin is shown as a loading control. 
(A) Western blot analysis of the dual specificity phosphatase PTEN in HFKs with stable 
expression of a control vector of HPV16 E6 under normal growth conditions (KSFM).  (B) 
Western blot analysis of PTEN, PTP1b and SHP1 in HFKs with stable expression of a control 
vector of HPV16 E6 under conditions of nutrient deprivation (PBS, 15 minutes). (C) Confocal 
Immunofluorescence imaging of PTEN (green) subcellular localization in control or HPV16 E6 
expressing HFKs. The nuclei are stained with DRAQ5 (blue).  
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mediated PTEN monoubiquitination increases PTEN localization to the nucleus (Wang et al., 
2007). It has also been shown that PTEN nuclear localization is increased when cells are 
deficient in ATP (Lobo et al., 2008). We found no detectable change in PTEN subcellular 
localization in HPV16 E6 expressing HFKs (Fig 4.5C). We next considered the possibility that 
HPV16 E6 may affect receptor internalization or degradation. Since HPV16 E6 causes RPTK 
and AKT activation under conditions of nutrient deprivation, the internalization of cell surface 
receptors was evaluated in the absence of ligand in KSFM lacking EGF and other supplements. 
HPV16 E6 increases the internalization of phosphorylated EGFR, IR and IGFR receptor species 
in the absence of growth factors (Fig 4.6A, lanes without supplements). HPV16 E6 also reduces 
EGFR half-life from 11.5 hrs to 8.3 hrs, which supports an E6 mediated increase in receptor 
degradation (Fig 4.6B). 
 These results suggest that HPV16 E6 mediated activation of RPTK signaling and 
downstream effector cascades is the result of a direct effect on the receptors, increasing the 
internalization and subsequent degradation of activated receptors.  
 
HPV16 E6 association with the signaling adaptor protein Grb2 causes mTORC1 activation. 
To determine if HPV16 E6 activates RPTKs through protein-protein interactions, we performed 
affinity purification/mass spectrometry experiments to identify HPV E6 interacting proteins. We 
transiently transfected 293T cells with amino terminally Flag-HA epitope tagged HPV16 E6 and 
performed HA affinity purification followed by LC-MS-MS (Fig 4.7). We confirmed known 
binding partners including E6AP (UBE3A), p53 and multiple PDZ proteins including LIN7C, 
Dlg, and hScrib (Appendix 1). We also identified novel potential binding partners including 
Grb2, a signaling adaptor protein that associates with autophosphorylated receptors, 
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Figure 4.6. HPV16 E6 increases the internalization and degradation of activated receptor 
species. (A). Western blot analysis of EGFR (middle) and IR/IGFR (bottom) following receptor 
internalization, with non-reduced (NR) measuring surface-bound receptors, starved (ST) 
measuring ligand independent internalization, and the time course representing time (in minutes) 
of keratinocyte growth media stimulation to promote receptor internalization prior to harvesting 
and immunoprecipitation. Internalization assays were performed as described in the Materials 
and Methods. Levels of EGFR and IR/IGFR in a 5 µg sample, representing 1% of the 
internalization assay/resulting streptavidin immunoprecipitation, together with actin, are shown 
in the top panel (Input). (B) Western blot analysis of EGFR half-life following 10 µg/ml 
cycloheximide treatment. Actin is shown as a loading control.  
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Figure 4.7. Identification of HPV E6 associated cellular proteins. (A) Silver stain of HA-
Immunoprecipitation eluate (10% of total IP) of 293T cells transiently transfected with Flag-HA 
epitope tagged HPV16 E6 or HPV16 E6 mutants (I128T, PDZ). All HPV16 E6 vectors lack the 
splice donor site and therefore do not produce the internally spliced ‘*’ or ‘**’ transcripts. 48 
hours post transfection, cells were lysed and HA affinity purification was performed. (B) Silver 
stain of HA-Immunoprecipitation eluate (10% of total reaction) of 293T cells transiently 
transfected with amino terminally Flag-HA epitope tagged HPV E6 proteins (Cutaneous: 5, 8; 
low-risk mucosal: 6b, 11; high-risk mucosal: 18; high-risk HPV16 E6 splice variants: 16E6*, 
16E6**). 48 hours post transfection, cells were lysed and the IP was performed.  
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specifically EGFR at phosphotyrosine 1068 and activates PI3K and MAPK signaling. This is 
consistent with our results that suggest that HVP16 E6 increases the phosphorylation of Y1068, 
an event that promotes the association of Grb2 with EGFR (Figure 4.2B). The association of 
HPV16 E6 and Grb2 was confirmed by immunoprecipitation/Western blot experiments under 
standard conditions as well as under conditions of in vivo crosslinking (Figure 4.8A). We next 
determined if Grb2 is important in the HPV16 E6 mediated activation of mTORC1 by depleting 
Grb2 and evaluating mTORC1 activation. Grb2 knockdown reduced the phosphorylation of the 
mTORC1 surrogate marker S6K in HPV16 E6 expressing HFKs but not in control HFKs (Figure 
4.8B).  
 Together these results demonstrate that HPV16 E6 associates with the signaling adaptor 
protein, Grb2, and that Grb2 is important for HPV16 E6 mediated mTORC1 activation.  
 
HPV16 E6 increases cellular migration through a RPTK dependent mechanism 
Our group has shown that HPV16 E6 activates two RPTK effector signaling pathways: 
mTORC1 (Spangle and Munger, 2010) and MAPK (Fig 4.3). The activation of mTORC1 and 
MAPK signaling pathways promote cellular events that are widely associated with 
carcinogenesis including cellular migration. Therefore, we hypothesized that HPV16 E6 
mediated RPTK activation increases cellular migration by wound healing and transwell 
migration assays. First, wounds were introduced into the primary HFK monolayer in the 
presence or absence of EGF. HFKs with stable HPV16 E6 expression efficiently migrated to 
close the wounded area over a 25 hour time course in the presence of EGF with greater 
efficiency when compared to HFKs expressing empty vector (Fig 4.9, relative reduction in  
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Figure 4.8. HPV16 E6 associates with signaling adaptor protein Grb2, which is important 
for HPV16 E6 mediated mTORC1 activation. (A) Western blot analysis of Grb2 and Flag-HA 
epitope tagged HPV16 E6 following HA immunoprecipitation of Grb2 in NCMV HPV16 E6 or 
control vector transfected 293T cells (right panel). Immunoprecipitation was performed under 
native DSP crosslinking conditions. Levels of HPV16 E6 (Flag) and Grb2 in a 35 µg sample, 
representing 1.5% of the IP are shown on the left, with actin as a loading control (Input). (B). 
Western blot analysis of S6K T389 in Grb2 siRNA transfected HFK populations with stable 
expression of a control vector or HPV16 E6. 48 hours prior to lysis, cells were transiently 
transfected with a siRNA pool specific to Grb2. An actin blot is shown as a loading control.  
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surface area at t = 25h, 0.25 ± 0.03 and 0.66 ± 0.04, respectively; p = 0.0065). Interestingly, 
HPV16 E6 expression caused an even more rapid and significant decrease in the surface area of 
the wound in the absence of EGF over the same time course in comparison to empty vector (Fig 
4.10, relative reduction in surface area at t = 13h, 0.2 ± 0.06 and 0.87 ± 0.09, respectively; p < 
0.0001). We next determined if the inhibition of RPTKs may inhibit the ability of HPV16 E6 to 
increase cellular migration in wound healing assays. Treatment with the EGFR inhibitor 
Gefitinib or the IR/IGFR inhibitor OSI-906 impaired HPV16 E6 mediated cellular migration in 
the presence and absence of EGF such that no statistical difference between HPV16 E6 and 
empty vector expressing cells were observed (Fig 4.9, plus EGF relative reduction in surface area 
at t = 25h, 0.80 ± 0.02 and 0.90 ± 0.16 (Gefitinib), 0.60 ± 0.40 and 0.82 ± 0.12 (OSI-906), 
respectively; Fig 4.10 minus EGF relative reduction in surface area at t = 13h, 0.63 ± 0.01 and 
0.96 ± 0.07 (Gefitinib), 0.83 ± 0.05 and 0.84 ± 0.17 (OSI-906), respectively). As expected, the 
inhibition of either mTORC1 or MEK signaling also inhibit the ability of HPV16 E6 to increase 
cellular migration in wound healing assays in the presence and absence of EGF (Fig 4.9, plus 
EGF relative reduction in surface area at t = 25h, 0.57 ±0.22 and 0.71 ± 0.21 (Rapamycin), 0.78 
± 0.07 and 0.84 ±0.17 (U0126), respectively; Fig 4.10 minus EGF relative reduction in surface 
area at t = 13h, 0.67 ±0.01 and 0.85 ± 0.22 (Rapamycin), 0.86 ± 0.1 and 0.87 ± 0.04 (U0126), 
respectively. 
 We also evaluated if HPV16 E6 increases the migration of primary HFKs through a size 
restricting membrane in the transwell migration assay in the absence of EGF over a short time 
course to eliminate cell division. Stable expression of HPV16 E6 causes an increase in cellular 
migration through the membrane as early as 1 hour, in the absence of EGF (Fig 4.10, fold change 
in migration relative to control, 1.75 ± 0.4, p = 0.0319).  
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Figure 4.9. HPV16 E6 increases cellular migration in the presence of EGF. Wound healing 
assay with HFKs stably expressing HPV16 E6 or pLentiN6.3 control vector following wounding 
of the cellular monolayer under normal growth conditions following RPTK and effector pathway 
inhibition with Gefitinib, OSI-906, Rapamycin, or U0126. Cells were treated with DMSO or 100 
nM Rapamycin, 1 µM Gefitinib, 150 nM OSI-906, or 10 µM U0126 and closure of the 
monolayer was measured over a 25h time course. (B). Quantification of wound closure as shown 
in (A). Surface area of wounds were calculated relative to the surface area of the wound at t = 0h. 
The bar represents the average and standard deviation of four experiments for DMSO treated 
samples and two experiments for drug treated samples; asterisks indicate statistical significance 
(P < 0.05).  
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Figure 4.10. HPV16 E6 increases cellular migration in the absence of EGF. (A). Wound 
healing assay with HFKs stably expressing HPV16 E6 or pLentiN6.3 control vector following 
wounding of the cellular monolayer in the absence of EGF following RPTK and effector 
pathway inhibition with Gefitinib, OSI-906, Rapamycin, or U0126. Cells were treated with 
DMSO or 100 nM Rapamycin, 1 µM Gefitinib, 150 nM OSI-906, or 10 µM U0126 and closure 
of the monolayer was measured over a 25h time course. (B). Quantification of wound closure as 
shown in (A). Surface area of wounds were calculated relative to the surface area of the wound at 
t = 0h. The bar represents the average and standard deviation of three experiments; asterisks 
indicate statistical significance (P < 0.001). (C). Transwell migration assay with HFKs stably 
expressing HPV16 E6 or pLentiN6.3 control vector following the seeding of cells in the absence 
of EGF on the top chamber of a transwell insert and determining migration to the bottom 
chamber in the absence of EGF. The bars represent the average and the standard deviation of 
four experiments for DMSO treated samples and two experiments for drug treated samples; the 
asterisk indicates statistical significance (P < 0.05).  
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 These results suggest that under both normal growth conditions (+EGF) and in the 
absence of RPTK ligand (-EGF) HPV16 E6 increases the migration of primary HFKs, and that 
EGFR/IR/IGFR effector signaling pathways are required for efficient HPV16 E6 mediated 
cellular migration.    
 
Discussion: 
 A combined approach of phosphotyrosine immunoprecipitations and Western blotting for 
activated receptor species under normal growth conditions and EGF withdrawal revealed that 
HPV16 E6 expression causes sustained activation of RPTKs including ErbB2, EGFR, IRβ and 
IGFR1β-R (Fig 4.2) under normal growth conditions as well as in the absence of their growth 
factor ligands. Activation of downstream signaling cascades including the RAS/MAPK pathway 
was also demonstrated. Previous studies demonstrated that HPV16 E6 activates mTORC1 and 
increases cap dependent translation through a PDK1 and mTORC2 dependent mechanism. Cap 
dependent translation is reduced in U0126 treated HPV16 E6 cells as well as in control vector-
transfected cells. The combined inhibition of MEK and mTORC1 further reduces cap dependent 
translation. This may suggest that HPV16 E6 activates cap dependent translation through two at 
least partially independent signaling pathways that are both downstream of RPTKs. This further 
supports HPV16 E6 mediated activation of RPTKs. We show that EGFR or IRβ/IGFR1β-R 
inhibition abrogates HPV16 E6 mediated mTORC1 activation as indicated by reduced 
phosphorylation of the surrogate marker S6K. We are in the process of testing the effect of 
EGFR and/or IRβ/IGFR1β-R inhibition on E6 mediated increase of cap dependent translation. 
We hypothesize that EGFR and/or IRβ/IGFR1β-R inhibition will have similar effects on the 
HPV16 E6 mediated increase of cap dependent translation as MEK and/or mTORC1 inhibition, 
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further implicating RPTK activation in downstream signal activation driven by the HPV16 E6 
oncoprotein. These results support previous studies that show that HPV16 E6 activates signaling 
cascades downstream of RPTKs. For example, HPV16 E6 has been reported to activate FAK 
signaling, causing disruption of the cellular cytoskeletal structure (McCormack et al., 1997). 
HPV16 E6 and the Bovine Papillomavirus type 1 E6 protein have been shown to associate with 
paxillin and disrupt actin cytoskeletal structure, which may have implications on the transformed 
cell phenotype through anchorage independent growth (Neary and DiMaio, 1989; Tong and 
Howley, 1997; Vande Pol et al., 1998). It has also been shown that HPV16 E6 targets TAp63β 
for E6AP independent proteasomal degradation, which promotes anchorage independent growth 
(Khalifa et al., 2011). Further, high-risk HPV16 and HPV18 E6 proteins have been reported to 
associate with and target scaffolding PDZ domain containing proteins including MAGI-1 for 
proteasome-mediated degradation, disrupting tight junctions and also promoting anchorage 
independent growth (Kranjec and Banks, 2011). It is therefore possible that some or all of these 
reported activities are regulated by the HPV16 E6 mediated activation of RPTKs.   
 Our findings that HPV16 E6 activates RPTK signaling are in accordance with previously 
published data. It has been suggested that HPV oncoproteins activate EGFR signaling. HPV16 
E6 and E7 have been reported to transcriptionally activate EGFR (Akerman et al., 2001; 
Sizemore et al., 1998). However, the HPV16 E6/E7 mediated EGFR mRNA increase is not 
universal, as it was only observed in approximately one half of HFK populations evaluated 
(Akerman et al., 2001). Here we have not identified any HPV16 E6 specific increase in EGFR 
protein levels. EGFR activation has also been studied in the benign respiratory papillomas 
caused by low-risk mucosal HPV infection (Johnston et al., 1999). HPV types 6b and 11 are 
associated with respiratory papillomas, and the E6 proteins from HPV6b and HPV11 have been 
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implicated in increased EGFR expression. EGFR expression was not due to gene amplification 
event, nor was it associated with an increase in mRNA expression. Instead low-risk mucosal 
HPV E6 proteins increase EGFR recycling to the cell surface by approximately 20% (Johnston et 
al., 1999). Low-risk HPV E6 associated increase in EGFR expression was shown to increase 
EGFR tyrosine phosphorylation and cause increased MAPK activity. In contrast to the studies on 
respiratory papillomas, we have not detected an increase in total receptor levels in HPV16 E6 
expressing HFKs, but rather a specific increase in phosphorylated receptor species.  
 We demonstrate that HPV16 E6 increases the internalization (Fig 4.6) of a subset of 
activated growth factor sensitive RPTKs, including EGFR, IRβ and IGFR1β-R in the absence of 
growth factors. These receptors are considered activated because they are phosphorylated at 
known residues that promote receptor association with signaling adaptor proteins and the 
activation of downstream signaling cascades. It is well established that receptor activation causes 
increased receptor internalization, and internalized receptors maintain signaling potential. This is 
consistent with our observation of increased phosphorylation of internalized receptor species. 
Following internalization, receptors are then recycled to the cell surface or are degraded through 
endosomal fusion with the lysosome. Thus, increased activated receptor internalization causes 
increased receptor turnover and degradation. EGFR half-life is shorter in HPV16 E6 expressing 
cells, which is consistent with increased activated receptor degradation.  
 The signaling adaptor protein Grb2 was identified as an E6 associated protein, and Grb2 
knockdown reduced HPV16 E6 mediated mTORC1 activation, suggesting that Grb2 is important 
in relaying EGFR, IRβ and IGFR1β-R activation to downstream effectors (Fig 4.8). It is possible 
that HPV16 E6 mediated receptor internalization following autophosphorylation and activation is 
mediated by Grb2 and it is tempting to speculate that the HPV16 E6-Grb2 association promotes 
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receptor internalization. Moreover, EGFR receptor internalization is required for the 
maintenance of AKT activation (Goh et al.; Sigismund et al., 2008). Indeed, Grb2 has been 
implicated in receptor internalization as it is reported to interact with dynamin, an exchange 
factor that is important for inclusion of receptors into vesicles during endocytosis (Wang and 
Moran, 1996). The mechanics of the Grb2-receptor association and activation is, however, 
different. Grb2 associates with EGFR directly following receptor autophosphorylation (Batzer et 
al., 1994). IRβ and IGFR1β-R form indirect interactions with Grb2 via the IRS-1 and Shc 
adaptor proteins (Skolnik et al., 1993). The PDGFR and Grb2 association is indirect, with SHP-2 
mediating the association between Grb2 and PDGFR (Bazenet et al., 1996). Similarly, the 
EphRA2-Grb2 association is indirect, requiring Shc to form a complex that then leads to the 
activation of downstream signaling cascades including MAPK activation (Pratt and Kinch, 
2002). Thus, we favor a model in which Grb2 and a specific set of adaptor proteins are required 
that cause receptor internalization. HPV16 E6 may associate with and functionally modify the 
complex that Grb2 participates in that contributes to receptor activation or internalization. 
Potential modifications include increasing the stability or activity of the complex or targeting a 
Grb2 inhibitor for proteasome mediated degradation. Targeting an inhibitor of Grb2 for 
degradation is a particularly attractive model given our recent data suggesting that the LXXLL 
binding motif of HPV E6 proteins is important for HPV E6 mediated activation of mTORC1 
signaling and cap dependent translation (see chapter three). HPV E6 proteins associate with 
several proteins via the LXXLL binding motif, including the E3 ubiquitin ligase E6AP. It is also 
possible that the HPV16 E6/Grb2 association may increase Grb2 localization to the cellular 
membrane, increasing direct RPTK association and the activation of downstream signaling 
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networks. Experiments are currently underway to address the subcellular distribution of Grb2 in 
relation to HPV16 E6, EGFR, and IRβ/IGFR1β-R.  
 The HPV E6 and HPV E7 oncoproteins share biological functions with proteins encoded 
by other DNA tumor viruses, including polyomaviruses SV40, Merkel cell polyomavirus 
(MCPyV), and murine polyomavirus, and adenoviruses. The PI3K/AKT/mTORC1 signaling axis 
is targeted for activation by many DNA tumor viruses. The ability of plasma membrane bound 
mouse polyoma Middle T antigen to activate AKT and other downstream mitogenic pathways 
through association and subsequent recruitment of the Class I PI3K p85 regulatory subunit has 
been well documented (Ichaso and Dilworth, 2001; Kaplan et al., 1987; Summers et al., 1998; 
Whitman et al., 1985). It was recently reported that the MCPyV small T antigen causes aberrant 
hyperphosphorylation and activation of eukaryotic translation initiation factor 4E binding protein 
(4E-BP1). This study claimed that 4E-BP1 activation is independent of mTORC1 or mTORC2, 
but no actual mechanism was proposed (Shuda et al., 2011). It is possible that DNA tumor 
viruses may be implicated in one or multiple of the described mechanisms to activate 
PI3K/AKT/mTORC1. These mechanisms are not mutually exclusive and may account for 
widespread activation of a variety of signaling pathways including activation of MAPK, 
mTORC1 and FAK signaling. It is therefore tempting to speculate that oncoprotein mediated 
RPTK activation through engaging Grb2 and promoting the internalization of activated receptors 
is conserved amongst multiple DNA tumor viruses. We are currently addressing this question. 
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CHAPTER FIVE 
 
Summary, Discussion, and Future Directions 
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Summary 
 Together with the high-risk HPV E7 oncoprotein, HPV16 E6 contributes to the 
transformed phenotype. High-risk HPV E6 and E7 reprogram the cell, driving S-phase entry and 
cellular proliferation through the targeted degradation of p53 and pRb, respectively. Other 
functions of HPV16 E6 may contribute cellular reprogramming. Previous studies implicated 
HPV16 E6 in the activation of insulin signaling through mTORC1 activation. The biological 
consequences of HPV16 E6 mediated mTORC1 activation had not been investigated. It was 
unknown if mTORC1 activation is shared amongst other HPV types, and therefore if mTORC1 
activation is associated with the transformed phenotype observed in high-risk HPV types. 
Therefore, through the studies described in this dissertation, we aimed to confirm that HPV16 E6 
activates mTORC1, to investigate whether this activation affects known mTOR-regulated 
cellular processes, such as translation, and to identify the mechanism by which HPV16 E6 
activates mTORC1. The results from each data chapter are summarized as follows: 
 
Chapter 2: The human papillomavirus type 16 E6 oncoprotein activates mTORC1 
signaling and  increases protein synthesis 
 HPV16 E6 was previously shown to activate mTORC1 signaling with an increase in S6K 
and S6 phosphorylation (Lu et al., 2004). It was proposed that HPV16 E6 activates mTORC1 
through the E6AP dependent degradation of the mTORC1 negative regulator TSC2. 
Interestingly, targeting TSC2 for degradation was restricted to HPV16 E6 and was therefore not 
degraded by other high-risk E6 proteins such as HPV18 E6. Our initial results confirmed that 
stable expression of HPV16 E6 phosphorylates and activates S6K and S6 in primary cells and 
other cell types. We found that HPV16 E6 activates also increases 4E-BP1 
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hyperphosphorylation, further supporting the model that HPV16 E6 causes general activation of 
mTORC1 signaling. We evaluated cellular processes downstream of mTORC1 and demonstrated 
that HPV16 E6 increases the association of translation initiation factors with a synthetic mRNA 
cap. Moreover, HPV16 E6 increased cap dependent translation in bicistronic luciferase reporter 
assays. Concomitant HPV16 E7 expression did not reduce the ability of HPV16 E6 to activate 
cap dependent translation, indicating that mTORC1 activation and subsequent increase in cap 
dependent translation is relevant in the context of viral infection. Mechanistically, HPV16 E6 did 
not associate with TSC2, nor did HPV16 E6 cause TSC2 destabilization. To dissect the 
mechanism by which HPV16 E6 activates mTORC1, we focused on growth factor associated 
signaling and tested AKT and mTORC1 activation under conditions of nutrient deprivation. Both 
short term PBS and EBSS starvation maintained phosphorylation of AKT S473 and T308, 
suggesting that the activation of PDK1 and mTORC2 is sustained under conditions of nutrient 
deprivation in HPV16 E6 expressing primary HFKs.  
 
Chapter 3: The mechanism by which mucosal human papillomavirus E6 proteins activate 
mTORC1 and increase protein synthesis is dependent on an intact LXXLL binding motif 
 To narrow down the biochemical activities of HPV16 E6 that are responsible for 
activation of mTORC1 and cap dependent translation, we investigated whether different mucosal 
and cutaneous E6 proteins share this function with HPV16 E6. While mucosal HPV E6 proteins 
increased protein synthesis, cutaneous E6 proteins did not. To complement these studies, we 
utilized HPV16 E6 mutants that do not degrade p53 (Y54D), associate with proteins via their 
LXXLL motifs less efficiently (I128T), and cannot associate with PDZ proteins (ΔPDZ). 
Although all three of the HPV16 E6 mutants did not increase cap dependent translation in 
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bicistronic luciferase reporter assays as efficiently as wild type HPV16 E6, the Y54D and I128T 
mutants were statistically similar to the empty vector. These results suggest that more than one 
biological property of high-risk HPV E6 proteins contribute to activating mTORC1 and 
increasing cap dependent translation, including p53 binding and association with proteins that 
contain a LXXLL motif. Multiple proteins have been reported to associate with HPV16 E6 
through an LXXLL motif, including Paxillin and E6BP, but the best characterized is the E3 
ubiquitin ligase E6AP (UBE3A). The increase in cap dependent translation was shared between 
high- and low-risk HPV E6 proteins, and one of the only known biological properties that are 
shared amongst all mucosal E6 proteins is the association of E6AP. To test the hypothesis that a 
functional LXXLL binding motif is required for the ability of mucosal HPVE6 proteins to 
activate mTOR and translation, we generated LXXLL binding motif mutants of mucosal HPV 
E6 proteins that had lost the association with E6AP and tested them for activation of cap 
dependent translation and mTORC1. Upregulation of mTORC1 activity and cap dependent 
translation were abrogated by mutation of the LXXLL binding motif, suggesting that mucosal 
HPV E6 proteins mediate these events by associating with LXXLL-containing binding partners.  
 
Chapter 4: The HPV16 E6 oncoprotein phosphorylates receptor protein tyrosine kinases 
and increases internalization of phosphorylated receptor species  
 In order to address whether HPV16 E6 expression activates signaling cascades upstream 
of PDK1 and mTORC2, we evaluated the tyrosine phosphorylation of receptor protein tyrosine 
kinases (RPTKs). Phospho-tyrosine immunoprecipitation demonstrated an increase in tyrosine 
phosphorylated ErbB family members but not EphRA2 or PDGFR RPTKs under normal growth 
conditions and a maintenance of tyrosine phosphorylated ErbB family members upon EGF 
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withdrawal. Moreover, HPV16 E6 maintained the tyrosine phosphorylation of EGFR and 
IRβ/IGF1β-R when starved of EGF. HPV16 E6 expression shortened EGFR half-life, suggesting 
an HPV E6 mediated effect on receptor internalization. HPV16 E6 indeed increased 
internalization of phosphorylated and activated EGFR/IRβ/IGF1β-R receptor species as 
determined by internalization assays. To identify HPV E6 associated proteins that may be 
contributing to RPTK activation, we performed large scale HA affinity purification followed by 
mass spectrometry. HPV16 E6 associated complexes contained both known and novel binding 
partners, including the signaling adaptor protein Grb2. Association of Grb2 with HPV16 E6 was 
confirmed, and subsequent Grb2 siRNA knockdown demonstrated that Grb2 is required for 
efficient E6 mediated mTORC1 activation.  
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General Discussion and Future Directions 
 The results presented in this thesis demonstrate that HPV16 E6 activates mTORC1 and 
downstream signaling cascades in primary human foreskin keratinocytes. The HPV16 E6 
mediated mTORC1 activation causes an increase in cap dependent translation. To determine the 
mechanism of mTORC1 activation, we evaluated growth factor associated AKT signaling and 
found that HPV16 E6 expressing primary HFKs maintain increased AKT activation during 
nutrient deprivation through PBS starvation. Although nutrient deprivation is not necessary to 
detect HPV16 E6 mediated activation of S6K, S6, or 4E-BP1, it is required to unmask the effects 
of HPV16 E6 expression on AKT activity. Under normal growth conditions, HFKs expressing 
control vector have a high basal phosphorylation of AKT at both S473 and T308. It is possible 
that primary HFKs maintain high basal AKT phosphorylation because their growth in a 
monolayer culture is different from the growth in normal stratified epithelia, where only cells in 
the basal epithelia are dividing. The monolayer culture might mimic the basal epithelia and thus 
stimulate proliferation in part through the activation of AKT. Starving the HFKs in PBS reduced 
AKT activation in control cells because the stimulus resulting in AKT phosphorylation had been 
removed. In contrast, HPV16 E6 expressing HFKs maintained AKT phosphorylation because the 
signal promoting AKT phosphorylation is associated with HPV16 E6 expression rather than 
nutrient availability. PDK1 and mTORC2 remained active in HPV16 E6 expressing HFKs 
experiencing PBS starvation, suggesting that PDK1 and mTORC2 are involved in HPV16 E6 
mediated AKT activation. Since this work was published, it was demonstrated that AKT may be 
phosphorylated by a third kinase, IKKε/TBK1 (Ou et al., 2011; Xie et al., 2011) at residues S473 
and T308. The potential role of IKKε/TBK1 in HPV16 E6 mediated AKT activation was not 
investigated in this thesis. It should be noted that HPV16 E6 had previously been reported to 
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activate mTORC1 (Lu et al., 2004). The reported mechanism for HPV16 E6 mediated mTORC1 
activation was different from what we observed. The authors showed that S6K and S6 
phosphorylation is increased in HEK293 cells with transient HPV16 E6 expression. GST 
pulldowns were presented that showed that only HPV16 E6, and not E6 proteins from other HPV 
types, associates with TSC2. We were unable to reproduce these experiments in model cells.  
 Mutational analysis of HPV16 E6 suggests that multiple biological properties of E6 
contribute to the activation of mTORC1 and cap dependent translation. Inactivation of the 
HPV16 E6 LXXLL binding motif decreased activation of mTORC1 and cap dependent 
translation. This may be the result of the association with the ubiquitin ligase E6AP/UBE3A with 
HPV16 E6 through its LXXLL motif. Alternatively, the association of HPV16 E6 with other 
proteins via the LXXLL binding motif may play a role in the activation of mTORC1 and cap 
dependent translation. Although the LXXLL binding motif is important for high-risk HPV E6 
mediated increase in cap dependent translation, mutation of this motif is not sufficient to 
abrogate the increase of cap dependent translation. The association of HPV16 E6 with p53 
additionally contributes to the activation of cap dependent translation, whereas mutation of the 
HPV16 E6 PDZ binding domain had only minor effects. Moreover, low-risk mucosal HPV E6 
proteins that lack PDZ binding domains also increase mTORC1 activity and cap dependent 
translation. Therefore, it is clear that HPV16 E6 and other HPV E6 proteins activate mTORC1 
and cap dependent translation independent of the association with PDZ proteins. Thus, multiple 
biological functions of high-risk HPV E6 proteins, including an intact LXXLL binding motif and 
the association with p53, play a role in these processes. These functions may be linked to the 
known biological activities of HPV16 E6. For example, the association of HPV16 E6 with E6AP 
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through the E6AP LXXLL motif targets many proteins for degradation, some of which may be 
important in RPTK or mTORC1 signal transduction.  
 Receptor protein tyrosine kinases (RPTKs) are one of several mechanisms that can 
initiate AKT activation. Since HPV16 E6 mediated AKT activation was revealed through 
nutrient deprivation, we evaluated RPTK phosphorylation and activation in HPV16 E6 
expressing primary HFKs under normal growth conditions and after EGF withdrawal. Indeed, 
HPV16 E6 caused an increase in tyrosine phosphorylation of a subset of RPTKs, as identified by 
a combination of immunoprecipitations and Western blotting. These receptors are considered 
activated because they are phosphorylated at known residues that promote receptor association 
with signaling adaptor proteins and the activation of downstream signaling cascades. HPV16 E6 
increased the internalization and degradation of phosphorylated receptor species, which suggests 
that HPV16 E6 causes increased receptor turnover. It has been shown that EGFR internalization 
is required for the maintenance of signaling events downstream of EGFR (Goh et al., 2010; 
Sigismund et al., 2008). It is possible that HPV16 E6 causes an increase in receptor activation 
and internalization, and increased receptor degradation is a bystander effect of increased 
activation. Interestingly, EGFR activation has been studied in the benign respiratory papillomas 
caused by low-risk mucosal HPV infection (Johnston et al., 1999). HPV types 6b and 11 are 
associated with respiratory papillomas, and the E6 proteins from HPV6b and HPV11 have been 
implicated in increased EGFR expression. EGFR expression was not due to a gene amplification 
event, nor was it associated with an increase in mRNA expression. Instead low-risk mucosal 
HPV E6 proteins upregulated EGFR recycling to the cell surface by approximately 20% 
(Johnston et al., 1999). Low-risk HPV E6 associated increase in EGFR expression was shown to 
promote EGFR tyrosine phosphorylation and MAPK activity. In contrast to the studies on 
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respiratory papillomas, we have not detected an increase in total receptor levels in HPV16 E6 
expressing HFKs, but rather a specific increase in phosphorylated receptor species.  
 In order to investigate how HPV16 E6 activates RPTK signaling, we aimed to identify 
potential binding partners of E6 that may mediate its effects on RPTK and/or mTORC1 
signaling. Therefore, we performed affinity purifications and mass spectrometry with E6 proteins 
from multiple HPV types (high-risk HPV16 and HPV18; low-risk HPV6b and HPV11; 
cutaneous HPV5 and HPV8; HPV16 E6 mutants deficient in E6AP binding and association with 
PDZ proteins). This approach yielded multiple previously known and novel candidate interactors 
(Appendices 1 and 2). Several of the HPV16 E6 associated proteins that we identified in these 
studies have been implicated in mTORC1 signaling. We validated that HPV16 E6 associates 
with the signaling adaptor protein Grb2, and showed that Grb2 knockdown reduces HPV16 E6 
mediated mTORC1 activation. Grb2 is important for the activation of EGFR, IGFR and IR 
signaling pathways and has been implicated in receptor internalization (Wang and Moran, 1996). 
Given these data we have developed the model that HPV16 E6 induces the internalization and 
activation of several RPTKs and causes the activation of mTORC1 and cap dependent translation 
(Fig 5.1). Moreover, the association of HPV16 E6 with Grb2 could potentially contribute to 
relaying EGFR, IRβ and IGFR1β-R activation to downstream effectors. The association of 
HPV16 E6 with Grb2 may functionally modify the Grb2 complex and in turn enhance Grb2 
function. This could be manifested as an increase in Grb2 association with endosomes, which 
would increase receptor internalization similar to what was reported in this dissertation. For 
example, HPV16 E6 may promote the association of additional proteins with Grb2, and enhance 
Grb2 function. This may be through the targeted degradation of a Grb2 repressor. Regardless of 
the specific mechanism, knockdown of Grb2 indicates its importance in HPV16 E6 mediated  
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Figure 5.1. Model: The ability of HPV16 E6 to increase the internalization of activated 
RPTKs causes mTORC1 activation and an increase in cap dependent translation. HPV16 
E6 expressing cells maintain activation of RPTKs and downstream signaling pathways in the 
absence of ligand. We hypothesize that the association between Grb2 and HPV16 E6 is 
necessary to increase the internalization of activated receptor species, which may cause the 
activation of both MAPK and mTORC1 signaling cascades described throughout this 
dissertation. 
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mTORC1 activation. Further experiments to test the above mechanisms, such as evaluating 
RPTK and Grb2 subcellular localization in the presence of HPV16 E6 are underway. We also 
intend to address whether Grb2 is important in the HPV16 E6 mediated increase in cap 
dependent translation. 
 The combination of affinity purification and mass spectrometry indicated additional 
known and novel HPV16 E6 associated proteins that have previously been implicated in RPTK 
or mTORC1 signaling. All three members of the CASK/Dlg/Lin7C complex were detected, 
which has previously been described to associate with HPV16 or HPV18 E6 proteins. This 
complex has been shown to recognize RPTKs through their PDZ domains, as EGF receptors, for 
instance, have carboxyl-terminal PDZ binding domains (reviewed in (Nourry et al., 2003). 
Moreover, this complex is involved in the biosynthetic trafficking and stability of ErbB RPTKs 
at the basolateral plasma membrane (Shelly et al., 2003). Dlg is targeted for ubiquitin mediated 
degradation by high-risk HPV E6 proteins (Thomas et al., 2005). It is possible that HPV16 E6 
may bind and functionally modify this complex, increasing the activation of downstream 
signaling cascades. This may be the result of targeted degradation of complex components, the 
association of new proteins with this complex, or both. Further, the affinity purification 
suggested that HPV16 E6 associates with the GIGYF2 protein. GIGYF2 interacts with Grb10, 
which is phosphorylated by mTORC1 and participates in the negative feedback regulation of 
insulin signaling (Hsu et al., 2011; Yu et al., 2011). The association between HPV16 E6 and 
GIGYF2 may disrupt this negative feedback loop, and thus result in hyperactive mTORC1 
signaling. In addition, the TIPRL protein was identified as putative E6 interactor. TIPRL 
negatively regulates the PP2A phosphatase that can dephosphorylate multiple components of the 
mTORC1 signaling pathway, including S6K and AKT (Peterson et al., 1999; Schalm et al., 
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2005; Ugi et al., 2004). We favor a general model in which multiple HPV16 E6 binding partners 
activate RPTK and mTORC1 signaling. While Grb2 knockdown is sufficient to abrogate 
mTORC1 activity as seen by a reduction in S6K phosphorylation, other HPV16 E6 associated 
proteins, including those described above, may activate MAPK signaling and subsequently 
mTOR (Figure 5.2). Future studies should deplete cellular Grb2 in combination with other 
putative E6 binding partners and evaluate S6K as well as ERK phosphorylation.  
 We also evaluated the ability of E6 proteins from other HPV types to activate mTORC1. 
E6 proteins from high- and low-risk mucosal HPV types increase mTORC1 activity, while 
cutaneous HPV E6 proteins do not activate mTORC1. This is in accordance with the regulation 
of cap-dependent translation by HPV E6 proteins, as only mucosal, but not cutaneous, HPV E6 
proteins upregulate cap-dependent translation and establishes a strong correlation between 
mTOR activity and cap-dependent translation in HPV E6 expressing keratinocytes. High-risk 
HPV16 and HPV18 E6 proteins increase cap dependent translation the most in primary HFKs, 
whereas low-risk mucosal HPV E6 proteins from type 6b and 11 do so to a lesser extent. We 
hypothesize that the observed higher levels of high-risk HPV E6 mediated cap dependent 
translation are caused by more than one biological function of the high-risk HPV E6 protein. 
This is supported by reporter assays using HPV16 E6 mutants and the identification of several 
putative E6 binding partners that are involved in RPTK and/or mTORC signaling. Although the 
LXXLL binding motif is important for high-risk HPV E6 mediated increase in cap dependent 
translation, mutation of this motif is not sufficient to abrogate this effect. In comparison, the 
LXXLL binding motif of low-risk mucosal HPV E6 proteins is required for them to activate cap 
dependent translation. RPTK signaling and internalization in low-risk mucosal HPV E6 proteins 
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Figure 5.2. The association of HPV16 E6 with multiple proteins may activate the RPTK 
signaling network. HA- affinity purification and mass spectrometry identified several associated 
proteins involved in RPTK signaling. These proteins, including Grb2, GIGYF2, TIPRL, and 
members of the scaffolding complex with CASK-Dlg-Lin7C are shown in green. Also depicted 
are the signaling networks that HPV16 E6 has been shown to activate by phosphotyrosine 
immunoprecipitation and Western blot, which are shown in red. Diagram modified from KEGG 
pathways. 
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expressing HFKs remains to be investigated. Activated RPTKs increase mTORC1 activity, 
which in turn increases cap dependent translation. We found that all mucosal HPV E6 proteins 
tested activate mTORC1 and increase cap dependent translation. Given the causal relationship 
between RPTK activation and downstream signaling events, we hypothesize that low-risk 
mucosal HPV E6 proteins will also increase the phosphorylation and internalization of RPTKs.  
 In high-risk HPV associated malignancies, the two viral oncoproteins E6 and E7 are 
coexpressed. HPV16 E7 was previously described to trigger the trophic sentinel response in 
serum starved cells (Eichten et al., 2004). The trophic sentinel response is a form of cell death 
that arises from conflicting signals of cellular growth in the absence of available nutrients and 
growth factors. This type of cell death is independent of caspase activation, and cellular 
mitochondria remain functional and do not release cytochrome C (Eichten et al., 2004). HPV16 
E7 expressing HFKs induce autophagy at low levels in normal growth conditions and higher 
levels in serum starved cells (Zhou and Munger, 2009). Additionally, HPV16 E7 associates with 
pyruvate kinase M2 (PKM2), causing a shift from the oxidative phosphorylation based 
metabolism to the less efficient anaerobic fermentation that is commonly observed in 
transformed cells (Zwerschke et al., 1999). By activating autophagy in the absence of serum, E7 
expressing cells survived, likely short term, on the brink of cell death. Although LC3B positive 
autophagic puncta were not evaluated in cells co-expressing E6 and E7, the ability of E7 to 
induce the tropic sentinel response was abrogated by HPV16 E6 or dominant negative p53 co-
expression. The HPV16 E7 associated trophic sentinel response was dependent on the targeted 
degradation of pRb and the presence of functional p53. These data suggested that HPV16 E6 
mediated p53 degradation keeps cells alive and growing even under conditions of limited 
nutrient availability, underscoring the importance of p53 binding in E6 mediated mTORC1 
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activation. Under conditions of abundant nutrients, mTORC1 phosphorylates the autophagy 
regulatory kinase ULK1, inhibiting autophagy (Kim et al., 2011). Indeed, HPV16 E7 activates 
low levels of autophagy under normal growth conditions and enhanced autophagy when cells are 
serum deprived. However, HPV16 E6 activates mTORC1 in the absence of nutrients and growth 
factors, conditions in which mTORC1 would normally be inhibited and autophagy activated. In 
this dissertation, we show that that activation of mTORC1 and cap dependent translation is 
maintained in which the co-expression of the HPV16 E6 and E7 oncoproteins (Fig 2.7). Our data 
support a model that HPV16 E6 mediated mTORC1 activation counterbalances the HPV16 E7 
induction of autophagy, instead increasing protein synthesis (Fig 5.3 and Appendix 7). One 
might envision that disrupting this balance by inhibiting mTOR activity may re-activate the 
trophic sentinel pathway and may be used therapeutically for HPV associated lesions and cancer.  
Consistent with this model a recent study in a mouse model of HPV associated anal cancer 
suggested efficacy of rapamycin in the treatment of such lesions (Stelzer et al., 2010). 
 There may be many reasons why HPVs cause RPTK and mTORC1 activation. Activation 
of growth factor associated signaling is likely to play a role in the viral life cycle. Since infection 
with low-risk mucosal HPV types are rarely associated with carcinogenesis, the ability of 
mucosal HPV E6 proteins to activate mTORC1 and to enhance cap-dependent translation are 
probably related to a common requirement during the viral life cycle. Moreover, HPV mediated 
activation of mTORC1 and cap dependent translation may support translation of viral mRNA. 
mTORC1 has been shown to specifically increase the translation of several types of mRNAs. 
mTORC1 activation increases the translation of mRNAs that contain a 5’ terminal 
oligopyrimidine tract (5’ TOP)  in a short and unstructured 5’ untranslated region (5’UTR). This 
includes genes encoding ribosomal RNAs. mTORC1 activation also increases the translation of 
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Figure 5.3. The regulation of mTORC1 and autophagy in the presence and absence of the 
HPV16 E6 and E7 oncoproteins. (Top) In the absence of HPV infection, abundant growth 
factors, energy and nutrients cause the activation of mTORC1. mTORC1 phosphorylates the 
autophagy regulated kinase ULK1, inactivating ULK1 and causing the dissociation of the 
ULK1/mAtg13/Fip200 complex (right). Under conditions of restricted growth factors, energy, 
and nutrients, mTORC1 is inactive. The AMP activated kinase (AMPK1) then phosphorylates 
ULK1, activating the ULK1/mAtg13/Fip200 complex and promotes autophagy (left). (Bottom) 
However, upon HPV16 infection, the HPV16 E6 and E7 oncoproteins are expressed. Conditions 
of limited nutrients such as serum deprivation causes an E7 induced trophic sentinel response 
and autophagy, through an as-yet identified mechanism that is dependent on the ability of E7 to 
target pRb for degradation. However, co-expression of HPV16 E6 counterbalances the effects of 
E7. HPV16 E6 causes ligand independent activation of RPTKs, in the absence of growth factors. 
This activates downstream cascades including mTORC1, which dampens the E7 mediated 
increase in autophagy by phosphorylating and inactivating the ULK1/mAtg13/Fip200 complex. 
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genes with long and highly structured 5’UTRs, typically greater than several hundred base pairs, 
including HIF1α, CyclinD1, and Myc. We have shown that the protein levels of the mTORC1 
target genes CyclinD1 and HIF1α are increased in HPV16 E6 expressing primary cells (data not 
shown). The post transcriptional increase of CyclinD1 level is promote completion of the viral 
lifecycle and tumorigenesis by promoting DNA synthesis at the G1 to S phase transition by 
activating the CyclinD1/CDK4/CDK6 complexes. HPV16 E6 mediated increase in HIF1α may 
increase its activity as a transcription factor, inducing the expression of target genes including 
glucose transporters that promote the uptake and utilization of energy. We have also detected an 
increase in the protein level of the HIF1α target gene and glucose transporter GLUT 1 under 
normal growth conditions and conditions of nutrient deprivation (data not shown). Collectively 
these data support HPV16 E6 mediated activation of mTORC1. Given that HPV transcripts 
contain a relatively short 5’ UTR, it is possible that one or several may contain a 5’ TOP that is 
regulated by mTORC1. In fact, nuclease protection assays demonstrated that a subset of the 
HPV31b E6/E7 transcripts include a short 5’UTR of 33 nucleotides and contains a four 
nucleotide polypyrimidine tract (5’ TOP) (Ozbun and Meyers, 1998). It is unknown if this short 
5’ UTR is unstructured; if so, these data would suggest that the translation of some HPV 
transcripts may be regulated by mTORC1. There is evidence HPV16 E7 expression is increased 
upon induction of cellular differentiation, and mTORC1 inhibition abrogates increased HPV16 
E7 expression. This further supports the hypothesis that the translation of some HPV transcripts 
is regulated by mTORC1 (Oh et al., 2006). I also evaluated the ability of HPV16 E6 to increase 
general protein synthesis with a pulse chase experiment using 35S-labelled Methionine 
incorporation. Unfortunately I was unable to detect an E6-mediated increase in general protein 
synthesis.  
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 Interestingly, all HPVs, including those that infect the cutaneous epithelia, require 
adequate production of viral and cellular proteins necessary for viral genome replication and 
progeny virion production. It is thus surprising that cutaneous HPV E6 proteins do not detectably 
stimulate cap-dependent translation (Fig. 3.1) or activate mTORC1 signaling (preliminary data 
not shown). Tissue tropism may have driven mucosal HPV E6 proteins to evolve a distinct 
repertoire of biological properties and could explain the specificity of mucosal HPV E6 mediated 
activation of mTORC1 and cap dependent translation. Infection of the mucosal epithelium and 
successful viral genome replication and progeny virion production involves unique requirements. 
This may be the result of different gene expression profiles between cutaneous and mucosal 
epithelium. Transcriptional regulation of viral genes is also different between mucosal and 
cutaneous HPVs. Introduction of HPV16 and HPV5 long control region (LCR) reporter 
constructs into cutaneous and mucosal epithelial cells demonstrated that appropriate cellular 
tropism is important for robust transcriptional activation of the LCR (Mistry et al., 2007). This 
cell type dependent promoter activation may be caused by the differential expression and 
participation of transcription factors or transcriptional coactivators. Given these apparent 
differences in the cellular environment of cutaneous and mucosal epithelia, it is tempting to 
speculate that corresponding HPV types may have evolved distinct molecular strategies to 
exploit the available host cellular environment. 
 HPVs infect the basal epithelium, which is nutrient rich. Basal cells then divide 
asymmetrically, giving rise to one daughter cell that remains in the basal epithelia and maintains 
stem cell like properties, and one daughter cell that begins the process of differentiation. 
Differentiated cells are non-dividing and, therefore DNA replication does not occur. However, 
expression of high-risk HPV E6 and E7 proteins maintain S phase competence and promote 
 
 
 152 
DNA replication through the targeted degradation of p53 and pRb, respectively. The 
maintenance of RPTKs and mTORC1 activity in an environment that is presumably limited in 
energy, nutrients, and growth factors is likely important to the viral life cycle. IR/IGFR and ErbB 
RPTK ligand binding stimulates the activation of multiple downstream signaling cascades 
including mTORC1 that are implicated in cell migration, proliferation and growth (Fig 5.4). The 
stimulation of RPTK associated pathways may serve to indirectly promote genome replication 
and/or package progeny virions by increasing protein synthesis. Since HPV genome replication 
is dependent on the expression of host replication factors, one could envision that the ability of 
HPV16 E6 to increase the translation of capped mRNAs ensures adequate expression of cellular 
proteins that are necessary for viral genome replication. Increased mTORC1 activation may also 
directly increase the translation of viral proteins. This is possible considering the viral mRNAs 
are capped and polyadenylated by cellular machinery and are therefore suitable substrates for 
canonical cap dependent translation (Stacey et al., 2000; Zhao et al., 2005). As previously 
described, several HPV31b transcripts may contain a 5’ TOP and are therefore suitable substrates 
for mTORC1 mediated activation of cap dependent translation. There is evidence for 
translational regulation of early protein synthesis during epithelial cell differentiation in HPV-
positive cells. When HPV16-positive CaSki cervical carcinoma cells were cultured in 
methylcellulose- or CaCl2-containing medium to induce differentiation, increased expression of 
the E7 oncoprotein was observed. This increase was not at the level of transcription or protein 
stability, but rather an increase in the association of HPV E7-encoding mRNAs to polysomes. 
Sustained phosphorylation of 4E-BP1 upon differentiation of CaSki cells but not with HPV-
negative HaCaT cells or primary HFKs was also observed. Moreover, mTORC1 inhibition by 
rapamycin treatment reduced 4E-BP1 phosphorylation and HPV16 E7 oncoprotein expression in  
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Figure 5.4. HPV16 E6 mediated activation of RPTK/mTORC1 signaling networks 
regulates cellular processes that may be important in the viral lifecycle and transformation. 
As shown in Figure 5.2, HPV16 E6 activates the RPTK and mTORC1 signaling networks 
through multiple proposed mechanisms including the association with Grb2. Ultimately this 
activation may maintain or further activate the cellular processes shown on the right (light grey 
boxes). Diagram modified from KEGG pathways. 
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these cells (Oh et al., 2006). Additionally, high levels of viral proteins, especially the L1 and L2 
capsid proteins, need to be abundantly expressed during the late stage of productive viral 
replication. Given the virus replicates in the differentiated epithelium that is presumably nutrient 
deprived, we hypothesize that RPTK and mTORC1 activation are important to the late events of 
the viral life cycle, such as late gene expression or production of progeny virus. To delineate 
whether RPTK and mTORC1 activation is important for late events in the viral lifecycle, viral 
titer and infectivity could be assayed under conditions of RPTK and mTORC1 inhibition in the 
organotypic raft culture system. This system is a well established tissue culture model that 
mimics the differentiation state of natural stratified epithelia and is amenable to productive HPV 
infection (Meyers et al., 1992). Primary HFKs that stably express a control vector or the HPV16 
genome can be grown in the presence of feeder cells at the media-air interface, promoting the 
formation of the stratified epithelia. The resulting raft cultures could be treated with RPTK or 
mTORC1 inhibitors and quantitative PCR would allow for monitoring viral titer and infectivity. 
 The mutational analysis of high-risk and low-risk HPV E6 proteins clarify that although 
the LXXLL binding motif is important for high- and-low-risk mucosal HPV E6 mediated 
activation of mTORC1 and cap dependent translation. Moreover, the association with p53 and 
PDZ proteins additionally contributes to the activation of mTORC1 and cap dependent 
translation by high-risk HPV E6 proteins. We favor a model in which mTORC1 activation that is 
mediated by low-risk mucosal HPV E6 proteins through the LXXLL binding motif does not 
support transformation. However, the association of high-risk HPV E6 proteins with p53, PDZ 
proteins, and proteins through the LXXLL binding motif leads to a more pronounced activation 
of mTORC1 that may promote a transformed phenotype. It remains to be seen whether HPV 16 
E6 mediated RPTK or mTORC1 activation promote transformation. Interestingly, an EGFR 
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mutant (ΔEGFR) that lacks the extracellular domain and thus activates downstream signaling 
cascades independent of ligand binding has been reported. ΔEGFR supports enhanced 
tumorigenicity and is associated with glioblastomas (Nishikawa et al., 1994). HPV16 E6 
activates RPTKs including EGFR, also in the absence of ligand (EGF withdrawal or PBS 
starvation), which would suggest that E6 may similarly contribute to transformation and 
tumorigenesis. In the future we would like to evaluate the effects of RPTK and mTORC1 
inhibition on cell migration and anchorage independent growth in HPV16 E6 expressing HFKs. 
The use of dominant negative p53 in place of HPV16 E6 in these assays may address if the 
additional HPV E6 mediated effects are due to the targeted degradation of p53. It is also possible 
that other functions of the high-risk HPV E6 protein may synergize with mTORC1 activation or 
even contribute to mTORC1 activation, and promote transformation. 
 mTORC1 integrates environmental cues of energy status, growth factor and nutrient 
availability and couples them with the activation of downstream signaling pathways. This allows 
for the coordinate regulation of multiple cellular processes including growth and proliferation 
based on the availability of nutrients. mTORC1 regulation is critical for normal cellular 
processes. The uncoupling of the upstream energy and nutrient supply with downstream 
signaling events is commonly observed in tumor cells. There is direct evidence that mTORC1 
activation is associated with cancers. Several heritable genetic disorders in which mTORC1 
negative regulators are mutated are associated with tumorigenesis. These include germline 
mutations in the TSC1/TSC2 and PTEN genes. Mutations of either the TSC1 or TSC2 gene 
products are associated with benign tumors or hamartomas in multiple organ systems (reviewed 
in (Tomasoni and Mondino, 2011)). Cowden’s syndrome, caused by germline mutations in the 
gene that encodes the dual specificity phosphatase PTEN, is also associated with hamartomas 
 
 
 156 
and an increased risk in the development of thyroid, breast, and endometrial cancers (Eng, 1998; 
Rustad et al., 2006). The importance of mTORC1 signaling is further highlighted by the 
observation that multiple proteins in the mTORC1 signaling cascade are tumor suppressors or 
oncogenes, and are frequently amplified or mutated in human cancers. Gene amplification of the 
receptor protein tyrosine kinase ErbB2 is a common event in breast cancers, which can lead to 
the activation of many downstream signaling pathways (Kallioniemi et al., 1992). The class IA 
PI3K catalytic subunit p110α (PIK3CA) is frequently amplified in cervical and ovarian cancers 
(Ma et al., 2000; Shayesteh et al., 1999). Alternatively, somatic PTEN mutations are amongst the 
most common mutations in multiple cancers, including glioblastoma, endometrial, and prostate 
cancers (Trotman et al., 2003).  
 The high-risk HPV E6 and HPV E7 oncoproteins share biological functions with proteins 
encoded by other DNA tumor viruses, including polyomaviruses SV40, Merkel cell 
polyomavirus (MCPyV), and murine polyomavirus, and adenoviruses. The PI3K/AKT/mTORC1 
signaling axis is targeted for activation by many DNA tumor viruses. The ability of plasma 
membrane bound mouse polyoma Middle T antigen to activate AKT and other downstream 
mitogenic pathways through association and subsequent recruitment of the Class I PI3K p85 
regulatory subunit has been well documented (Ichaso and Dilworth, 2001; Kaplan et al., 1987; 
Summers et al., 1998; Whitman et al., 1985). It was recently reported that the MCPyV Small T 
antigen causes aberrant hyperphosphorylation and activation of eukaryotic translation initiation 
factor 4E binding protein (4E-BP1). This study suggested that 4E-BP1 activation occurred 
independent of mTORC1 or mTORC2, but no actual mechanism was proposed (Shuda et al., 
2011). DNA tumor viruses may activate the PI3K/AKT/mTORC1 axis through multiple distinct 
mechanisms, which are not mutually exclusive. The activation of RPTKs by DNA tumor viruses 
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may account for the activation of multiple downstream signaling pathways including MAPK, 
mTORC1 and FAK, as we described for HPV16 E6 in this thesis. Divergent types of DNA tumor 
viruses have possibly evolved unique mechanisms to perturb the same signaling pathways, as 
these are limiting for tumor viruses in general. This appears to be the case for AKT signaling, 
and the activation of RPTKs may also be shared, be it through similar or divergent 
mechanism(s). It is therefore tempting to speculate that oncoprotein mediated RPTK activation 
through engaging Grb2 and promoting the internalization of activated receptors is conserved 
amongst multiple DNA tumor viruses. We are currently addressing this question by evaluating 
MCPyV small T antigen for its effects on RPTK signaling. 
 The results of this thesis clearly indicate that HPV16 E6 activates RPTKs and mTORC1 
signaling. The activation of RPTKs or mTORC1 may promote transformation together with 
other functions of HPV16 E6, but either function alone may not be sufficient. Nonetheless, high-
risk HPV infection is the leading cause of cervical cancers. Therefore the ability of high-risk 
HPV E6 proteins to activate growth factor associated signaling cascades that are aberrantly 
activated in human cancers cannot be ignored. Inhibition of these signaling cascades appears to 
be a potential therapeutic target for HPV associated malignancies. Currently mTORC1 inhibition 
is in Phase I-III clinical trials as a viable treatment for a variety of cancer types. According to the 
National Institutes of Health, there are currently a number of clinical trials in which the 
mTORC1 inhibitors Rapamycin and Rapamycin analogues, or ‘rapalogues,’ Temsirolimus®, 
Sirolimus®, Everolimus® are being tested for the treatment of cervical cancers 
(clinicaltrials.gov). These drugs are also in various stages of clinical trials for treatment of head 
and neck cancers, which are approximately 25% HPV positive (Kreimer et al., 2005). Moreover, 
Rapamycin has been used successfully to treat HPV associated anal cancers in two preclinical 
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mouse models (Stelzer et al., 2010). EGFR inhibition is also under evaluation as a suitable 
treatment for cervical cancers. Moreover, mTORC1 inhibition with Rapamycin analogues is 
especially promising in cervical cancers as Rapamycin treatment has been shown to sensitize 
HPV positive CaSki cells to the apoptotic inducing agent paclitaxel/Taxol® (Faried et al., 2006). 
The EGFR monoclonal antibody inhibitor Cetuximab® is being tested for treatment of advanced 
cervical cancer (clinicaltrials.gov). Interestingly, combinatorial EGFR and mTORC1 inhibition is 
being tested in the treatment of multiple types of cancers including those of the head and neck. 
We could not identify any existing trials that aim to use combined EGFR and mTORC1 
inhibition in the treatment of HPV associated cervical cancers (clinicaltrials.gov). This combined 
approach might be more promising in order to eliminate aberrant activation of EGFR and 
mTORC1 in HPV associated cervical cancer. It should be noted, however, that inhibition of 
EGFR can enhance the activation of signaling events downstream of IGFR (Knowlden et al., 
2008).  
 To date, research with HPV16 E6 has identified many novel functions of this small 
protein, both in the viral life cycle and mechanisms that contribute to transformation. Together 
with HPV16 E7, these proteins have demonstrated their potent oncogenicity through targeting 
the tumor suppressor p53 and pRb, respectively, for degradation This dissertation identified 
novel functions of the HPV16 E6 oncoprotein that potentially contribute to unrestricted cell 
growth and proliferation during productive HPV infection. Therefore, these studies provide a 
basis for the continued exploration of using mTORC1 and RPTK inhibitors in the treatment of 
HPV positive human cancers. Furthermore, these studies provide insights into similarities and 
differences between high- and low-risk mucosal HPV E6 proteins and how they may 
respectively contribute to the viral life cycle. Therefore, studies regarding the perturbation of 
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growth factor associated signaling cascades by HPV E6 proteins will broaden our knowledge of 
the mechanisms by which HPV replicates in nutrient deprived tissues and potentially aid in the 
development of new therapies and treatments for high-and low-risk HPV associated lesions.  
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APPENDIX 1 
HPV16 E6 associated proteins as determined by HA affinity purification followed by mass 
spectrometry 
Gene Symbol #Peptides 
# Unique 
Peptides 
Shared w/ 
HPV16 
E6no*I128T 
Shared w/ 
HPV16 
E6no*PDZ 
SCRIB 54 54 + - 
UTRN 27 27 + - 
UBE3A 23 23 + + 
GOPC 21 21 + + 
HUWE1 21 21 + + 
CASK 18 18 + - 
DLG1 17 17 + - 
SNX27 17 17 + - 
IMPDH2 15 15 + + 
MPP6 12 12 + - 
AIFM1 11 11 + + 
USP9X 11 11 + + 
ILK-2 11 11 + + 
SNTB2 10 10 + - 
PSMD3 10 10 + + 
KPNB1 9 9 + + 
PSMC1 8 8 + + 
PSMC3 8 8 + + 
TP53 8 8 + + 
YWHAE 8 8 + + 
PSMD2 8 8 - + 
CAPZA1 7 7 + + 
DTNA 7 7 + - 
PSMD1 7 7 + + 
MAGI3 7 7 + - 
SAPS3 7 7 + + 
PPP2R2A 6 6 + + 
PSMC5 6 6 + + 
STRAP 6 6 + + 
CAPN2 6 6 + + 
PPP2R1A 6 6 + + 
PSMC2 6 6 + + 
YWHAQ 5 5 + + 
CAPZB 5 5 + + 
PSMD11 5 5 - + 
DDB1 5 5 + + 
RFC4 5 5 + + 
ERP44 5 5 + + 
GIGYF2 4 4 + + 
PSMC6 4 4 + + 
CAPNS1 4 4 - + 
RPL36AP37 4 4 + + 
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KPNA2 4 4 + + 
RNH1 4 4 + + 
SNX27 4 4 + - 
PSMD4 4 4 + + 
CPVL 4 4 + - 
UBC 4 4 + + 
PPP2CA 4 4 + + 
PSME3 3 3 + + 
UBE2L3 3 3 + + 
MAPK1 3 3 + + 
PTPN3 3 3 + - 
LIN7C 3 3 + - 
PDZRN3 3 3 + - 
CSDE1 3 3 + + 
USP7 3 3 + + 
DLD 3 3 - + 
PPP6C 3 3 + + 
EIF4E2 3 3 + + 
GPS1 3 3 - - 
TJP2 3 3 - - 
SNTB1 3 3 - - 
AMOT 3 3 + + 
PSMC4 3 3 - + 
CTNNAL1 3 3 + - 
DLAT 2 2 + + 
MPP7 2 2 - - 
PSMD12 2 2 + + 
UBA1 2 2 - - 
LIN7A 2 2 - - 
TPM3 2 2 - + 
PSMD13 2 2 - + 
PPP2R1A 2 2 + + 
PSMD6 2 2 + - 
LOC646057 2 2 + + 
PSMD7 2 2 - + 
EFTUD2 2 2 + + 
COPS5 2 2 + + 
TPM1 2 2 - + 
CBX3 2 2 - + 
MPP2 2 2 + - 
GAPVD1 2 2 - + 
LIN7B 2 2 - - 
TXNDC5 2 2 + + 
LOC344382 2 2 - - 
TP53 1 1 + + 
TPM4 1 1 + - 
SCRIB 1 1 + - 
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LRRC1 1 1 - + 
LGMN 1 1 + + 
HDAC2 1 1 - - 
GIGYF2 1 1 + + 
RPS26P54 1 1 + + 
BOLA2 1 1 + + 
ALDH2 1 1 + + 
TIPRL 1 1 + + 
SKP1 1 1 - + 
DTNB 1 1 + - 
IMPDH1 1 1 - - 
HAT1 1 1 + - 
WDR68 1 1 - + 
PSMD8 1 1 - + 
PPP2R2C 1 1 + + 
SORT1 1 1 + - 
AKAP8L 1 1 + + 
DICER1 1 1 - + 
PPM1G 1 1 + - 
SMN2 1 1 + - 
DLG4 1 1 + - 
SAPS3 1 1 + + 
COPS4 1 1 - + 
UGCGL1 1 1 + + 
AKAP8 1 1 + - 
CAPZA2 1 1 + - 
DCTPP1 1 1 - - 
CACYBP 1 1 - - 
PSMD14 1 1 - + 
ECD 1 1 - + 
CALM1 1 1 - - 
NUP37 1 1 - - 
PPP1CB 1 1 + - 
SEH1L 1 1 - + 
SNORA7A 1 1 - - 
USP47 1 1 - - 
SIPA1L1 1 1 - - 
PGAM5 1 1 - - 
TPM3 1 1 - + 
PPP1CA 1 1 + - 
RPA1 1 1 - - 
HUWE1 1 1 - - 
GTF3C5 1 1 + - 
PTGES3 1 1 + - 
PKLR 1 1 - + 
DCTN2 1 1 - - 
GRB2 1 1 - + 
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APPENDIX 2 
HA-affinity purification/mass spectrometry identified associated proteins with E6 proteins from 
HPV types 5, 8, 6b, 11, and 18 
HPV5 E6 interacting proteins 
Gene Symbol #Peptides 
# Unique 
Peptides 
EP300 34 34 
CREBBP 26 26 
IDE 22 22 
RBL1 9 9 
HUWE1 9 9 
ILK-2 7 7 
RB1 7 7 
ATAD3B 7 7 
CTBP2 6 6 
SFPQ 5 5 
SMAD3 4 4 
UBC 4 4 
MMS19 3 3 
SMAD9 1 1 
HIST1H4J 1 1 
NUFIP2 1 1 
INPP5D 1 1 
ATAD3A 1 1 
PTPLAD1 1 1 
MYO1C 1 1 
CDK3 1 1 
   
HPV8 E6 interacting proteins 
Gene Symbol #Peptides 
# Unique 
Peptides 
CREBBP 35 35 
HUWE1 33 33 
AMOT 32 32 
EP300 31 31 
MCM3 29 29 
MCM5 20 20 
ATAD3B 16 16 
LRPPRC 13 13 
UBAP2L 12 12 
PLEKHA5 12 12 
RB1 11 11 
PFKM 10 10 
RBL1 9 9 
SFPQ 8 8 
PEF1 7 7 
NSUN2 7 7 
ATAD3A 7 7 
IWS1 7 7 
ILK-2 7 7 
ZNHIT2 6 6 
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NDUFS2 6 6 
YWHAQ 5 5 
AMBRA1 5 5 
UBR5 5 5 
CTBP2 4 4 
AKAP8 4 4 
ATAD3B 4 4 
AKAP8L 3 3 
MCM7 3 3 
HOOK1 3 3 
ARNT 3 3 
UBC 3 3 
WDR68 3 3 
NDUFS3 3 3 
FAM115A 3 3 
LONP2 3 3 
KIF5B 3 3 
KIF22 2 2 
PFDN2 2 2 
SMAD3 2 2 
MYO1B 2 2 
FAM96B 2 2 
CDK2 2 2 
UBAP2L 2 2 
RIF1 2 2 
POLR2B 2 2 
CHD4 2 2 
SATB2 2 2 
NDUFA5 2 2 
HELLS 2 2 
TIMM50 2 2 
YLPM1 2 2 
PGAM5 2 2 
MMS19 2 2 
VBP1 2 2 
PFDN6 2 2 
CACYBP 2 2 
ATP2A1 2 2 
LEMD3 2 2 
SPC24 1 1 
CCNA2 1 1 
FOXP4 1 1 
ATAD3B 1 1 
NUBP2 1 1 
MTHFD2 1 1 
GNL3 1 1 
SPC25 1 1 
CTTNBP2NL 1 1 
USP9X 1 1 
TRIM37 1 1 
RABL5 1 1 
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PTCD3 1 1 
SLC39A7 1 1 
PPP2CA 1 1 
IQGAP1 1 1 
POLR2A 1 1 
KIF11 1 1 
CITED2 1 1 
PMF1 1 1 
SF3B1 1 1 
LZTS2 1 1 
MYO1A 1 1 
PRPF8 1 1 
PSMC5 1 1 
WDR77 1 1 
SET 1 1 
PTPLAD1 1 1 
HUWE1 1 1 
CDK3 1 1 
SYMPK 1 1 
EFTUD2 1 1 
CANX 1 1 
HDAC1 1 1 
NUFIP2 1 1 
IGF2BP3 1 1 
LAS1L 1 1 
SIPA1L1 1 1 
AAAS 1 1 
PDCD11 1 1 
PSMD4 1 1 
SMAD9 1 1 
MRPS31 1 1 
HUWE1 1 1 
FTSJ3 1 1 
DLD 1 1 
LUC7L2 1 1 
OCRL 1 1 
SF1 1 1 
SLC25A4 1 1 
TRIM33 1 1 
RARS 1 1 
USP7 1 1 
MTHFD1L 1 1 
   
HPV6b E6 interacting proteins 
Gene Symbol #Peptides 
# Unique 
Peptides 
UBE3A 16 16 
HUWE1 15 15 
SFPQ 7 7 
CANX 5 5 
ILK-2 5 5 
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ATAD3B 5 5 
UBC 4 4 
MTHFD2 3 3 
PSMA2 3 3 
ATP2A2 3 3 
HM13 3 3 
BAT3 3 3 
ATP2A1 3 3 
ATP1A2 2 2 
PTPLAD1 2 2 
HLA-B 2 2 
SLC39A7 1 1 
TIMM50 1 1 
HLA-H 1 1 
PSMC5 1 1 
U2AF1 1 1 
AKAP8L 1 1 
SNRPF 1 1 
SLC1A5 1 1 
YWHAE 1 1 
PSMD3 1 1 
ANXA2P2 1 1 
CNP 1 1 
ATP1B3 1 1 
AMOT 1 1 
PSMA7 1 1 
PSMB1 1 1 
PSMC1 1 1 
   
   
HPV11 E6 interacting proteins 
Gene Symbol #Peptides 
# Unique 
Peptides 
UBE3A 25 25 
STXBP3 16 16 
HUWE1 9 9 
TRMT61B 8 8 
STX4 7 7 
ILK-2 7 7 
ATAD3B 7 7 
AIFM1 5 5 
SFPQ 5 5 
KIF3A 4 4 
UBC 4 4 
USP7 3 3 
LRPPRC 3 3 
CANX 2 2 
PGAM5 2 2 
PYCRL 2 2 
UBE2L3 2 2 
YWHAE 2 2 
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PHGDH 2 2 
PSMC1 1 1 
ATP1A2 1 1 
AKAP8L 1 1 
CBLB 1 1 
IMPDH2 1 1 
NUP188 1 1 
HERC2 1 1 
UBA1 1 1 
MYBBP1A 1 1 
AGK 1 1 
SLC25A4 1 1 
PSMD11 1 1 
RANBP2 1 1 
SLC1A5 1 1 
SLC39A7 1 1 
PSMC6 1 1 
ATAD3A 1 1 
TARDBP 1 1 
PSMA6 1 1 
   
HPV18 E6 interacting proteins 
Gene Symbol #Peptides 
# Unique 
Peptides 
UBE3A 26 26 
SCRIB 26 26 
DLG1 21 21 
UTRN 20 20 
CASK 16 16 
CLPX 14 14 
HUWE1 10 10 
MPP7 9 9 
PSMD1 9 9 
SNTB2 9 9 
CANX 9 9 
TP53 8 8 
PSMD4 7 7 
PSMD2 7 7 
PSMC3 6 6 
SFPQ 6 6 
MAGI3 6 6 
PSMD3 5 5 
PSMC2 4 4 
PSMC1 4 4 
PSMC6 4 4 
DMD 4 4 
PSMC5 4 4 
UBC 4 4 
DLG4 4 4 
PSME3 3 3 
PSMB1 3 3 
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AMOT 3 3 
DTNA 3 3 
LIN7C 3 3 
MPP2 3 3 
SNX27 3 3 
PSMD11 3 3 
PSMD12 3 3 
IRS4 3 3 
MPP6 3 3 
ATAD3B 3 3 
DLG1 2 2 
KPNB1 2 2 
PSMB6 2 2 
PSMD6 2 2 
PSMB5 2 2 
PSMD14 2 2 
YWHAE 2 2 
PGAM5 2 2 
CTNNAL1 2 2 
AIFM1 2 2 
LIN7B 2 2 
PSMC4 2 2 
ADRM1 2 2 
TP53 1 1 
YWHAQ 1 1 
MTHFD2 1 1 
SLC39A7 1 1 
ATP1A2 1 1 
UCHL5 1 1 
USP4 1 1 
U2AF1 1 1 
SNX27 1 1 
PSMB2 1 1 
MYO6 1 1 
PSMD13 1 1 
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APPENDIX 3 
HPV16 E6 * associated proteins 
   
Gene Symbol #Peptides 
# Unique 
Peptides 
TGM3 3 3 
CALML5 2 2 
LGALS7 2 2 
SFPQ 2 2 
ANXA2P2 2 2 
NCL 1 1 
CALML3 1 1 
ASPRV1 1 1 
EPPK1 1 1 
   
HPV16 E6 ** associated proteins  
   
Gene Symbol #Peptides 
# Unique 
Peptides 
XRCC6 8 8 
WDHD1 7 7 
MTHFD2 4 4 
EPRS 4 4 
SFPQ 4 4 
ACLY 3 3 
IMPDH2 3 3 
PPP2R1A 3 3 
DARS 3 3 
ASNA1 2 2 
LUC7L 1 1 
BOLA2 1 1 
KPNB1 1 1 
PPP2CA 1 1 
UPF1 1 1 
RCC2 1 1 
HAX1 1 1 
MCM7 1 1 
PKLR 1 1 
KPNA2 1 1 
 
